var title_f39_27_40368="AR as heard at the second right intercostal space";
var content_f39_27_40368=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/76340/aor2rics_conv.mp4?title=AR+as+heard+at+the+second+right+intercostal+space\" style=\"width:382px;height:440px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Phonocardiogram of aortic regurgitation as heard at the second right intercostal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 221px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Carotid artery pulse tracing and phonocardiogram of aortic regurgitation as heard at the second right intercostal space. S1 (mitral and tricuspid valve closure) is followed by a systolic ejection murmur due to the large stroke volume seen in aortic regurgitation. After S2 (aortic and pulmonic valve closure) there is a faint and short diastolic \"blowing\" murmur of aortic regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Provided by John M Criley, MD, The Physiological Origins of Heart Sounds and Murmurs, Little, Brown, Boston, 1996, 1-800-527-0145. This program contains a complete interactive tutorial integrating over 200 heart sounds and murmurs with cineangiographic, echo-Doppler, and hemodynamic motion picture sequences.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40368=[""].join("\n");
var outline_f39_27_40368=null;
var title_f39_27_40369="Pulm AVM PA gram III";
var content_f39_27_40369=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57719&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Multiple non-communicating arteriovenous malformations detected on a routine chest radiograph in asymptomatic patient",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A right selective pulmonary arteriogram shows abnormally dilated and tortuous segmental and subsegmental pulmonary arteries without early venous drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40369=[""].join("\n");
var outline_f39_27_40369=null;
var title_f39_27_40370="Patient information: Menopause (The Basics)";
var content_f39_27_40370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15488\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/23/29051\">",
"         Ways to cope with menopause symptoms",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?25/59/26546\">",
"         Patient information: Menopause (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?31/16/32001\">",
"         Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?24/49/25366\">",
"         Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?32/4/32835\">",
"         Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?12/4/12357\">",
"         Patient information: Sexual problems in women (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Menopause (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/menopause-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H538637410\">",
"      <span class=\"h1\">",
"       What is menopause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Menopause is the time in a woman&rsquo;s life when she stops having monthly periods. At this time, her ovaries stop releasing eggs and stop making the hormones estrogen and progesterone. Menopause usually occurs between the ages of 45 and 55. The average age is 51.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637417\">",
"      <span class=\"h1\">",
"       How do I know if I am going through menopause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women start to wonder about menopause when their periods start to change. If you are going through menopause, you might:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have periods more or less often than usual (for example, every 5 to 6 weeks instead of every 4)",
"       </li>",
"       <li>",
"        Have bleeding that lasts for fewer days than before",
"       </li>",
"       <li>",
"        Skip one or more periods",
"       </li>",
"       <li>",
"        Have symptoms of menopause, such as hot flashes (described below)",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If your uterus has been removed, it might be tough to tell if you are going through menopause. Still, women who do not have a uterus can have menopause symptoms. If your ovaries were removed before menopause, you had what doctors call &ldquo;surgical menopause.&rdquo; That just means that you went through it early, because your ovaries were removed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637424\">",
"      <span class=\"h1\">",
"       What are the symptoms of menopause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Some women go through menopause without symptoms. But many have one or more of these symptoms:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Hot flashes",
"        </strong>",
"        &ndash; Hot flashes feel like a wave of heat that starts in your chest and face and then moves through your body. Hot flashes usually start happening before you stop having periods.",
"       </li>",
"       <li>",
"        <strong>",
"         Night sweats",
"        </strong>",
"        &ndash; When hot flashes happen during sleep, they are called &ldquo;night sweats.&rdquo; They can make it hard to get a good night&rsquo;s sleep.",
"       </li>",
"       <li>",
"        <strong>",
"         Sleep problems",
"        </strong>",
"        &ndash; During the transition to menopause, some women have trouble falling or staying asleep. This can happen even if night sweats are not a problem.",
"       </li>",
"       <li>",
"        <strong>",
"         Vaginal dryness",
"        </strong>",
"        &ndash; Menopause can cause the vagina and tissues near the vagina to become dry and thin. This can be uncomfortable or make sex painful.",
"       </li>",
"       <li>",
"        <strong>",
"         Depression",
"        </strong>",
"        &ndash; During the transition to menopause, some women start having symptoms of depression. That&rsquo;s especially true for women who have been depressed before. Depression symptoms include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Sadness",
"       </li>",
"       <li>",
"        Losing interest in doing things",
"       </li>",
"       <li>",
"        Sleeping too much or too little",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Trouble concentrating or remembering things",
"        </strong>",
"        &ndash; This might be caused by lack of sleep that often happens at menopause, or by the lack of estrogen. Some experts suspect that estrogen is important for good brain function.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637431\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If your periods start changing and you are 45 or older, you do not need to see your doctor or nurse. But you should see your doctor or nurse if you have symptoms that really bother you. For instance, you should see your doctor if you cannot sleep because of night sweats, or if you start to feel sad or blue and don&rsquo;t seem to enjoy things anymore.",
"     </p>",
"     <p>",
"      You should also see your doctor or nurse if you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have your period more often than every 3 weeks",
"       </li>",
"       <li>",
"        Have very heavy bleeding during your period",
"       </li>",
"       <li>",
"        Have spotting between your periods",
"       </li>",
"       <li>",
"        Have been through menopause and start bleeding again (even if it's just a spot of blood)",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637438\">",
"      <span class=\"h1\">",
"       Is there a test for menopause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is a test that can point to menopause. But doctors usually use that test only in women who are too young to be in menopause or who have special circumstances.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637445\">",
"      <span class=\"h1\">",
"       Can I still get pregnant?",
"      </span>",
"      &nbsp;&mdash;&nbsp;As long as you are still having periods, even if they do not happen often, you could get pregnant. If you have sex and do not want to get pregnant, use some form of birth control. If you have not had a period",
"      <strong>",
"       for a full year",
"      </strong>",
"      , it is probably safe to say you have been through menopause and can no longer get pregnant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637452\">",
"      <span class=\"h1\">",
"       How are the symptoms of menopause treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Hormones",
"        </strong>",
"        &ndash; The hormone estrogen is the most effective treatment for menopause symptoms. Women who take estrogen usually must also take another hormone, called progesterone. Although these hormones are effective, they can also cause problems of their own. If you want to take hormones, ask your doctor or nurse what the possible risks and benefits are for you. If you have a history of breast cancer, ask whether hormones are safe for you.",
"       </li>",
"       <li>",
"        <strong>",
"         Antidepressants",
"        </strong>",
"        &ndash; Antidepressants can ease hot flashes and depression. Even women who are not depressed can take them to help with hot flashes.",
"       </li>",
"       <li>",
"        <strong>",
"         Anti-seizure medicine",
"        </strong>",
"        &ndash; One of the medicines used to prevent seizures seems to help some women with hot flashes &mdash; even if they do not have seizures.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637459\">",
"      <span class=\"h1\">",
"       Can I do anything on my own to reduce the symptoms of menopause?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. There are some steps you can try (",
"      <a class=\"graphic graphic_table graphicRef82045 \" href=\"mobipreview.htm?28/23/29051\">",
"       table 1",
"      </a>",
"      ). But ask your doctor before you take any &ldquo;natural remedies.&rdquo; Some natural remedies may not be safe, especially for women who have a history of breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637466\">",
"      <span class=\"h1\">",
"       What can I do to protect my bones?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Take calcium and vitamin D supplements",
"       </li>",
"       <li>",
"        Be active (exercise helps keep bones strong)",
"       </li>",
"       <li>",
"        Ask your doctor when you should start having bone density tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If needed, your doctor can prescribe medicines to help keep your bones strong.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H538637473\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=see_link\">",
"       Patient information: Menopause (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=see_link\">",
"       Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=see_link\">",
"       Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=see_link\">",
"       Patient information: Sexual problems in women (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=see_link\">",
"       Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?39/27/40370?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15488 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-77.94.48.4-B85F2FADC7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40370=[""].join("\n");
var outline_f39_27_40370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637410\">",
"      What is menopause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637417\">",
"      How do I know if I am going through menopause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637424\">",
"      What are the symptoms of menopause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637431\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637438\">",
"      Is there a test for menopause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637445\">",
"      Can I still get pregnant?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637452\">",
"      How are the symptoms of menopause treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637459\">",
"      Can I do anything on my own to reduce the symptoms of menopause?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637466\">",
"      What can I do to protect my bones?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H538637473\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15488\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/23/29051\">",
"      Ways to cope with menopause symptoms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?25/59/26546?source=related_link\">",
"      Patient information: Menopause (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?31/16/32001?source=related_link\">",
"      Patient information: Nonhormonal treatments for menopausal symptoms (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?24/49/25366?source=related_link\">",
"      Patient information: Osteoporosis prevention and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?32/4/32835?source=related_link\">",
"      Patient information: Postmenopausal hormone therapy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/4/12357?source=related_link\">",
"      Patient information: Sexual problems in women (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_27_40371="Palivizumab: Drug information";
var content_f39_27_40371=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Palivizumab: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/0/40964?source=see_link\">",
"    see \"Palivizumab: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F205781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Synagis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F205782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Synagis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F205800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Monoclonal Antibody",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F205792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/0/40964?source=see_link\">",
"      see \"Palivizumab: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prevention of RSV:",
"     </b>",
"     I.M.: Infants and Children &lt;2 years: 15 mg/kg of body weight, monthly throughout RSV season (first dose administered prior to commencement of RSV season).",
"     <b>",
"      Note:",
"     </b>",
"     The AAP recommends a maximum of 3 doses for patients born 32-34 6/7 weeks without significant congenital heart disease or chronic lung disease; maximum of 5 doses for all others (AAP, 2009).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <i>",
"      Cardiopulmonary bypass patients:",
"     </i>",
"     I.M.: Administer a dose as soon as possible after cardiopulmonary bypass procedure, even if &lt;1 month from previous dose.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F205766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Synagis&reg;: 100 mg/mL (0.5 mL, 1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F205753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F205768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection should (preferably) be in the anterolateral aspect of the thigh; gluteal muscle should not be used routinely; injection volume over 1 mL should be administered as divided doses",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F205767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants and children at high risk of RSV disease",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The American Academy of Pediatrics recommends RSV prophylaxis with palivizumab during RSV season for:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants &lt;3 months of age who were born between 32 and 34 6/7 weeks gestational age and have one of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Day care attendance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - One or more siblings &lt;5 years of age living in the same household",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants &lt;6 months of age who were born between 29 and 31 6/7 weeks gestational age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants &lt;12 months of age who were born &lt;28 weeks gestational age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants &lt;12 months of age with congenital airway abnormality or neuromuscular disorder that decreases the ability to manage airway secretions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants and children &lt;24 months of age with chronic lung disease (CLD) necessitating medical therapy within 6 month prior to the beginning of RSV season",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     &bull; Infants and children &le;24 months of age with congenital heart disease and one of the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;\">",
"     - Receiving medication to treat congestive heart failure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Moderate-to-severe pulmonary hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;\">",
"     - Cyanotic heart disease",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F205806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Synagis&reg; may be confused with Synalgos&reg;-DC, Synflorix&trade;, Synvisc&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F205798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fever (27%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%: Miscellaneous: Antibody formation (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Anaphylaxis (very rare - includes angioedema, dyspnea, hypotonia, pruritus, respiratory failure, unresponsiveness, urticaria); hypersensitivity reactions, injection site reactions, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F205771\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     History of severe prior reaction to palivizumab or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F205757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Very rare cases of anaphylaxis have been observed; rare cases of severe acute hypersensitivity reactions have also been reported. Use with caution after mild hypersensitivity reaction; permanently discontinue for severe hypersensitivity reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory syncytial virus (RSV): Safety and efficacy have not been demonstrated in the treatment of established RSV disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Interference (false negatives) with immunological-based RSV diagnostic tests (antigen detection) and viral culture assays has been reported; rely on reverse-transcriptase-polymerase chain reaction-based assays and clinical findings.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F205762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abciximab: May enhance the potential for allergic or hypersensitivity reactions to Monoclonal Antibodies. Also may cause thrombocytopenia or diminished therapeutic effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F205764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F205774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for adult use; reproduction studies have not been conducted",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Synagis Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/0.5 mL (0.5 mL): $1487.04",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg/mL (1 mL): $2807.98",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6729951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor for anaphylaxis or acute hypersensitivity reactions",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F205775\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Abbosynagis (IL);",
"     </li>",
"     <li>",
"      Synagis (AE, AR, AT, AU, BE, BG, BH, BO, BR, CH, CN, CO, CR, CY, CZ, DE, DK, DO, EC, EE, EG, ES, FI, FR, GB, GR, GT, HK, HN, IE, IQ, IR, IT, JO, JP, KP, KW, LB, LY, MT, MX, MY, NI, NL, NO, NZ, OM, PA, PE, PL, PR, PT, PY, QA, RU, SA, SE, SG, SK, SV, SY, TR, TW, UY, VE, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F205756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Exhibits neutralizing and fusion-inhibitory activity against RSV; these activities inhibit RSV replication in laboratory and clinical studies",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F205770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;display:inline\">",
"     Half-life elimination: Children &lt;24 months: 20 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics (AAP) Committee on Infectious Diseases, &ldquo;Modified Recommendations for the Use of Palivizumab for the Prevention of Respiratory Syncytial Virus Infections,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 124:1-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40371/abstract-text/19736258/pubmed\" id=\"19736258\" target=\"_blank\">",
"        19736258",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Johnson S, Oliver C, Prince GA, et al, &ldquo;Development of a Humanized Monoclonal Antibody (MEDI-493) With Potent",
"      <i>",
"       In Vitro",
"      </i>",
"      and",
"      <i>",
"       In Vivo",
"      </i>",
"      Activity Against Respiratory Syncytial Virus,&rdquo;",
"      <i>",
"       J Infect Dis",
"      </i>",
"      , 1997, 176(5):1215-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40371/abstract-text/9359721/pubmed\" id=\"9359721\" target=\"_blank\">",
"        9359721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-Risk Infants. The IMpact-RSV Study Group,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1998, 102(3 Pt 1):531-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Subramanian KN, Weisman, LE, Rhodes T, et al, &ldquo;Safety, Tolerance and Pharmacokinetics of a Humanized Monoclonal Antibody to Respiratory Syncytial Virus in Premature Infants With Bronchopulmonary Dysplasia. MEDI-493 Study Group,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1998, 17(2):110-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40371/abstract-text/9493805/pubmed\" id=\"9493805\" target=\"_blank\">",
"        9493805",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9849 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-458F631DC3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40371=[""].join("\n");
var outline_f39_27_40371=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205781\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205782\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205800\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205792\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205766\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205753\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205768\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205767\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205806\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205798\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205771\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205757\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299812\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205762\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205764\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205774\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323593\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6729951\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205775\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F205770\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9849\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9849|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/0/40964?source=related_link\">",
"      Palivizumab: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_27_40372="Physostigmine: Drug information";
var content_f39_27_40372=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Physostigmine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"    see \"Physostigmine: Pediatric drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/60/33731?source=see_link\">",
"    see \"Physostigmine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F209713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acetylcholinesterase Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F209696\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Reversal of toxic anticholinergic effects: Note:",
"     </b>",
"     Administer slowly over 5 minutes to prevent respiratory distress and seizures. Continuous infusions of physostigmine should never be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.M., I.V.: 0.5-2 mg to start; repeat every 20 minutes until response occurs or adverse effect occurs; repeat 1-4 mg every 30-60 minutes as life-threatening symptoms recur",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F209709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=see_link\">",
"      see \"Physostigmine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Reversal of toxic anticholinergic effects",
"     </b>",
"     (reserve for life-threatening situations only):",
"     <b>",
"      Note:",
"     </b>",
"     Administer slowly over 5 minutes to prevent respiratory distress and seizures. Continuous infusions of physostigmine should never be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: 0.01-0.03 mg/kg/dose. May repeat after 5-10 minutes to a maximum total dose of 2 mg or until response occurs or adverse cholinergic effects occur.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F209697\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F209674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as salicylate: 1 mg/mL (2 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F209658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F209678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Injection: Infuse slowly I.V. over 5 minutes. Too rapid administration can cause bradycardia and hypersalivation leading to respiratory distress and seizures.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F209720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Ampicillin, epinephrine, famotidine, heparin, hydrocortisone sodium succinate, potassium chloride, tolazoline, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dobutamine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F209677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reverse toxic, life-threatening delirium caused by atropine, diphenhydramine, dimenhydrinate,",
"     <i>",
"      Atropa belladonna",
"     </i>",
"     (deadly nightshade), or jimson weed (",
"     <i>",
"      Datura",
"     </i>",
"     spp)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F209722\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Physostigmine may be confused with Prostigmin&reg;, pyridostigmine",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F209711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Asystole, bradycardia, palpitation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Hallucinations, nervousness, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, nausea, salivation, stomach pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urinary frequency",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Twitching",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Lacrimation, miosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Bronchospasm, dyspnea, pulmonary edema, respiratory paralysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F209681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to physostigmine or any component of the formulation; GI or GU obstruction; asthma; gangrene; diabetes, cardiovascular disease; any vagotonic state; coadministration of choline esters and depolarizing neuromuscular-blocking agents",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F209662\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmias: Patient must have a normal QRS interval, as measured by ECG, in order to receive; use caution in poisoning with agents known to prolong intraventricular conduction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cholinergic effects: Discontinue if symptoms of excess cholinergic activity (eg, salivation, sweating, urinary incontinence); overdosage may result in cholinergic crisis, which must be distinguished from myasthenic crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity/overdose reactions: Due to the possibility of hypersensitivity or overdose/cholinergic crisis, atropine should be readily available.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anticholinergic toxicity: Not intended as a first-line agent for anticholinergic toxicity.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Asthma: Use with caution in patients with asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease, including bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gangrene: Use with caution in patients with gangrene.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parkinson's disease: Not intended as a first-line agent for Parkinson's disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of seizure disorder.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Choline esters: Concomitant administration of choline esters is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depolarizing neuromuscular-blocking agents (ie, succinylcholine): Concomitant administration of depolarizing neuromuscular-blocking agents is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Products may contain benzyl alcohol which has been associated with \"gasping syndrome\" in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium bisulfate: Products may contain sodium bisulfate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; I.V. administration: Administer slowly over 5 minutes to prevent respiratory distress and seizures. Continuous infusions should never be used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tricyclic antidepressant (TCA) poisoning: Asystole and seizures have been reported when physostigmine was administered to TCA poisoned patients. Physostigmine is not recommended in patients with known or suspected TCA intoxication.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F209667\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F5951843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Herb/Nutraceutical: Ginkgo biloba may enhance the adverse/toxic effect of physostigmine; monitor.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13823806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F209700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323686\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Physostigmine Salicylate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1 mg/mL (2 mL): $5.64",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F209672\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, vital signs",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anticholium (AT, DE);",
"     </li>",
"     <li>",
"      Fisostigmina Salicilato (IT);",
"     </li>",
"     <li>",
"      Fisostin (IT);",
"     </li>",
"     <li>",
"      Physostigmine Salicylate (AU);",
"     </li>",
"     <li>",
"      Physostigminum Salicylicum (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F209661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits destruction of acetylcholine by acetylcholinesterase which facilitates transmission of impulses across myoneural junction and prolongs the central and peripheral effects of acetylcholine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F209680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: ~5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: I.M.: Readily absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Crosses blood-brain barrier readily and reverses both central and peripheral anticholinergic effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic and via hydrolysis by cholinesterases",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 15-40 minutes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Beaver KM and Gavin TJ, &ldquo;Treatment of Acute Anticholinergic Poisoning With Physostigmine,&rdquo;",
"      <i>",
"       Am J Emerg Med",
"      </i>",
"      , 1998, 16(5):505-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40372/abstract-text/9725967/pubmed\" id=\"9725967\" target=\"_blank\">",
"        9725967",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Burns MJ, Linden CH, Graudins A, et al, &ldquo;A Comparison of Physostigmine and Benzodiazepines for the Treatment of Anticholinergic Poisoning,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 2000, 35(4):374-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40372/abstract-text/10736125/pubmed\" id=\"10736125\" target=\"_blank\">",
"        10736125",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Caine ED, &ldquo;Anticholinergic Toxicity,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1979, 300(22):1278.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dysken MW and Janowsky DS, &ldquo;Dose-Related Physostigmine-Induced Ventricular Arrhythmia: Case Report,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1985, 46(10):446-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40372/abstract-text/4044537/pubmed\" id=\"4044537\" target=\"_blank\">",
"        4044537",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jenike MA, Albert MS, Heller H, et al, &ldquo;Oral Physostigmine Treatment for Patients With Presenile and Senile Dementia of the Alzheimer's Type: A Double-Blind Placebo-Controlled Trial,&rdquo;",
"      <i>",
"       J Clin Psychiatry",
"      </i>",
"      , 1990, 51(1):3-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lugassy D, Manno R, and Barrueto, Jr F, &ldquo;Diphenhydramine Overdose Reversed With Aggressive Physostigmine Administration,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2006, 44:715.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Donnell SJ, Burkhart KK, Donovan JW, et al, &ldquo;Safety of Physostigmine Use for Anticholinergic Toxicity,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2002, 40(5):684.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pentel P and Peterson CD, &ldquo;Asystole Complicating Physostigmine Treatment of Tricyclic Antidepressant Overdose,&rdquo;",
"      <i>",
"       Ann Emerg Med",
"      </i>",
"      , 1980, 9(11):588-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40372/abstract-text/7001962/pubmed\" id=\"7001962\" target=\"_blank\">",
"        7001962",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Theesen KA, Boyd JA, &ldquo;Dementia of the Alzheimer's Type: An Update,&rdquo;",
"      <i>",
"       Consult Pharm",
"      </i>",
"      , 1990, 5:535-40.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9770 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-9FDBE1AB85-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40372=[""].join("\n");
var outline_f39_27_40372=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209713\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209696\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209709\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209697\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209674\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209658\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209678\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209720\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209677\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209722\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209711\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209681\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209662\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299877\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209667\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5951843\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13823806\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209700\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323686\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209672\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038767\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209661\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F209680\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9770\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9770|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?32/60/33731?source=related_link\">",
"      Physostigmine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?8/52/9028?source=related_link\">",
"      Physostigmine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_27_40373="Normal lung High";
var content_f39_27_40373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F80140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F80140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Normal lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High power photomicrograph shows alveoli containing capillaries within a narrow interstitium. The alveoli are lined with thin, elongated type I pneumoctes (red arrow) and smaller numbers of cuboidal type II pneumocytes (green arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Weinberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40373=[""].join("\n");
var outline_f39_27_40373=null;
var title_f39_27_40374="MRI acute hamstring tear";
var content_f39_27_40374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85937&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 618px\">",
"   <div class=\"ttl\">",
"    MRI acute hamstring tear",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 598px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The T2 weighted images are from a 22-year-old professional baseball player who complained of acute pain in the posteromedial aspect of his knee. Image A is an axial section just above the knee joint and shows a fluid collection (red arrow) with an absent semitendinosus tendon. The region of interest is magnified in image B. Image C is taken slightly more cephalad and reveals the low intensity retracted and torn semitendinosus tendon (green arrow), detached from the tibial insertion. Image D is a magnified view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40374=[""].join("\n");
var outline_f39_27_40374=null;
var title_f39_27_40375="Confluent and reticulated papillomatosis - back";
var content_f39_27_40375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F67566%7EDERM%2F76296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F67566%7EDERM%2F76296&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confluent and reticulated papillomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticulated, hyperpigmented patches and thin plaques with fine scale are present on the upper back.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Confluent and reticulated papillomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFDAbADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDprmKe8Km5csFOQuMYqIRFXEUS7nPatm5jCpz29Kbp8H70yv8AeryWz6JRbJ7DSPkD3Dlm6gAcVppZ7ANpx6cVZtVyFAPHWrDjaoBwc++KRKumUAzowDAHHcVZilyMsOB14xmmFADt25z2pJCNmO4oTG1cfPdpHCWJHHYVymr6u7Dy4ss7fdUDk1p3aNITuOFPpVeCzEZBRMZ79zQ2VGKRjW+mSXDBr5mwTlol7+xNdHbWuFAVdi9AvtU0VqPl2ybT345rUitxgAsGz2PU/SkkVKV9WUo7cxr93GOw6ioLgblPzbT7DqfStp7Qrkyls9OO31qk8QJOc49M9abjYUZLcyow0w2IoWQdqtmNWCMCQf1qdokY4j+Vl5ViKrXMmVDngg5IBpbGmktiwZ8IBkg9qqzzDnJHQdao3F0I93OMc1garraRozl1VemSaLiVNt6GnqmoJEhGcvXHI17rWom10yBp5AfmboifU1f0jRtT8UzZjEtrp5OGmcYaQe3pXq/h/QrTSLFbS1jCIp5Pcn1NVGm5avYVStGirLVnJ+HPAiQXKXWrSC8uV5VBxGn0Hc16DaJsAAGNowB2piRhWI9DU5GFwBzW8YqOxwzqSqO8ncmDbeCeTT+p4GMetRoeBkZb3pX8wgFQMdxVGZE24D94c9agnkKOEVcJjGR2q9wwxxnuKo3u5XwhGe+cmolcqLuVpiMbmbj61XeQK4yrbW7k5pt45CiQKpJ7Dv71GjK8eWbcF7ZrC93Y2UdC/bOFgO488/nTfOTnt25qFFDsfmGTx8vSpHKBSnYEE+9WmyOVXHLh1xk7fyzUwxnnOOlRoN46YA96sDuo5NWiHoPVV28HJPA4qdRgYGN2M5xUabuCRgdKmTg98dq0JYSYOMdev1qldSMF2qfmfv6VdkwAc1lXkyQuHkJKAYJHbNJtJ6lwVwjiBGSeaGt1OcDOKhFwVzhTs9dtNmv4Y4y0r7QOvvVqUTp5H0MTWrUy3kSbRlE3NzjAJ4qI2eFVQvzE80lvcPc3kkkgwHPQ8nHb6VoOyjO7p1wK5JtSldG1mlZmQLeMzcjC1cWxQL9wc0tpHuO7PJAPPr1rWSJWVR1OKSVzOUtTGFnuIAXAx3o/s4EA4rooLZGYA8IelOktFj+gPXHWr9kZup0RzL6fx8pYfQ4xVSaG6hHyTsy/3X+YVvXWIyVwcH9KzZ1Mj5Xk/wAqzas7FxV1dnPzxzrN58MSRTjjcnRx6MKvW2oAx4uF8t+5IyPzqyERt4I6HqKkmsFcfMcH1HShXKY2G6ORgqyjuprStbsMRg9K5iW0aGXEJK8dR601by5t2JkXeoPJ6GmmiZRZ3sM24cnr6UkgDrjbXMWGtxMApfax7Nxit+C8DKAzjBrRSMXF3uV57cMc44PtWZcQAqQO/brW+ZI3XGSSemKpXMJJ6YXHWhoE31OSvrAyNjAzXPahod1CxlhxIvXb0P4V6BJGoByM/TvVO6HyDIwPQd6m5Td9i08YYjjIqSKIAkYAxjgU9MMRtHOevrVyGPaeCDU2uac1ie2QqACPmP6VJIBgDdn1NKgCocn5jTXIJAz+tU9EStSF1IPGMVXlXPIP4VOxJJBIxSRp0I796zZaKotskYzx0qUW47jK55X1qyAuRjIPX6VIAQwY4yaaRVxsUeUTB2/73Srlv5a53oqkc8nGf/rVVLDccdB60ZPpye/tWy02M3qWZ7jghOM/rWa0gJxnLDqaJ5CBjt1FZtzdKh3MwH41E5XKjElnucBuhxxWDqGpiPIBGPeszXtcSBG3SKobpjlj9BUXh/wnq/iuUS3W+y03OTu4eQf4VmrydkdKioR556Izn1G81a8a20m3e4n/ALw+4v1Ndt4b+HUaFLvX5vtV0MMIh/q0/Cu60TQLDRbNbawgSNAPvAct9TV4IEPoTW8aSjqziq4tz92Gi/ErwQxQRBIgAo6DFTKAQQKbINpyORTHYHDAcela3OZIjlBBJUgH1FIXJ5BBxUN1PFGu5ztI6CsufUpAD5KbB1y3U1Lkkawg5HRxsAoLfKPU1JHIuTt6euc5rjIb+WWR4mZpWf8AvGtGL9wAUUq+ME54NCd9UVLDtbnToo3Ek9TxxVO/couQB/Oq9jfiYeTKfn7Yp94nIGTtxzzRUehjGNpWZk3LqDl88dKz2YvKxRdoOM84qzdkO+W5A9qpNvS4YHG1QMfWuR7nTsaVjKScEYYcc1YZVYbuSc1lefLgeV1POcc1bt5S25S3zDGc9q0jIlrW5oJ9zg4qVHGTgnOOtVlJYAcAdqsxEBgP1rVMysXYVZyCzZ4q2I/7zCq0PUZqzknp0rVGU7kMylgeazbiIuHVwCp4rTkBznkiqc6nPHTNZTRpTdjnpkvLYN9lJmj6bWOGH0PesS+vPnCXIeNx/fXA/PpXatEw5yfy6VWmt0kXa6KwJ6MM1i4s7YV7dDkraSOQgIy5J4OetXnZ4/mI3DuKuzeHrJySsfln+9Gdv5VENCu4R/o14zKeNsybv1FCiVOrGWpSFzsOAQPStK0ui4BLDjtWXcwzWhZb223J/wA9Ihkfl1FRRSp9+1mEijtmjVE6SR1UE4GAx9qsvcg/KeSBXLQ6gM4kJBFXReKSCCeRVqbMnTL98olK8HOM8Dmst4xHGwjBBHX3qf7WNw+fH4047WwpOS3Wk9dRq6VjOjtZAinqxPHue9XxA2xQQCpGCR3q5GsauSB0GFPvUyzKucKvtkU4w1CVRmLdWbqoyoUfTn8ay7i0R0bCn/eHGTXUySIxAwuTyTnk1l3iKOC5XvjGaUooIyZylzYr1XJx2xyTVQvdWq4imkVT1XPAFdPMmOSWI7cY5rPliByhHToM1mXuR6brMykLKxIrcS/EqK3OTwawPso6DHFWocqcegpqTREoo1XcEZ5xVK5+bjByKVGOAQxFMfJb7wOe9FyErGlEpUDn5u3tV+EFfvd6rwJtO4+uOuMVd5z8rZz6jpVbMHqMckuB+hqpM4V+WwM1efCHGDmsi9CseHJwelKRrTV3qWRL5kilSfr2q0ik9OBUNmiKBu5IPFXjtDcnBpKJUmk9CJeCeefTFKWA69+M0jcDIxx2FR+YCRnt2q1oS3cmXGMZOO5qOabaMl8frUF1cxQRMznA9TXnvirxReJFIum2sspXvg4ocioUpSOm1jWYbVGBfHcZNcXJqt9rV19l0WFriU8bsfKvv71J4O8G6n4pKXusSmO0PPzcA/QV6/pNroPh2BYrExKQOdo3O31xRGm5avRFSr06PuxXMzmfB/w4jtJo7/Xn+13p5w/KpXpEUKQoFQbQOMYrFm8QJwLe1lb3bCg1Um8QXxBWOGGIHoTlq2jKnDRHFUjXru8jpy3YY9aoXd5bwMDLKoPpnJrmJbq9ugfNuH2+ifKKSOEK2SePU1Mqt9kVDC23ZqzaxHnEEMkg9TwKoTaleupCpHGO3GTUqxoPlPcVFMFQYYgHPX1+lQ5M0UIroUTK+4vMdxP8ROaguZ8wHBp2oTbY228Y6/WsWOfdDICT8pyKzvc3irK5Y026MGqqTyHBXP610M16hQNnj2rhLuc+VuHyuOQRxzUkmqxiz3XM5iQADav3mPpWlOpZWZc6fM7nQprGNXsoEIM0swVUB5xnk/TFdfeZi3EnJ7AGuT8FaQIw2rXNt5NxOMQq5yY4x6+5610lyQSrb8/3qTvZtnJUs5+6UWbc4ypJPFRumZGWRcN3I5OKmdwzEpjA6kd6ZcMXZyRg4GPXNZjEt5okO8AsCCM4pEwzM4J5PNV42MMY8xQTg4Hv6VJayoxOMYIyMdqcX0JkupoRqXGM1aiRxgkAgVSikTgA/N2FXreQNn5unB+taxsZvUvw5I6/pVtDxyOapwEtyDkVbGegNbIykMd1Kt1JqNl35yDzU5j4OB19aZ5JUDjn0pSTFForMmcqppPJB+nrVlVy5+vNKUzxjip5bl85TMADjA4FTqmB6A8VLsOeTTlRSQf0qlETmVJYicfKCD3xWVfeG7K6y8kQSQfxRnYT+IrocZ+lHl7sg9KHC+4Ko0cDeeFbpAWtLwuAeEnH/swrLudO1WzVmltZCn96P5x+nNeoiIDtnFKEwMHHNL2KZrHEyXmeOrqbRylJVYMOxGD+tadnqqvwX68c9a73WNLtNRhZbqBJAOhI+YfQ1wer+Ep7cNNpzecg6RSHDD6HvWcqTjqjeNaE9HoaEN7zgnIPFWhcfKPmrzz+1pLK58m5LpIOscvyn/69bVnrMUuBu5HYVlcp03udO0h5JJGRnNQvLkkDPPJNUo7tXHysD7ZqxG465zTvchKxFMQ4+7z05qBkGR+varbKGwc/hSCEFhmlYpMreWNvHWm4ZV5OOO1WtrY+UcUvlq+4/dx3osFyi0h2nHccVWaRzjaeT1rQlTyw2cEetYt9MURmTjB7UWBeR2IjAPOTnqKmXhPkH65pqbTGADyTzzTSDn5c4z1zVSMiNpWbIJxz+dU2jYy5fO0npVqRTuOeGx1FLgKQo59eanVm8ZWH20ZUAE8jt2FWQeOOvrUSdAMdBz9acd2DuNWTuOLZ6DAphiJwV7frRxs4PGfWlhkwSQfmHQYoD0GvZrKAZMYqOTTrdVwEAU1ZMr5wMe9M8zP3uTU3RSXchSyhiQBEG0cAZOKmRVXHAA+lNfcR64Pf0qZMBSwxgdR60LUew7YCOBzVaY9TwMCrMx8lM5JGcjHXHvWTeXDJMoByp6GiWg46j7edjyOByKmhmOXjOAw5HvWbZEbnDuV2tlQe+ac7jzgSfWktipxRq/aF8sYIyORVO5uMj5COKoTT7ThT0FUprrbEx3AU7kKIX1x94bjjvzXPz6gIVYAjJ6Cq+r6ssaO0jBVHUk8VkaJpup+Krsx2SNFag/PIeuKS8jZJJXb0JrvV90ojhVpZzwqIMnP9K7XwN4Pnmni1TxCOQQ0NsRwp9TXSeEvBenaIiukQmuO8knJ/CuseMKOB9OK1jStrI46uL5vcp/eU7vAOMADr+FUJmILFifnG0cdKdeSZP3iMdjUEn77yhEQMDnd0qZu7IhGyGk/II1Ue+e9I0bTRtlQFxwasW9ksx278BTwPWrcii3hYKoKj0FJLuVJpaGG42zxvJwV+Ur7GoLJ8PLjHyt09qdfvI7btmFHXjpVFZMXgJbac4OO9QnqOS0NqJwtwGK8MK0oMD5gOp5FZKOCFJ+lXUm/fBR908nmtVZGRt2x6AcDrVpX2tjGfes6BsrkH5u9SlZDHw3PYVqpW2M3G5rKRtBPemt8oJOAB1NULWWQIRP8AeHpTbp2nJQjP+z2FbRfMrmXJaVh8l9ArYMifWpUuYCMrMhI9DVHyCUCAAfhWVq8BgiDsBjOOBjFZy5oq50RpRk7XOnPzZII/CkXAXA61xduJ1XMc0oA7KxwKtxajeQnmYsOnzKDWarJhLDtaJnVIc1KjAZA6etcymq3vRViYH1GKmGpXp/hjz9K0VWJDoSZvtj8jTCCTxkc9RWEdQvQPmVD+FRnWLpQf3EbfiaPaxEqMjckzkkZ49KpTjCENnPXp2rLbxFMnDWf5PxVGbxOeB9kYZ77uKl1IlqnLaxl+LdNtdRtzHcQxyj1ZeR9K8e8S6VeaNK0mhzTNCi7milOcfQ17BdvJesWXCE85zmsm60Npt2ZFwV2nK5zXPzXkdS5oxtFnluneMb+wKrqFtNAx7sMqa7/RvFFvcxpu3KWHBI+U/jUF94RupMrHPCUP8MqZ+laPh7w7BpsPkyxCRc5UdR7/AP6qqST+EpTdrTR0FpNHMoYPnPvVwgAY7fSmWenWcYzGmwHsOlaCwIvCkYHekZtozwrBeSfyqJmUJgnnk89KuXIEak5JHesy4G/oc7T+YxRYQzcTb4brkgYPWsW9GeDx34rV/j2j7o5wOxqleJ8xwQORSZUWdGHKyA5DD29atRyDI/XHWqiLjaQalIwcgAMepq2RZMkkb7zH5SfWoTkEspGDyc06Vg8R5yKiAzkPgjPHPSkUifzSEAx97r7U/wA0EkDIA4BqnJJsXDjkZOQaqi4LSBUPJGDUtlRVzSeTcoIP4UkRwPfrUEeQeOVxiplOBjI4pMtKxOGPQnrTS4OVJ9vSoC2455+opWPXHQfzosF7MsiQeWclcLzk05ZVJwMAEYz6Gs9p3BPzdOMVW+0lOv3h36DFVdhualxMuXJA3cA+9VZtjKGAAIOQKzHug25t2T6iqc9+EQ5bA+tJu5S8i/dOOSDyOR+dVZrsRsckE9PwrC1DXI0UhmBx3NcpqfitHYi3/esegXp+dK9jSMXI6+71ZVYndyOOD1rmNW8TJkxQZll6bUPH4mqOlaLrfiScKitHETzgYFeneGvhxZaYUlvcTSjqvUVUYuWxFSpTpbvU4Hwz4U1PxHdxz6gGjtc9MYAFe26TY2+j2kdraQhIx1K9T9atxRJCgWNFRQMAYp+DtG3HBrWMOXY4qlV1d9izE5CjceT0xRE7sT5mcAVCSSQoyMH0qctke/eqMinqEW6F3CrnGAfSs23iYIH25LEcEfrWzcjdGUGM4z9KpSgxW3y/eIIrGa1NoSurDTHKWBQhSR/D2q/boAACwYNwQai04hgAx+UcVcjjgixIGzTiupM5a2M/ULYFJDtwx6gdK4rUYWinJJxg7hj/AD0NeiXrBoyRyvrXGatas4x/EpO0g1MlZl03pqNs7vzItoHzAdas2rySsc4HbOazbRZIJdpOVIxx0rTtsK7kKB+PWlYV0jet5CicfeAyau27EY3YwelZlnNkLngj0NXomAlJJyPSt0zJl2ZCIXZclgMgmsa3vyly5JHJzWx5uUGR8pHeuLv0tdL1Lyr9nSGQ5hl3YBz/AA56ZHvWnPy7FUY3lqdjBqUfG9VYVS1+6tHsXBOCSAB+Nc/51ugLR3LOvpgZrH1C+aedCcFEB2gevvROvaNjeOGXNdaHdB7EwKLc4bGScdaybny1cDIJyBj+Zrn4dQKQBdzZ+vAp0eoZLZIZscfWuWU01sUqTi9GdLpzpKMlRwa2FtkkHHBx1rlLCbyYlXI4Fa0OosgA3YHrVU2ramdSLvoaxscrletUbmAKMYwc80+PVAq4PHGM+tQ3F4JUwDn61rLla0MoqaepnTxjHTg1mahGmyRRyBnFWb65w3HQcVjSb/LV2Jw2f51g2tjojFtXNCHbsyOfWpSqiPd69qybGciFyc5LEVqxkFlCtiQj/gIH+NTFcxU24siMnUAHK8moWc85IqZvlX5uUU/QE/1qlMflPGcnBx2pNMpNMsxXLAZzyelTpeEYyQO31rK3lQFxz709ZArLnBY0ldCaRpXE28BtwBA59xVUuGGT6Z46U0HcPXINRknbxxjmquRYRgseWHfjFULogBu+OelWJpgq+5IBrMnkJyw78U9xJM7BZAWweOMZxSFj0zyOmajjjZfvEhe2ac2M4BGW9e1aPUzWgiFn3Flx7CpGHqTjHU0iHAB9Bjmhs47k56Ukh8xVlhLHoQME8elQwRYkwwPGSDWm6rsGTgnrjioiB/D26VElc1U9B6AgDGRSyABxgjPtTVJyOccUMM5APOM1QlJshd8cL1x+FQTzeWuTndUjAj73FYGtXrRZW2RpZT0VRmkWo3dizcX4j4ZgM9ayLzXreLJaUH8a4nxJNrfmRp5ckIkbaMCreieC73UMSXMgRD1Z2/xoSb2NWoQ+JlnUPF0anbBl/ZRWG+rarqLYtoWVT3PJr0/SPh9pUQU3VzCz+gPWu0sNC0izi/cRQkj+IkEmqVOT3JeKpx+FXPC9L8E6zrDbrhZdh9TwK9F8O/DOy0/bLe4kc9FFd400S7fLdVA42g8U83EJGQ67qpQitTGpXqT0WiG2lpbWUQihRET2HWh5CrhV5FRfa0GdpB9aryzM74ixg8Fu4+lNy0MY07luaYcIT/8ArqTzBjjn3rMmK4yxJf3NRqxLhUJ3exouzX2F1c2o7gP8oJz0wafv2ng/N+lZ0VpKk0bSH5W9+c+hrQKDf8ygE96fvdTnkknYoS3Wxm3bhx0B5Y022ZJWXnqCPzqS8RWIIGW6bvT6VPawqijc45wKytqaJq1yWyQrJtI+Rhj6VYnCxrsjjLNnjHamxSrvwBuC9AKswyh2DY2n071okrWMpt3uZ7HyLdxMCWPUDtWLcwPLhlwFJ5rpL9fk6bvUnqOaw7gyRTDG4KvOPUVlONmaQd0YOqu8D/KpLKwJ9vf6U5ZxG8bn7jdT6VLqxE8jNDkoRyT61npIjRbHPbIx3p7q5T8zaF8Fyq4yeBjrWhZzjICsCVGAc9a5uIAwh8g7eas2lxiVXbdzxijm7ismdfDISwBB/OrF1ZW2o2xt7y3SWFhyrDINZVtMrKrKTjvWpFMox1K9q3i7mLOQ1P4c2x3No+o3Nmx6Ju3p+Rrl7zwj4ps8+X9nvkHXYdjV7GGQjIalXb8oHSk6UXsaRxdWOjd/U8HeTVrPK3ulX0frhdw/Skg1y3SSNWLRyscASKV/OveGVSCMDn1qld6VZXaFLi2glDDkOgNJ0PMtYvvE8st9W4Bcg5/KtSDU0I4cZ/lWvqXw806VWbTJZrOTrhDuT8jXHan4P8RWRdrdYryNT1jbY35Gs3SlHoaKtTnomdGL0OBtYUpuuQScnsfavOptYutOfy9QtbmAg8l0OB+Iqa38V2kmF+0LuHTJwf1qC/ZvdHcSy73y3PPApCmbUP8AdIBx6Zrn7fV4ZcFZFPHrV1dUiKjJGB1HrSsD0NeO2SKGLgZHXNLNLgEgDZWWNTDsDuwP1qGW/HZs+tUiW+5oSzZ4PzHt6Cqhm3NxyAc1Sa9Gcg1H9oBI5OOposTzF8SHHI/Kp0OFzzjHas/7TkHripYpmI7j3NKwKp3NMsFjzyCSBTSfmPTpiqwlJODxTvMDHgfLnvSsNMhuwAGyenIasuUgz4znnj61pXPzgL/CPWs4RMW4z2PHU0DTR2itj7rDI6g0+MgsRxyfpVJZAvXPJ4NSNLjPOfYdq0TsY8pYdgASMY9qj4HJOQailmQLgDnHb0pFddoyRgU7gk0PZxx24pBJgkZ9jVeWTKfPjNUXum3OOgH3vapuUo3NZXyBg854qxCRkYA57ntWHFcgMNw/Grcd18vB6UXsaJGwkSzMVfoeScVaisrSPO2JeQMHHNZFvdAcZ54PFaEE6kswPXjnrS5iuW+5ZOn2z8tFGxzxuXNSLYRDPyL09BTYZuM7hj3qcXax4zgiqVnuTJPoVZrKJnCmMEn0FRS6fEuUMfpkY7Vbl1OOL5sDcfeqh1dGaZwBgHA/Ch8q6jipPoM+yheAuPSpFgzgYANRHUVIA4yBj8Kmju14IIxgVOhbTGvAAOg4qBmWDJJ564Jp1zqChHyw9q5rVNTUyDnBxxzQ2ug4xb3NDU9RG0gEY9qt+H7mIWSzkgyPk5PauB1HUcr97GRgVQbxELOzS1jkklvGPywQjJ/E9qdOfLK7NKkPdSR6FrfiGOzUTO4+8FA/vEnAFdVuV0j5wHA6HBIryvw74UuLm8i1HxBKWmUh0tw2QnoK9Qt9rAbgGIGOO30rRSbu2cVbluuUm2bxv3ZXpnH6YpJSI4SrZC1bQEgcYx90mq92ibOcHPpUsyUtbEdo6q5x6dakFwqn5wS3sMVnxvh1GQPUg9avkIQrEgHpz1pLYclqM+1SMGJjI+tVRK88h449a0nKNGVftjJHQ+1ULmUwKqRDgnn/AAokrbscXfoVJoIjFJEAFJ/U+tcner9juiTwCcnI4z613UlqLhUcgh+oxXM67bMZSs0e4YwOeKm9txxd9DHlnETKRny39+M1etJcrjIBJ4x2ql5DRoqSgtHjg0MvkKGjYgdx6U5RBPobtnLPFJgn5T1K81r22pkFVf06+lc5pN4HcpI2MjAI/rV19okAU8k9PWhNpXQNXep1kd6u3nuKmhug3H65rmYZnVSSTx0zUyX2yVHGB2q+d9SORdDphLyBUiuCeTkGskXSAks455605LgMpXcBj0NapmbiaTThcDpzj0qF5lIYk59sZqg0oI5bIz0NR/alIIz0p8wclwuora4Q/aIo5UPUMAa5PWfBWhX7OWtVjbH8AxXSTXIY4UAHtUEsn7vOeMUpSVtSoRlH4dDy3Uvhm8Pz6bdOncDcRXN32i+JNOY/vJHT/aGa9uabC4ckAc1WM6zR4kAA/XFYy5eh1Qq1V8Wp4V/aOtwcSR7vXIIp66/eqcvCfwavZL2y0+7Q5tlPHZcVzt34XgmZvJQrn+9g1HLbqaqqpbxOCTxQinMqSr+GRVu08U2c52xy/OOzAg10v/CuYbr/AFsxH+4oFSWnwm0+GbzftVyWPGPlx/KnYhyi3sZ9vqsLYy9attexMo2sHJ7ZratvAmlWwy5lc+hIxWjFoOn2q7ooowev3aauiJ8m8TFgbeDwxHSpW+5tIx/M1fuGjX7qpgdCBjFUJ3UgBc5Jp6E2ZE2MnjjPWq7sAvJwf5UTyMAR0xzis64mLE9cDoDSsiXc60swXC8juMU4EqMA5+lVjPzgNx+VBlPcAMOuKRqixFkMzAf/AFqlwGXLde3FVDJzjPUUvmkAZbI6UgsPl+ZWGOnpWZcxyBiwG0GtATArkHn0qCeQEbgec469KBrQpxncPvf/AK6kVnVTz1qOaVQ2BVaS42/SgaNGC4IOScHpVyO8x689RXOvfAHimG+HUnkds0rFpo6v7fsAIJwfSlOosevBB4xzXKm/Qrgtx9aQ3yhfv7SfTtRY0SRv3V5u24OSSM5qBrorBt3Dc78f1rDl1SMLtLCs251uGCQSSSqFUdScUJA2dgb0B85AGOlN/tPsWA4rzK98YwB28ti+egUVkXHiq7myIYsDtuOf5U1EXPHqz1DUdcSPqxPoK5DVvFMMUj4fc3QKvJrlFk1LUXAdnweMAYFddonglhEk92oIY8A0KJLrKK0MOGXVtfuBDaI8aseo64+tem+DvCdvoYE8mJ75xyW5x+PrWpo1la2Uax20apjjP9Sa24LYl96su4+vUCmlcwnUctxY18tgznjq3PU1tWRiiQORtZuevArPMTFESMAgnk1aaJmQLGOnGT3qldGbs9DSW4Dodpzkckd6yL9yxZULBehGOKnVGtky7Z4yTVC6mVSS6ZyeSD1FTJ3CEbPQfapwNxUsPfpVss8qbT8qA4GP51mRSEAGIhW7hh3q6l80MW0qGbPTtRFrZhJO4s0nkoFQt6nPeq3nKWJnYg9hije00wMinHQe1NMAZzgHb656VLLS7l+3u3dkVQNoHX0q1IsU6EMufU4rPsYfLU8c55PStRVAU4B7ZHrVw21MppJ6HP6vZp5Z2HafTGK5W5mVA6k7scED0r0C7iV42Hc9zXCa1pUsczOsZ3ZyGHemJGfBc7HJVhgHIrXivFZPmz69a5uVAeYgFYfeXFTWkqyHaeHHbpUOLWxpodVb3jOCqnIHWrMUhkbjg9sisOz3pJtZgQO/Q4rWt8oRg5APY0JN7ibS2LsxkTaM89eatQTZjAHBPWq7SK8ZZlBxT7SNrg4hGAOdwq7O+goPmJZbjGBnp61XFyCBkjd3rR/s6KMbpQHPqx/pSwW5aUqkSgZxkDihqXU3UUlcyRO7OCkbN2ztNO8u7kxtjEa/7RrceIxqd2AOp47U2LyfMVXkBc8cHilZsV4pXMmHSn3l5pHbd2BwKtpYxIMpH9STW9FbQhcGUZqCZ7ePOMY9BT9n3M/a3eiMc2wwxI+6cU1UjR9mcnGevak1PUIUSQITgtzg1yNzrbLNHKpxtYo351m0kbRTkrnaJjPyhcgd+M1G7lfSsmDUvMjUs3fIp8+oKqYIzVXuJRsWppSR2qhPKwxyCOvWq0t7g8tyTgVQmviWYHBGaQ7E11IpByBk981QaQnlhgVDPeB1+nX396oy3BC53HHriqWgmXLwSC3jZ8BJDhCTjPv9KxdQlZbwwGPy5UADLuzn3z3z1rSONRt4hJBeExKY/MhTcrDrjnoaz513XvzwSQbEWJUkPzBQOM+5qjNPU3luAzHf9CKRrrDEDAA9TWDJfqOV+97GqkuqKCdxzTSuFzpzeZBJzTZNR2gZbHY8VyMurlVwpBB561RudY3Z+c596Vh83c7VtSCnhuD3NV31RSDh8Z9a4GbVpNrc8DuTgCs2bXlXIEjOfRR/Wly30Qc6W56Q2qKRsYjOOuao3GqIF+UjivOn1u5c/u0xnjLHNRD7deNgtIQeo6Cq5LC9onsdbe+JrdGKmUbu4XmsebxOx4hSQj1YgVZ0nwjNdEHYzZ644ArqLHwH5agzNGmfxp8pLq2OJHiG9blUXP1zQda1Nx8m0Z/2Sa9KtfCFonJm3f7qirP/AAilor48xsY9BSsrXGqvmeU+bql023fJ+AxV+x8LX184372J7csa9WsdA0yBxuQyt155FbNxPFbxKkKhQOyjFHKHO2/dPN7L4euFHn7FP+22f0rWg8F2sBw0oIHUKAK3mvCzkyPke9DqZcFWCj0qHrsVeS3ZFYaNZ2xDRQ5YYwzc4q5dwTtIER8KOoHQCpPtUcEOCApA6k9aqW00t7KEbAUnjbmlykpvc0rEEMi4yRz04H1rVS6VMBdrtnnPIrPtbcq7wjd5QOTnjNbulWEcceY2DHuxHSiPZBOz3L9sT5Sn+JuSxGPyp8soiydpOTxmqvnSrNggEZ+9nmo7m5OcKck9Tiq5kEYF9WSf5ZAB34p0kEYV9qqRj0rJt5SNu8Etg/lWnaSCRTgc+maSdwlHlehnuoR8lfl46CkWJJBnBBz1Bq3LDG0mZXH9DUWzYCT8w+vWlbUaaJbe3GAQ7E9DnpVtQqJ8vI68DFULabDctgZ5A7VeQqFzISd3TH9apCaaIVG1zuwc89amRW2/KpZu1K7qOVGMD8KZ9p2JgDIPoelMiWuxWnWcMpwAO4zWTq9vOAsgy6Z5A7VrXMpLAJ0IzRGS4xJ+ZGKlu+hSVkcPeWaz/MU2MejY4Nc5qytbYJyGHf1r1Se3iKkbcA8E4zXN6ho8dwWA4B/hPNO9tw31ONt9WkYKrYOBwe9b+m3r7MOwIzwawdW8PT2rF4iT745qhBqU9mxjuF4/vDnFGwNcy0O+a9ZYy2cn2rqPC13bPp370ojs3Jxk15THqkgbqXQjqKc3id9JwzIXtX5yvVGqoys7jjDoz2ySSwZCGy2PTiuU1XU/7PvCltKwik5Az90964qDxrZ3Ay9/FDxyCDms7W/EunTOhgvUfaOWY96qpLmjobU4JSs3dHdTa2zqwLkjHr1qCDVgJ1LOCdvNeZTeKLdVCrcIfxqt/wAJRCSc3cQJ9M1z8smaPkS0PZTrIYZ3cHpzVaXWOCQ4wO1ePS+L44x8lyj/AEBrOuPGTknaXP0Wq5ZGS5F1PWL3VRIXXd94A4zWNaATfaCQxG7NeajxOxk3SGXH06Vs2PjW1t4nDFiT6qaOR9h+0itmejpcCFOW+bGagl1TKHDEkD1rzW68brIxKZC/Q1mXHi52zsJz9Kapt9BOtFbs9MvNUVU+9k/WqD6wuCdw7YBry+48QySNyT69Kh/t5yfmd/yq/ZS7GcsTDoz09tSDH5W5+vFK1+pHzMCK80j18A/e/wC+hWhZeIWhnSaGRRInKsPX6UcjRCrJ7M9H+121xbWayak0EkcZQxhG2jknPHeq01xHHKRFOJ1wD5hBB+mDzxXMJ4z1Dr9sIP8AuD/Cql1r0t5cGa4l8yRgAWYAdPpTaBTtuV7zWjuJDbfxrObWWZuGfj0Fc3fX6pfuswJAxhh2q1bTwyjEcik/XmtlTsrs5/bqUnFPY121ZjniQ/XimvqTtjYig+p5ql5ePXFTQwlmwKnlSK5mNkaW4YeY5c+nb8qu22mSyKC/yrVi0hSA5YZaum0uGJmDTn5ewFF+iEUNJ0FpXURxF2HdugrudH0G3hw92QSOdg4FUI78QgCJdqgemMVaTW8oeMt396hOw2pPY6VLmCNAqAIo6AVEbs5wxzXLHVB5ozyasnVgBgqWHrSbuUocqN0XXlgZxgHHSp/tyvwcA+tc5/akbKCQBTW1GPkhV96mxol5G3LdPyUIP0NRx3POXfB9OvFYkmo545J7ACpLBbiZifKOD3oskXqbUksbDcqF29WPFCvcuuBsHoqjFSWWmzSYLAgH0FbtrpaQ/e6dzmldIFrucyI5pptr5Iz6V1ukWH2eFRuUseSfSrVtbW0aBgqk5wOP1qWJHWSRm5B4C4qGxy1VkLAWZijx4Hqe9WY4wJSyueDnANJKd8amME9wBUlgFU7W++BjmlfUWyJHDysNqgA9zxUlvEisAACwHb9aLsSgEwr09agtmQzkyEA9wD3o2YbomzCpC+Vls4FPJETk5K/yq0oRwXUAEeveoJyGTfgHjpVvQlO7KkpQycv93nGDg5qSQILdnXLAjsKy5SzhwQcA8YHT3oS9KYiBBdgcE/1qOY0sW4ZDK5G0KB97AqaVpUXBPPfjkCptIbzGICfMByat3oQ8KCWx1HeqtdXFze9YoiTMe49/WrdsBy7KMc8j1qqsgBbKj0JHartvtLY4GRyD3FCJlsRCWIzFcZxxnFObaSCDlfUikuIVVvlGT/So1ugMrKCCOKd7CtfYeUUqe+ePpVZrOFiflKkHJqwLiBmOxuTUbS4f7pVSMDmndCsyhdWKMrKxUg1zOseHLeYNiMH3FdpJzns9VZEAUL+Zo2CN0eQajoN9ZlzbHev9zoRXN3skmDFcIyn0avdbq2V4+QM+tclrmmwXAaK4txtIwCOtK/c0TZ5VHZxuTvB9sU6TRlkH7tGJrc1DwteQkyadIHTsrdRWZJd3+mti+tZFXpuA4pobtcii8KSSjd5ZH1NXIfBsZU79o9+uKlstft3ChZee4Nadtqisfv8ABpktPoZ8fgq3LfNKmB6LUy+C7bd8siAepXrWol5EWznJ+tOfUQjjqFHrQZPmKa+D7PHMin/gIqhf+B7dxvgkRvqMVsnUiGLIRk96VtRBA+cfjxiq5ieWXc42XwXKqkrHu+jdKz5vCsked0Ep/Gu/e+DALyATxjvSm5GBluR71Sd9iG7bnmj+HmwSIpQaoS6OwJxHIMdzXpN3e4csMbcd6zLi6Vx2C+lUm0S7djzuawZMgN09RVKW3eMnI/Ku51Ca1aMiRVye44xXKXexS21jg9Mc/hWsZMwnFENnpupXD2wt1ZVuQ5jd3CrtT7zZ7AetP1a6uLadbW4srSCWJV+eH/loMcNuzhg3XNbEE1xN4bluE09srbGzN2ZgqmDfltinktzgkcVzvim6Yao0Ulq1mbaJLeK3Zt5VFHy5bvnrmtlHmOWU5Q2Zlauc6jNjscfpVQE5B5yKkupPMuZn/vOTUVbxVkkznqS5pNl221G5hwFkLL/dfkVq2+tSDmSFW+hxWJFGXYYBrTt7J3A3DFZVIw6mtGdV6RZsR6+oI3QPz6NWhB4nhVQDBNn6isVbBQAcn6Vs6b4WubuISRxOUPO48VyyVNHfH2zLS+JLaQcmZPquRU8evQZ4lOc+hq5YeA55Yy7si84x1NdDpfgG2j5uCznPQDFZPk6HTFzW7Rzi6skp/ducnvirVtLc3DYt4Z39wK9E07wzZ2qkRW0efdcnFawsNke2JdvXoMVm2jWLPPLbQ9VnwJAqL6E81tWXhabzAZH6+ldZb2c0RLyyfKvQYq5bndIqLGRnv6UuYuzMrT/D0MAyVDOOcnmtu106KJgQijPIzVuQQw8v9KjaRZFVkRsDpUOQRVy3F5SjAK5HXFTyeSxXeh3Dpx/SqlgCswXZndzjFb/kJsDMDv8AWhaoJWiZrsMoqoAMce1VIomjdpJAw9Oc/pVye3KSM29hn8qcF3fKoOfU1DetiloNtzuON4XtwORTLiVY5CB1z97FRXEbQSZlyATx9KWMQyjcxLEjqO9K/QVtbifbJJeHPsP6URBvOPI3dMAcUqRqhBG5cjmo52kKALz26VOpSsbVrOUtyH7dMVXubkHIOAO3Y1DBKyKFZdzgbjxVWTMoG8LtIyea0b0ISSGyOpBwxYdqY8MfBQAYPJqeKJQFUPwBgCrUNtE0ZYnj3H60h3sSaW5CEx8EHrnrViQMWLNhgeuKakkUCHawC9qRplkB2ZUHuapPQnrcRwWjZRk59BVWC4eORtsZCp1JBNTLcvCgIwc9c04Puhyed3T0zRvsFxtzdyNHiMjkZBqsqtKFLffB+bPXP+FKYbkzqFGFB+7ViSMojdRzmpepV0kMtbcu3zYBzziprpzAMeWSCcUlmJllK5JU881avX8uP7m709qpJWIbd9StGGdgwbCjjmqV+0it7CtS2ljdAp4zTbq3SSM/MPbFXuhKVpamVBJ9oTIXBHqMVBd2fmY3deuQKv8A2VrcFhjgcgGqNzcOx/d8EHBFTstStW/dMZ9PdXynTvnvVW5sY51KNGpH90jNdBDIJcrL8r9veorq1ZhlTtb19aENvXU831jwPpt5vZEME395On5Vx9/4Q1rTyz2Fy00Y5A6/pXt0ludmGXnHWqEsG0lRgN6U1JoHrseESanq1gxjurNWIOSQCpNLH4qXP76OaI9c43Yr2m706C5UrNAsg/2lBrktU8D6dcliiGFv9nkD8K1UovdGb5ujOMi8TW46XgyTkh1wKsJr8TNn7TA2ec5wKj1L4fXMZJtmSX2U4NcvqHhm8tiwmt3XHqtWlB9TKTqrZJnVvrrMpVZouT0DfyqtJrBGMyAjqPmrh5NMlXjBxVWS0lAxtPtWqpRf2jmliJx3gdpdas7HJlRR7tWdNrCrnNwhP+9XKvbyd1P41C0TBsbT+ArWNCPc55Yyf8tjbuNUibJaZn9gKz5tRU/6tD/wI1SZSOxpuDzwa2jTijCWInLc6+yv7XUNM8u+mubSUWLWQ2WzSRsu/cHGPxBHeuf8R3Ud1fxmCOaO3hgjt4jMuHdUGNx+v6Vv297qE2i6ZDoutx2Qtoys0EtyIWV9xO7n7y4xjHT0pfEuqxX+magJtQjvSGgSDnJMyj97Ig6qh/U1S0ZL1Rxp60q9aSnxDMqj3qzI2dNhCqp7mui02xmu3CxLn37VU0Kwa6JYjCKefpXp9hBDYWsb26Aqa82tU1sexQppRRFofhiCKMPd/O5HQ111tBHCgSNRtXgelVIDvBw42OuAPQ1dtlEUCrk5B/Cudu7N+hZiVVO44C1fixgE9O1YzuZblICCAeuK2SGEeIyDgcA1I+UsGbYoVMbj2xVuFTtG7k9KxY5ibgK/3geucVpyyNGoCEYPNRc15bFxmRWIdlBNNaIwMHHzuegPSqQQSSqzEnHJ9zWtaW7lw7HIxkCpu5Fr3RbayMqF5U3sO2cVba1cJhQqjvgUiXi7v3Y6d6sR3O8HcPmPemuUn3upWjgkQqQPoS1XIllZ9uTkVWYSFyMEnt7VesQySfOCG/vZ6URXQcn1J/seU+ds+mKpyB4nClcc/nW2owMn5Se/rUF2i7d20Zx1rSUNNDOM+5lSyh1zk9cH/Cqpi8uUbkUZ6kdKmOPNHy/uwfu56VqxJG8XzDIPWs+XmNX7pjMCWwQAM5BHcU5kBU5zycZxWwIYVKqq4OOhqFkRH5B2g85ocQUrlOGKQMSCPmGCTSyQBAvmNkY7VpFFI3R7cE+lVbi2eZgM4x60+UnmuzLuC3JABzwasRRkxgDcvHXNTpZkuMk7lq8qnPzAAYxxRYG7GGLN1I3ncrdO1X0tg0BOTnGMelWWQMVDEEetMj3RkgnIPIz1o5SbsovCwiwMbhyCaSMM3zKxJ9MfrViaaSSMpwoJ5XHNPt4I0UsxYseAScYxTSHccJiuPlGT1Pap2WJztJB4yaqwESBwfu54NaKRKEXb96qsS2kZ82In+VWyP1p8lyjR7nwD1xV9wvG8Y98VUezVmYDaV9+tDTWw009yrAnncphQDwfWrDWm9fmfkdMDip4bdYDtU9Dx9KnZ8OBn86cY6akylroVDGgUZ9OaqvbQkFtvPoK0HIYkg+31qnI6SEoG6dsdKbSJuzG1CFVcMF4I6+lSxriNc5q265yp59Khbg5BzxU8utxuV1YqSqpb6VRmt43cuc7uvFaMqZ6cVWmUfU/zpNFRdikyqc4NVZokJ9B+tW3Qk5A6VWl6gAdevtQDKEltGRz196pz2qHBK5X860bmMvEUBxnvWdFDJDuD/d6imJMxNT0O1u1J8mM574FYEvgyyky0m6Ngf4Txiu1Py9/lPtVPUl3wsEbBHPpVX6ib6HA3Pg2PJ8m4H0asu48JXSAlfLb3FdhE5+04Y9aszu0qrsyiqeQe9ONRkyhbc8xutAuo+Gt847is240+WMDdAeuOleo3s4iKAg/PwBVaYIUJYAY/lWyqswlTT6HO6fEItPsre0sLFzPZytG8sKyM90pyUOfbHFcj44Rl1ndJHHDK9vEzwIoUQsV5Tj0/PmvR72x006bbyrps98ZULNLHIyhGBxtG0cEcV5l4ot0h1B2htJbSNgP3Urlmz/eyeea6qM+bc4q9PlV0Y1TWgzcoPXioDWn4egFzq8CN0OT+QreTsmc0Vdo9B8N/6LDHGy5DkZPpmu2tUBiCEcA9K5DTY8qg6Dbt/HNdPp7ubfaW+crjPvXkz3PcjsbtuAqAKMD6VcQ9j3rNhkCqu9iAMZz3q7C4OGzlTUjsW4SBOSQOn3j1q3CztcDDfu6w2Z5bhlUnbjIxWzp6kKcnt09Km5tblRZezEsu/JweorVt1jnXYMHbxz1qorAA89R1qpDchJOM8HH/ANeoloVC8zehto0bOfer0cm1SGIAPGM9qztPkaVRn86fdDYVMnPPGDReyuhWvKzZoW1oC+8YIJ4GKfIVjchB8w60lrcRiIfNgY79RVto45QpYY9MVXLpoK7vqQRyy53E59BVsTS7hsXJPb0pVhWNT16elSxyCMhQud3oKFFoHJPoXYwTFu25P16VVmlZjh1A+oqwkg/u9PemySoSRtA/CrZmt9islpvUseGNPCeSeMlvU/zpguxvUIOO+e1TD58t+NRoaO/UWKZZCwwMjqR3pkqGSNgDgmorbaxfcCqk8D0qxHzvC/gc0MnZlPfJFyvB/u+oqP8AtIrL++2qOme1W5Im65zx3rJvLeQMw2A7+i+1Gw73NmORH3FWDZ7iiRyqsAeMday7BDBwFYDH4Us9yEUsScDqKTYWLBkWMHkn0oUtKwfG3aMEZrM+0M0hyfkHfvik+0SRqhOWANF9Q5TUlkSMMc/OOvtVRbh7hxGOQe+ODTWdZVLLkNnmrULxLFwctnJ9TQ0C7Fi0iWPceOTnBH8qtSSeUMqRjH41RMjtkc49qUorDEudtOJNhyI9yWd2yo5C9CKtgbT/ALAHTvmo49qjA49M96JZ1RSMAEc4J61Wwr30JQQQNwHHSmEbiD0FV/M80LjpjkU8yfKST8w9eKdxMSbC/dPfmoPkX5gAPekdy2OVDemarTzog8tjz6j1qWyuUeXHUHI9ulVGk3sVA247+tQxh/NbZkIfSmiFkkL78+1LmvsOyRFfTvFGPL5z61Wt7h3OHGexNXHww6ZH51jzvJDNhQNv0pSumVGzVi3Mx2nHX3qhczojgNwfarUknyA87T2rI1J0DDcDnHGDTJjqyyXBXKnJ/mKqTscjjNRxOrfMp59KfKw2kEAdsmnF3IkrFSYHOc8VQvQXidc4JrRmySFHI7VmTsOS3UVQjLuYVhsyDtLj+Kq+T5ILnOBk1LeAzpszgZzUBGF29exNCG3pqVpAsqhmXtxmqdy4SN2b7qrz71bf72BzxVJ7iS2l86FtrqcqeuKZD1HS6gk+i2Ai1s6cyJteJUfA5PJ29/WvOPGD77xv9ON+cAfaCG59vm54rudQ8TaqsbFLsLjp+7Tn9K848SajcalqBnu5PMl2hS20DgdOBXZQV3c4cS/dsZZra8IAtrkGOwY/pWNXR+Bo86q0hHEafzrpqfAzko6zR6JFtLAKBuA5A6Vp2UjJcInO1weQO9ZloMOoxywJzWpatyOpx0rzJbntQ2LTvuvVjbdg1qqjRW5AIwo4zxWUlwskcU4TOGwR3FakEq3IeID7y9Se9ZmrvZE+lFX3EnmtSNjG5ctgAc1g6ZMsDMkuQ2efat8bXi453Diktglo9SxDcrcRMEJwOpHWo4FAzv6nsKpWgeAzEg5HQ+tTaazPPy/J9ah6m0VZOx02myjyAiKRj0p97IXlWMZLfyptvlWXAAyPzqaSMSEdj6jrTadrGd0pXIbOSNZf3v4+lbcFxGoUAkselc/KixzAAtk9a17TCp6tSjJrQuequax+V89Se59KmtnG04IY1SEwI9sc05JSoXaoPPAFXcytoWnDhgcDHpVa5ZsjaQuf0qfdkkjqT3qndxPuDAn39KT1Kix1uhd/fGRWnEu1MDBHtWLDIwYAAkg9B2rVVwTGVfkDmmkKQkhfayttVB780zc6yqsbNtIqdipY7vrn1qGfLshAKt1z/hQK/ckldmGSoBXH41E7ZwzcHocdqlLKXw57dM9KZIc8hSM9KH3EU5y22Qg/eGOPSqLJ+8AJAGMVotggAryeCB/OqsilSc49ye9Syk1YpH5Q5Ybge+MGpYAzRLwT9fSnOFAG0H5m7+lMLl2IUFRz0oQ3qW4RtkK5+UjkGnwIqS4Y4K9BjrVSG4DvhQCR0GeTTnmJk7qfemgL6gqrdB35p6yt5isQeRg8VTt2kkzuIwepp4nZZimOvc0bBa5fTgEEcdRTJeeuRj2qJWP8ZpwIZDnkjjJqr3M2rD5DmM7eo6ViXlxKZApVvetPcAxAI96gkjDMNoIz3Hapkr7FwaT1K9ur7ASSDnjPpVe+KbiFGWPXFabAKh46VlXUZMpKLkGpasiou7uNtXYLtJHBxUzMSCeCOxqgQwcDpnuKtt8q4boeaI32JnYZJMsYy3Q8jFY99dGRiFOR61oXEZKkE5B6ADp71U+zRoC2MtjnNN3aFFpGfK85UFeVFViplBEh+b+VacjqBjB+vpWMS/2k4zjNFhp3H28TRlix47d6jdw2fmyR2qW4mKAHByTjiqbDYzHIBNNaEPXcJ5jGpCNg1lXUoJweoprRSI7u0md3aqlwRvZzyfWqWorJbDHkBLFePas+/V5ZwQ+2IDnBxUlzLsUt6dKzPtEs8hPSMAhjjiqExZbnzYpEiVgQBye4rMS4NverJKscgU5McnKn0Bq3DvSQqMbDzxWdqaASqzgbicgHvVJGcmbjxvdWC3Mlh4fhQoZlWfcrBM43EZ4Ga8x8YQtBrs0TpZxuqruW0B8sHGeM9+me1d3d3SwWOnS38AEU0MliT5oBkhY8Nj+HBJ5PBxXDeMyy615DQtClvBHDFucOXRR8r7hwcjnNd1BHBiHqYtdt4BhH2aabqxlC4x2Aria9B8AKBpDMe8xz+VaVfgZjh/4iOutkIAPcHAq1BkXBU8qRTYiAqIccc+5qdz/pAwOGrzpRPWiyS0CtMIguI2Yk+5zWpahI2dEPzA5I71n2qlZ2AIJPKj0qZy2RMQVfvj2qGjZO+hoT2yyHePlOQTWik4hjUkZ4wBVO3kV0VxzuHSmIzLMqSHK7uT61D02HHXRm3CwlhIGMOOSaq+S1vKpXHHQnpTxuhixEeAefatKNQ0Y3gHIqWrlJ21LlpO00I2nDetXJJ/LQEkk/SswkwoqwL1OBWhDl4/3uCRSDTcsRotwoLgLjkGp7aFo93pUMeFyAAfXmrCzptO09OTimgu9kTLIm4IQSe9W4flzswQvNVHjDHco6/nU6PhVAVqYm9B7XKq4U9/aqtxeMWIUEL9etSRp5rZ6HsKd9nBypOSe4p20C6RFC5aNtjcnkH3prmV2Hlhsgc89asRwCPJ27c9aeY1jXKk564oeugJjonYDGSCo+anfaFY9GwvTJqo2SpJ+8e3qKWFH2OWGD6ZoQepYE/BbbkjtTnk3A5OQQagACqGjGT0IqvJvDdeT1pBZD57jYhOGJ4xjqKXz90fmMCGxjB71Tbh0Zs5z90ChiuCzgZJ/M0raDsWJZlbgDBAwppnlhlQcDHVhx+FPtl8sYYZL8An+VTsoydgIUUgK3kqm3qrMetRKCshDjMmcAg1Ym55J4K8e1QIju4C9u+arQLlhSxAbGSTznjFOz5jnJwcHBpyxCKPliWPY0iAl+OjDFHUEJHIFiPzHcOc9qbJOSvHepZVIQ5OWz6YqoI2L5P3evFHoJWJoJMnGc+pNTScfcbn0qozbOce3vVeWdgWK54xQga1Lxk6ZPB7VWMu5yF4wOajjkMoyoIJ6imzgqvyDmi4JaiyMmRwCc8nFMlfPFNhVtgLj5vSopOAcZNFxNDZJCOOpqhfSMitg4PSrEjc5/I+lZ13I2G2kMcelO4ktSukplQkmopphGueOPTvVaK4Icr+IFQX10C4jCZJ6n0qU7LUpx11A3yMw34Q9s1VuSXmD7sAdqrXiATRBeh/GnyyI2UU/MvWn5A0lsR3E2dwH3exHes2eQKhZzhBzmnrN+8bcPlHTHas+8mMgdZeIxgqvrVrUmWhWvXWV1Bb5EBZiKgcrcQrHGSqZ+aluP9XI7dWOMA8U61iKrFGANx6DPU1VrGTdysT5ayySjBAKpnpntWfNBNeaisUcbSS/cVe7GrcjSSl95wgY7R6Y71UlXAIyc9frWqatYxtqW5dObU9KtDd6XfyiKPZHNayovmJkkAhj2JPIrgfF5uBrHl3NmbIQwpFFblgxSMD5cnue9dpqp06y0/TmutKlupriIyNItw6KfmIwAO/HIrD8WaTp8UF69laz2stqkEx3yl9yy/wALA/dYH06iuui9Djr7nIDrXo3gZPL0VDg5dy/4V51ECzhVGSeAK9U0OH7NZQwkj5EUH645qqz0sThl71zoI1wwJ6EdKlKlsE5GDxUcRyoJ54qzESNwYDawxk+tcLPST0L1tH86sSSQOMCpHCvOsTE7iKdZKBEzZAJwBlutPEY+0I2cMB09azktS4svQKEiULjjtSPGGbf/AHTxUoBzjPHrUcCN9om3/wCrb7tQy4svxyefD+7H0q9buQFDcH3rN01GiZ1LblPI9q0vLEhQ85B4FSUyYuRMnTjqD2rWTGzP8u1Yc8MhmVkORjB9q1YWwEDdcUht6FpwTGxU8nv61DCmQNuenJ96sIc4wwz6AVIyjGRjPoaLApWJFkCIuWycc0n2hdxK9f5e9QpJkkMRxxirCxRqQSRgdqaBj7djtZtxOelW4mAXng1Ai/L8uBjoDTHd1BI5Pf2pi3L7fKgI/I1Xkf5WbGT0GKI5cx5Y5IPHvS7lD9QC3ah7gisu5iH2n2xVzYzLu3EDHfvTsfMBj60MNwzzu+vFNPoMiRgPun5R607aAykEEN1FIgCsc9Dwv1qKaIkgFuvQelTbQZDdRhmYAkMPu1SVOcFsd8461pyYCqSM7c5NRSEKOnGODnFTfUuJHG4cAqDnGOvSro5wvJBFZ8kmwgx/eHBHcfSljaV3+9sJ6UvMbiWANw2KQDnOT1xTZVEC7ifv8jHNPGS3zYBxg+hqRkUKNwG3GBmqTJasRyM/lxhiDkZGetWIWjESI+7c3QjoKjYAqCpGQOuO1Kjkd1A7U0tSGJv/AB5x0qNjkk8/SgSDzWBz16elIWCHBJ9aAIpcFcnn0Peo8kqDgY9DUhcEcge1R5z3X6UCuRyShQAeOeMd6XzA23IwR29KjlUOeSM9sVCowDuPPqOaRVkySc+aOGKkc8VRvJWVCVPzD2qSVzvChcg857CoZVBzgnOOg6UC2Me7upHjfk5BA/Os95ZdzqGO0Hg+tasyICQB94+vGaqSqFH3R70WKujLh3Rzh5Tw3A5/lVRZn+2yq4BCqSAfXtV8x75wZDnHTtim+Wu45UZPU4prclyKCtI84LBQSuSfSmzbLdWlY5LnA9qdO4ScoBgHvVe8QtGNzcDvTtqSyk0ZlO5WwazrhN0iIuWA+9mtKJvlIXnHA+tV5sLkjg5zVrsS2Z8v765SJQSq8AjgA96HDvcHJBRfu4qVCyTtIvBK4/8A1CmXH7vaAclu9WjLW5VuMHCDhfWqM+FBJ5q9L6k8Vm3j4QnuPSmtyZFxb5dF06FpbrUWa5QziK2ZFSJSSAfmB+Y4PTFcR4uNxbXTWwvZ7iyudt8hk4LlxwXH94dK3zrU0NmtvLbWl3BFkxC4i3FMnJAOeme3Suf8ZLO2pxzXU/nSz28U2doUKGXhQB0AHFdtLc4K/cn8F6Z9pumupF3RwnC57t/9au6tlIlkAHFM0axSysooI/uoBz6nvVlBtuHx6ZrKdTmZ00qfIkXrZhgVdUhgCaoR9RV1eQMdPWsWdCNO227NrLliQf8A69XQynbvUE7s59vSs+0yVXI5xV9eikgHnPPpUNu40i1G2UwM8cDNTq2NpxyarRbsjJFWOqYrMsliYq27qBk4rRt5BJAJFBPFUbVQBt2844zV+2AVdoABH5VLKbHWUxlXL8Y61dzzgZBPSqoG3IHy59KeXIIAHFIpFyOUsAgVl9/Wpopxvwck9MmqySEAA56cZ7VKmWZcH5qYyw+C4YIfTI7VYiODyeKrxnJPP41MhyOMZ6YpAWUYjJz16Z7e9CgmQE/iagVucEEk96nU7iDkYJ5qtydiIpIr78jaDwpqVX3S5ZR05HpT2GCpwMetRof3hPc9hU2He6LEZyd5JAAqOOQ8ueCTzTsZjIY7R7dqHjUR8AH61TBMPMO7HQnp7UhkjOOT8vPNQqzCQNkYwRih2wjk53Yxg1JSGyTKyAkgBicD1qlcSqcgnkYwBUlxuKbUALH1qh5cgOWAGP71QbqxZWUM5ycHGD9KnjuF4x26CqAACnOcH3pWfbCzKMEY24qkgL32skgAHCjOB3qyrktuJyJBge1Z0C7iHZsgj7tXYshETA54JzjA9qXUUkThiP3ZILA9c9KUnAAbDY6VAflTGWIXtTiQiAkscfiapXMWLzuz39PWmuVBPzCgkli2M8dqhc5PAA9s0CElcDjnBqJmAHIyD61G0oYsI2zj1pN7YywzSCwb1zkHpUcj5HyEg4546UH7zE4yO570wMWz8wDZoAjychjlhUU2Wz6GpieMHqf1qGdvLjJbn2AzTSE3cpSqqoFAyM9D2qrKAPmK8Dv6VZDebyNyjupqG4HJHOPSgRkyFmfJxtzjinMOu08D1qSVG38YEY796jcE/dIGOvuKdrCbMgOxlkcgEA4WoJdxTaec8EjjBq9eRFY2ZVwD3z/SqkCYVg3KnqfUVaE31KuzyvkOeOTVO5bO4Ac9j3q7M6Mx8rlQSKosvdhk56DtVWIbISpUryCcYBFMnOQW6ACpTgKx545xVN3dlIxjPJHrVEleVhliOtZxlRLmOSSFJ0U5MTk7X+uOauS4AO481XsrX7fqVvaq4TzX2lsZx9B3PFNESILnV7Ebh/wjunMB6tJ/jXM+JbxtSu0n8iK3ARIVjiJKqqjA6810d7e6EjmM6deSYJBZrsK/124wD7VleJNNjsbyFIXdoZIknj8xcOFcZAYeorqg7HJVjzI9CWMKcY7UmzLHAqy64HvikjjJJHT3rlO61yFOOMc1diwccDk81WZQMY4BqxCflwcg+ooGkaMGEGQPlzxVxDnrxiqNudnXj29auR57DIP6VMhlyNs9OlWojznqe1UoSN6ljgY4xVpDzkkEdsVD8xoux5HY5qwH4749aqRggZPNTxYC7TyDUsstxnODyaeM5yD8vp6VXjcqfm/CrIXCliByc0rDRYjbGQSBU6tyFyPqO1VY8YyOQakQ/Lg8UDtcuBivIAOakTk8Nk5z8tVVJA6c9s0qE4JOQfakMuAsfYipYmcZBIxmqsbYBJzipkwuSScHmmiWTs4IAznikicKo4GOuaiyxxgZP1xgUp67c4GRnijZgWoJNwOenrT1YbWORxxVORjt2o2cdQKRS+QPfmmO11cnkOTnoQOmKpyn5TgEE8561bbLswcYTGVIquyqHBzjPf0qWtS42EdzgYx061QupWJPPHYYq5IAcYxnuazi2+5xIu3nAGev4VKNYpInRVdRu4zU4tlEO4tgj7o/GmQbSgB6LnNWGYCNfmJH+eKpAxdikj5RjqcCpEbK8c46Gq29i54Hvj0qaE7jyMAdDSsJ7EwJHy7tpPJOP0pgbLMUzj0qOViHALZB9BTSTuIYbV7EHrTuZND5GY9fujtVdmweuc1OB8nBAFQPgqCPu+/egVyJsr0U57013OMqCR3FHVtwJ/HpSMVyc4zjjFIZECdoA6H1ppwM7SMnv3qQknGNpXrmomI3cqc+tOxN2JyCe/0qObG0MG4HUU4sBnb+JqGWQMuM8+1NIRXlYKc9s1XlYPwDSu3OAcHOcGop/lOQRuNFgIJW25wMiqjHd1GDVonnGTkH86qzsNuX454pklSdyRlsbTwKqyghMp16ZNTXUgkUZXcAfpVV5GkQbcgCqJRVlQRsxAIyM8VTIbPBzk4PqParAk8yMr84OSTzx7VEV6MSMDmtHaxGrK0gzuxnjrVWYqADnHFWZXyoAGDnk561QuPu/MfxoApzMC+Ocd6rLFK15HFBxOWHl/Nt+btz2qZ3AOBz9KqLbSXlytvGhkllYKqDqSaqJnI3PL8U+b+++xmVTgtJ5BcH3J5zXM6/BdpfP/aDb7psO7bw+c9ORxXQX2mGe4DXeraSLoKI2Hmc/KMDcwGCexNY97YS2dybe5ULIuDwcgg8ggjqDWqZnynoEkeMZ+lOSPI4qVV3YB/CnzLtXAG1sYFYXOpFCRfn6cZ71NEgwD70Mh3ensasW6n0HP8AKi4EiEEjceexxViMshHNMClVOAO2KnQblwQAf5VLYyxGeQVHPerCnHGKqxKQQc4+lWoskgn14qWx2LSsMZyB6VYjJU5PQ1TUZGCT61ZDMwBC/nSKRZXGd3+RVqNsDruFUkcbhnjNTRSJjAoDUuBuMqAPWhMEkZ561Du9GqRXI4ABpMZYXtk5Hoe9PD9jkEdutRYyAQMn60q5zjORSBMuIwCgnt1FT7gMn171SjkIOCv4ipgeeeh6GmkS2WA/HPUUbs85IH9arhihyckZ60p/1nUj2oGixvRU78cGnrIuAFHA796qryxIPSlLEfeIz/KmFtSwWJUk5+melRgLzuwwHQA0xpAAWJ59KrXEoCKo4Y8nAqGaRLLFVdkH8XQH1qBsMU3YLd+Kiz5uNpJHQnpSKx3AN1B4A9Kk1SJoidpP8JJNSKdxI6dB9KjVwOOnsTTg3KkjPuKoLihlEhQZLA+mKfHkPt5wOf8A61RMcs3Udyc9famiQJgs2DjO30oJuSseSwPB7UjEqpOCT6E1EH8whjkDOAP604uCCy8/XtRYm5IrllAK/L0NNZh1II9j3qvuyTubJPOBQdxX5T09adidBjEAgnnOaYWG3OST70pcgk7cfjmoWbIyuBTsFxXYAklf1qNZA+8Ybchxn1ph3sThh9DTMtznBoExZpCflzgk/gahdvl65x2FKTv3DIGDUZdFGAxHt3oZJG67stkL+FVpWbKg/n1qeSTHBHJ6VXmYkktgY9KAIXfBY8YA4qhOxCDdlj09quMR8wJH4is27lABX+VNARzuGkLkgDbjGOhqtNJ9zIyhJLY7elNJJz3FRyb88HHGa0utyHHQbtCiVmJXOSoIx9B/OqkhHl9CPY+tOl+5liWIPGarO5OQDyfanKV3oSo2I5GCFsVl3r5wo/Gr0vyqfWqOwl8kHnmgGV1TavSpNLle21GK5gUPKrjCkZ3dtv41K0XHBq5o8qWOoW1zIm5YpNzAdfqPcdaFIjlH6hYadZ4a+0vVrUPnanmLt9wGxn8+az9ZaWW8QyW/2ZBDGsMec7Y8fLz39c1ox3UdrPcW0kr32mTn5wQQST0dc9GH61B4hlgnv4zZymaFbeKIOV25KjHI9aq5NjsIAC5NOlHIpLc/ITjk96XAyfXvUGyZXZNzKTnj3qzEm1QMHNIFBznAJqzDwOcelJsYscYUfN1P405V6elSRqCmck0RICW/L6Umxiqu3gZ49asxjGOv0xTSmRxj3p6DAXIwakpImUZUAg08NgDGaSM4wSeO9SEAHIIzSuNDkkwemajidvOAIOCe9Ox6ZpF4bLYIouVYvgDBORgVMpwOmT61SjZlXIAPoAasI46569vShk2LasVUgDilR+M/nUKsMZU+1KzMpyAStILFpG57YPSpDJgAEVQMh7kHPan5PHNFwsXS/pnaeMe9Kpboccd/WqRmkRcdfcUn2g5G4Nu7U7hY0lfaAOKPM4A7nmqSzDqRg9sinxyjq4+lK4rWLI+csCQR0x70rAsgHWmeagXIPTtTGnywA4HYigdwdORtG0dwKjYO8g24UDgkjrTmnGDgjdnOaRW3Nlmxj0pWNFLqSiI7cs2G9u1KFxgjk+majMqpznmovO4+TkHnNArtliZsHavfqT2qLKEgrhifXrUbybhgZyaiLgEkD7vX3pjT0LjKCrAH8TUBHygAsqnoQMGoZLrAUkqF7A+tR/ankyG5z3HamKzLYOMHeOO1Qks2/P3fTPWo0I5B5J4z60PhW+UH86ZDDzOnBH1pGkORx9cVGSwOT8oNIAxzyfypMBHZT98Y71Cy5YNlh9KVtxPBOO9Ju2k4bI9KLg1oRuGGMPkdelMJGMnr607d1HbOcelQszKvX/GkwCViAcMGz+lUJZGwQSPY1LLJntx/KqjDd7UwTK87k/K3P6VUcHK8cd81ddNzZx+dQOQoywAPoKYrlfysLgH61FIcAgDOKsbyMqeSaqTuMkYyR6U1uIqTKT8xOB3qpIMDodvUZq0zbu+W7VVcfXnnpV3RLIDmQtnoBmoFGWLMu0DgDvVxlCrwOSKhWMnkjkmlcViPbntjFPjhee4jhiALO20ZOB9fpS8dF6dantJRBdxSyIWQZDqvXaRg/jg0kxNEv2G1+0LB5d5K7p5izIVG5f7yoeSO45yRWRfWzW07R7lYYDI69HVuQw/Cum+zxi4iux5ckkQXbN9pVYjtGFZlPzAgAZUVjao8U0yiAloo0EasRgtjq2O2Tk1ZB0tv0b8KsSAYX60UUMtbjsYepIhyx74ooqWUW05QfXFOgGH/ABoopLcZZjA547VNcKBtwKKKT3KQsQGRxT2ABGPWiioZZKVAOAOKXau8cd6KKQDmABIA4p0RJXn1oooYiUjbnbxxUiMfIY55FFFAMUjBUjrjrQQF+7xnk0UU2JCqTtHuKMDIoooH1DAZGzzQ33c0UUgQKx3gZ4xT16YoooKZDL/rgOwOKlh5357GiimtwewsY3Bg3I3Yp+AEGKKKSE9hvdj3Apv/ACzA7UUVYirJyjE880sZwNo+7t6UUUGkth0RwJP9k8UISZTk9qKKDJ7h61GPn3BskYoooJRXk+79MU/Ax07UUVLKexXn6ioLjhRj0ooo6DXQqNy/NRHvRRVEleUkheehFV3+Zsnk9KKKSAhk45HeqdyMEYooqhFcffHuajnH70jsKKKQnuQS8JxUIPP4UUUw6DyAMADtmnH7o+tFFC3JZE6gtkgZqOQ/e+lFFWQf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Reticulated, hyperpigmented patches and thin plaques with mild scale are present on the chest and inframammary areas.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40375=[""].join("\n");
var outline_f39_27_40375=null;
var title_f39_27_40376="Prednisolone (systemic): Drug information";
var content_f39_27_40376=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednisolone (systemic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/12/29894?source=see_link\">",
"    see \"Prednisolone (systemic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/54/1896?source=see_link\">",
"    see \"Prednisolone (systemic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9505542\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flo-Pred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade;;",
"     </li>",
"     <li>",
"      Millipred&trade; DP;",
"     </li>",
"     <li>",
"      Orapred ODT&reg;;",
"     </li>",
"     <li>",
"      Orapred&reg;;",
"     </li>",
"     <li>",
"      Pediapred&reg;;",
"     </li>",
"     <li>",
"      Veripred&trade; 20",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F9505543\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hydeltra T.B.A.&reg;;",
"     </li>",
"     <li>",
"      Novo-Prednisolone;",
"     </li>",
"     <li>",
"      Pediapred&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9518574\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Systemic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9505639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose depends upon condition being treated and response of patient. Oral dosage expressed in terms of prednisolone base. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose. Patients undergoing unusual stress while receiving corticosteroids, should receive increased doses prior to, during, and after the stressful situation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Usual dose (range):",
"     </b>",
"     Oral: 5-60 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Rheumatoid arthritis:",
"     </b>",
"     Oral: Initial: 5-7.5 mg daily, adjust dose as necessary",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Multiple sclerosis:",
"     </b>",
"     Oral: 200 mg daily for 1 week followed by 80 mg every other day for 1 month",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute exacerbations of chronic obstructive pulmonary disease (COPD) (unlabeled use):",
"     </b>",
"     Oral: 30-40 mg daily for 10-14 days (GOLD guidelines, 2013)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Bell&rsquo;s palsy (unlabeled use):",
"     </b>",
"     Oral: 60 mg daily for 5 days, followed by 10 mg daily for 5 days (Berg, 2012)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Severe alcoholic hepatitis (Maddrey Discriminant Function [MDF] score &ge;32) (unlabeled use):",
"     </b>",
"     Oral: 40 mg daily for 28 days, followed by a 2-week taper (O'Shea, 2010)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hyperthyroidism:",
"     </b>",
"     Prednisolone dose may need to be increased to achieve adequate therapeutic effects.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9505638\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/54/1896?source=see_link\">",
"      see \"Prednisolone (systemic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose depends upon condition being treated and response of patient; dosage for infants and children should be based on severity of the disease and response of the patient rather than on strict adherence to dosage indicated by age, weight, or body surface area. Oral dosage expressed in terms of prednisolone base. Consider alternate day therapy for long-term therapy. Discontinuation of long-term therapy requires gradual withdrawal by tapering the dose. Patients undergoing unusual stress while receiving corticosteroids, should receive increased doses prior to, during, and after the stressful situation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Acute asthma:",
"     </b>",
"     Oral: 1-2 mg/kg/day in divided doses 1-2 times daily for 3-5 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Anti-inflammatory or immunosuppressive dose:",
"     </b>",
"     Oral: 0.1-2 mg/kg/day in divided doses 1-4 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Nephrotic syndrome:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Initial (first 3 episodes):",
"     </i>",
"     2 mg/kg/day",
"     <b>",
"      or",
"     </b>",
"     60 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day (maximum: 80 mg/day) in divided doses 3-4 times daily until urine is protein free for 3 consecutive days (maximum: 28 days); followed by 1-1.5 mg/kg/dose",
"     <b>",
"      or",
"     </b>",
"     40 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /dose given every other day for 4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maintenance (for frequent relapses):",
"     </i>",
"     0.5-1 mg/kg/dose given every other day for 3-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hyperthyroidism:",
"     </b>",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9505640\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use lowest effective adult dose. Dose depends upon condition being treated and response of patient; alternate day dosing may be attempted in some disease states.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F9505641\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Hemodialysis: Slightly dialyzable (5% to 20%); administer dose posthemodialysis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peritoneal dialysis: Supplemental dose is not necessary",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9506803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as base: 15 mg/5 mL (240 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as sodium phosphate [strength expressed as base]: 5 mg/5 mL (120 mL); 15 mg/5 mL (237 mL, 473 mL); 25 mg/5 mL (237 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade;: 10 mg/5 mL (237 mL) [dye free, ethanol free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orapred&reg;: 15 mg/5 mL (20 mL, 237 mL) [dye free; contains ethanol 2%, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediapred&reg;: 5 mg/5 mL (120 mL) [dye free; raspberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Veripred&trade; 20: 20 mg/5 mL (237 mL) [dye free, ethanol free; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, oral, as acetate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Flo-Pred&trade;: 15 mg/5 mL (52 mL) [contains propylene glycol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade;: 5 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as base [dose-pack]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade; DP: 5 mg [scored; 12-day pack/48s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Millipred&trade; DP: 5 mg [scored; 6-day pack/21s]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral, as sodium phosphate [strength expressed as base]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Orapred ODT&reg;: 10 mg, 15 mg, 30 mg [grape flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9505545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally disintegrating tablet, oral suspension, tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9505655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer oral formulation with food or milk to decrease GI effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Flo-Pred&trade;:  Administer using the provided calibrated syringe (supplied by manufacturer) to accurately measure the dose. Syringe should be washed prior to next use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Orapred ODT&reg;: Do not break or use partial tablet. Remove tablet from blister pack just prior to use. May swallow whole or allow to dissolve on tongue.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9505546\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of endocrine disorders, rheumatic disorders, collagen diseases, allergic states, respiratory diseases, hematologic disorders, neoplastic diseases, edematous states, and gastrointestinal diseases; resolution of acute exacerbations of multiple sclerosis; management of fulminating or disseminated tuberculosis and trichinosis; acute or chronic solid organ rejection",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F13844855\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Severe alcoholic hepatitis; Bell&rsquo;s palsy; acute exacerbations of chronic obstructive pulmonary disease (COPD)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9505495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       PrednisoLONE may be confused with predniSONE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Pediapred&reg; may be confused with Pediazole&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Prelone&reg; may be confused with PROzac&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9505593\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Cardiomyopathy, CHF, edema, facial edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache, insomnia, malaise, nervousness, pseudotumor cerebri, psychic disorders, seizure, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Bruising, facial erythema, hirsutism, petechiae, skin test reaction suppression, thin fragile skin, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Carbohydrate tolerance decreased, Cushing's syndrome, diabetes mellitus, growth suppression, hyperglycemia, hypernatremia, hypokalemia, hypokalemic alkalosis, menstrual irregularities, negative nitrogen balance, pituitary adrenal axis suppression",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal distention, increased appetite, indigestion, nausea, pancreatitis, peptic ulcer, ulcerative esophagitis, weight gain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs increased (usually reversible)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia, aseptic necrosis (humeral/femoral heads), fractures, muscle mass decreased, muscle weakness, osteoporosis, steroid myopathy, tendon rupture, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Cataracts, exophthalmus, eyelid edema, glaucoma, intraocular pressure increased, irritation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Epistaxis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased, impaired wound healing",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9505558\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednisolone or any component of the formulation; acute superficial herpes simplex keratitis; live or attenuated virus vaccines (with immunosuppressive doses of corticosteroids); systemic fungal infections; varicella",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9505559\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis. Withdrawal and discontinuation of a corticosteroid should be done slowly and carefully. Particular care is required when patients are transferred from systemic corticosteroids to inhaled products due to possible adrenal insufficiency or withdrawal from steroids, including an increase in allergic symptoms. Patients receiving &gt;20 mg per day of prednisone (or equivalent) may be most susceptible. Fatalities have occurred due to adrenal insufficiency in asthmatic patients during and after transfer from systemic corticosteroids to aerosol steroids; aerosol steroids do",
"     <b>",
"      not",
"     </b>",
"     provide the systemic steroid needed to treat patients having trauma, surgery, or infections.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cataracts: Prolonged use of corticosteroids may result in posterior subcapsular cataract formation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Glaucoma: Prolonged use of corticosteroids may result in elevated intraocular pressure (IOP) and glaucoma. Monitor IOP in any patient receiving treatment for &ge;10 days.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use of corticosteroids may also increase the incidence of secondary infection, mask acute infection (including fungal infections) or prolong or exacerbate viral infections. Exposure to chickenpox should be avoided; corticosteroids should not be used to treat ocular herpes simplex. Corticosteroids should not be used for cerebral malaria or viral hepatitis. Use with caution in patients with tuberculosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myopathy: Acute myopathy has been reported with high dose corticosteroids, usually in patients with neuromuscular transmission disorders; may involve ocular and/or respiratory muscles; monitor creatine kinase; recovery may be delayed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Psychiatric disturbances: Corticosteroid use may cause psychiatric disturbances, including depression, euphoria, insomnia, mood swings, and personality changes. Pre-existing psychiatric conditions may be exacerbated by corticosteroid use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF; long-term use has been associated with fluid retention and hypertension.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; may alter glucose production/regulation leading to hyperglycemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Use with caution in patients with GI diseases (diverticulitis, peptic ulcer, ulcerative colitis) due to perforation risk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment, including cirrhosis; long-term use has been associated with fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myasthenia gravis: Use with caution in patients with myasthenia gravis; exacerbation of symptoms has occurred especially during initial treatment with corticosteroids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Myocardial infarction (MI): Use with caution following acute MI; corticosteroids have been associated with myocardial rupture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteoporosis: Use with caution in patients with osteoporosis; high doses and/or long-term use of corticosteroids have been associated with increased bone loss and osteoporotic fractures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; fluid retention may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; seizures have been reported with adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thyroid disease: Changes in thyroid status may necessitate dosage adjustments; metabolic clearance of corticosteroids increases in hyperthyroid patients and decreases in hypothyroid ones.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Because of the risk of adverse effects, systemic corticosteroids should be used cautiously in the elderly in the smallest possible effective dose for the shortest duration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: May affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Discontinuation of therapy: Withdraw therapy with gradual tapering of dose.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F9505596\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9505597\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Corticosteroids (Systemic) may enhance the hypokalemic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the bioavailability of Corticosteroids (Oral). Management: Consider separating doses by 2 or more hours. Budesonide enteric coated tablets could dissolve prematurely if given with drugs that lower gastric acid, with unknown impact on budesonide therapeutic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Corticosteroids (Systemic) may diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Immunosuppressants may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Corticosteroids (Oral).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcitriol: Corticosteroids (Systemic) may diminish the therapeutic effect of Calcitriol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Bepridil [Off Market].",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Coccidioidin Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioidin Skin Test.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of PrednisoLONE (Systemic). PrednisoLONE (Systemic) may decrease the serum concentration of CycloSPORINE (Systemic). PrednisoLONE (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids (Systemic) may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Echinacea: May diminish the therapeutic effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Estrogen Derivatives: May increase the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: May increase the serum concentration of Corticosteroids (Systemic). The active metabolite aprepitant is likely responsible for this effect.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indacaterol: May enhance the hypokalemic effect of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: Corticosteroids (Systemic) may decrease the serum concentration of Isoniazid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Corticosteroids (Systemic).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May diminish the therapeutic effect of Corticosteroids (Systemic). Mifepristone may increase the serum concentration of Corticosteroids (Systemic). Management: Avoid mifepristone in patients who require long-term corticosteroid treatment of serious illnesses or conditions (e.g., for immunosuppression following transplantation). Corticosteroid effects may be reduced by mifepristone treatment.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mitotane: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): May enhance the adverse neuromuscular effect of Corticosteroids (Systemic). Increased muscle weakness, possibly progressing to polyneuropathies and myopathies, may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (COX-2 Inhibitor): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (COX-2 Inhibitor).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     NSAID (Nonselective): Corticosteroids (Systemic) may enhance the adverse/toxic effect of NSAID (Nonselective).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of PrednisoLONE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: May decrease the serum concentration of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: May enhance the adverse/toxic effect of Corticosteroids (Systemic). Risk of tendon-related side effects, including tendonitis and rupture, may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of PrednisoLONE (Systemic). Management: Consider prednisolone dose reductions in patients receiving ritonavir and monitor for increased adverse effects with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: May increase the serum concentration of Corticosteroids (Systemic). Corticosteroids (Systemic) may decrease the serum concentration of Telaprevir. Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Corticosteroids (Systemic) may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or other non-disease modifying antirheumatic drugs (non-DMARDs) is permitted, and this warning seems to particularly focused on more potent immunosuppressants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Corticosteroids (Systemic) may enhance the adverse/toxic effect of Vaccines (Live).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Corticosteroids (Systemic) may enhance the anticoagulant effect of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F9505601\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase gastric mucosal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Prednisolone interferes with calcium absorption. Limit caffeine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease prednisolone levels. Avoid cat's claw, echinacea (have immunostimulant properties).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9505553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (Flo-Pred&trade;) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9505554\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Adverse events have been observed with corticosteroids in animal reproduction studies. Prednisolone crosses the placenta; prior to reaching the fetus, prednisolone is converted by placental enzymes to prednisone. As a result, the amount of prednisolone reaching the fetus is ~8-10 times lower than the maternal serum concentration (healthy women at term; similar results observed with preterm pregnancies complicated by HELLP syndrome). Human studies have shown an association between first trimester corticosteroid use and oral clefts.  Additional adverse events in the fetus/neonate, including low birth weight, have been noted in case reports following large doses of systemic corticosteroids during pregnancy. Women exposed to prednisolone during pregnancy for the treatment of an autoimmune disease may contact the OTIS Autoimmune Diseases Study at 877-311-8972.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9505556\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F9505557\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prednisolone is excreted into breast milk with peak concentrations occurring ~1 hour after the maternal dose. The milk/plasma ratio was found to be 0.2 with doses &ge;30 mg/day and 0.1 with doses &lt;30 mg/day. Following a maternal dose of prednisolone 80 mg/day, a breast-feeding infant would ingest &lt;0.1% of the dose.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9505654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken after meals or with food or milk to decrease GI effects; increase dietary intake of pyridoxine, vitamin C, vitamin D, folate, calcium, and phosphorus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F9506885\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (AsmalPred Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (237 mL): $328.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Millipred Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (237 mL): $571.06",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Orapred Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (20 mL): $48.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (PrednisoLONE Sodium Phosphate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     6.7 (5 Base) mg/5 mL (120 mL): $98.09",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (237 mL): $74.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg/5 mL (237 mL): $186.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Veripred 20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/5 mL (237 mL): $239.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suspension",
"     </b>",
"     (Flo-Pred Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     16.7 (15 Base) mg/5 mL (30 mL): $124.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Prelone Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (240 mL): $128.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Orapred ODT Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (48): $376.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (48): $565.44",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg (48): $805.74",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Millipred DP 12-Day Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (48): $36.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Millipred DP Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (21): $164.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Millipred Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $788.10",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9505657\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Blood pressure; blood glucose, electrolytes; intraocular pressure (use &gt;6 weeks); bone mineral density; growth in children",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10962004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adelcort (GR);",
"     </li>",
"     <li>",
"      Aprednislon (AT);",
"     </li>",
"     <li>",
"      Compresolon (TW);",
"     </li>",
"     <li>",
"      Danalone (IL);",
"     </li>",
"     <li>",
"      Decortin (DE);",
"     </li>",
"     <li>",
"      Decortin H (BG);",
"     </li>",
"     <li>",
"      Delsone (IN);",
"     </li>",
"     <li>",
"      Deltacortril (AE, GB, PK, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Deltastab (GB);",
"     </li>",
"     <li>",
"      Dermosolon (DE);",
"     </li>",
"     <li>",
"      Dhasolone (MY);",
"     </li>",
"     <li>",
"      Di-Adreson-F (BF, BJ, CI, ET, FI, GH, GM, GN, HN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Fantil (UY);",
"     </li>",
"     <li>",
"      Fisopred (CO);",
"     </li>",
"     <li>",
"      hefasolon (DE);",
"     </li>",
"     <li>",
"      Hydrocortancyl (FR);",
"     </li>",
"     <li>",
"      Lenisolone (ZA);",
"     </li>",
"     <li>",
"      Lepicortinolo (PT);",
"     </li>",
"     <li>",
"      Meticortelone (VE);",
"     </li>",
"     <li>",
"      Nisolon (MY);",
"     </li>",
"     <li>",
"      Opredsone (TH);",
"     </li>",
"     <li>",
"      Panafcortelone (AU, HK);",
"     </li>",
"     <li>",
"      Pelonine (TW);",
"     </li>",
"     <li>",
"      PRD Syrup (KP);",
"     </li>",
"     <li>",
"      Preconin (TW);",
"     </li>",
"     <li>",
"      Predmix Oral Solution (AU);",
"     </li>",
"     <li>",
"      Prednecort (PH);",
"     </li>",
"     <li>",
"      Prednimax (EC);",
"     </li>",
"     <li>",
"      Prednisolona (CO);",
"     </li>",
"     <li>",
"      Predsolone (AU);",
"     </li>",
"     <li>",
"      Prelone (BR, CR, DO, GT, NI, PA, SV, ZA);",
"     </li>",
"     <li>",
"      Prenin (TW);",
"     </li>",
"     <li>",
"      Preson (TW);",
"     </li>",
"     <li>",
"      Prezolon (GR);",
"     </li>",
"     <li>",
"      Redipred (AU, HK, NZ);",
"     </li>",
"     <li>",
"      Rubycort (KP);",
"     </li>",
"     <li>",
"      Scherisolona (CO);",
"     </li>",
"     <li>",
"      Solondo (KP);",
"     </li>",
"     <li>",
"      Solone (AU);",
"     </li>",
"     <li>",
"      Solu-Dacortina (PT);",
"     </li>",
"     <li>",
"      Solupred (FR);",
"     </li>",
"     <li>",
"      Spiricort (CH);",
"     </li>",
"     <li>",
"      Ultracortenol (NO);",
"     </li>",
"     <li>",
"      Walesolone (SG);",
"     </li>",
"     <li>",
"      Wysolone (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9505616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases inflammation by suppression of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability; suppresses the immune system by reducing activity and volume of the lymphatic system",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9505618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 18-36 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding (concentration dependent): 65% to 91%; decreased in elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Primarily hepatic, but also metabolized in most tissues, to inactive compounds",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.6 hours; End-stage renal disease: 3-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (as glucuronides, sulfates, and unconjugated metabolites)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abraham E and Evans T, &ldquo;Corticosteroids and Septic Shock [editorial],&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):886-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12186608/pubmed\" id=\"12186608\" target=\"_blank\">",
"        12186608",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Annane D, Sebille V, Charpentier C, et al, &ldquo;Effect of Treatment With Low Doses of Hydrocortisone and Fludrocortisone on Mortality in Patients With Septic Shock,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(7):862-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12186604/pubmed\" id=\"12186604\" target=\"_blank\">",
"        12186604",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beitins IZ, Bayard F, Ances IG, et al, &ldquo;The Transplacental Passage of Prednisone and Prednisolone in  Pregnancy Near Term,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1972, 81(5):936-45.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/5086721/pubmed\" id=\"5086721\" target=\"_blank\">",
"        5086721",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Berg T, Bylund N, Marsk E, et al, &ldquo;The Effect of Prednisolone on Sequelae in Bell&rsquo;s Palsy,&rdquo;",
"      <i>",
"       Arch Otolaryngol Head Neck Surg",
"      </i>",
"      , 2012, 138(5):445-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/22652942/pubmed\" id=\"22652942\" target=\"_blank\">",
"        22652942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cooper MS and Stewart PM, &ldquo;Corticosteroid Insufficiency in Acutely Ill Patients,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(8):727-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12594318/pubmed\" id=\"12594318\" target=\"_blank\">",
"        12594318",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Coursin DB and Wood KE, &ldquo;Corticosteroid Supplementation for Adrenal Insufficiency,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 287(2):236-40.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/11779267/pubmed\" id=\"11779267\" target=\"_blank\">",
"        11779267",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      de Jonghe B, Sharshar T, Lefaucheur JP, et al, &ldquo;Paresis Acquired in the Intensive Care Unit. A Prospective Multicenter Study,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(22):2859-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12472328/pubmed\" id=\"12472328\" target=\"_blank\">",
"        12472328",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frey BM and Frey FJ, \"Clinical Pharmacokinetics of Prednisone and Prednisolone,\"",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1990, 19(2):126-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/2199128/pubmed\" id=\"2199128\" target=\"_blank\">",
"        2199128",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Frey FJ, \"Kinetics and Dynamics of Prednisolone,\"",
"      <i>",
"       Endocr Rev",
"      </i>",
"      , 1987, 8(4):453-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/3319533/pubmed\" id=\"3319533\" target=\"_blank\">",
"        3319533",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gambertoglio JG, Amend WJ Jr and Benet LZ, \"Pharmacokinetics and Bioavailability of Prednisone and Prednisolone in Healthy Volunteers and Patients: A Review,\"",
"      <i>",
"       J Pharmacokinet Biopharm",
"      </i>",
"      , 1980, 8(1):1-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/6991663/pubmed\" id=\"6991663\" target=\"_blank\">",
"        6991663",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gamsu HR, Mullinger BM, Donnai P, et al, &ldquo;Antenatal Administration of Betamethasone to Prevent Respiratory Distress Syndrome in Preterm Infants: Report of a UK Multicentre Trial,&rdquo;",
"      <i>",
"       Br J Obstet Gynaecol",
"      </i>",
"      , 1989, 96(4):401-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/2665800/pubmed\" id=\"2665800\" target=\"_blank\">",
"        2665800",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Global Strategy for the Diagnosis, Management and Prevention of COPD",
"      </i>",
"      , Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2013. Available at file://www.goldcopd.com",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gronseth GS and Paduga R, \"Evidence-Based Guideline Update: Steroids and Antivirals for Bell Palsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology,\"",
"      <i>",
"       Neurology",
"      </i>",
"      , 2012, 79(22):2209-13.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/23136264/pubmed\" id=\"23136264\" target=\"_blank\">",
"        23136264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hotchkiss RS and Karl IE, &ldquo;The Pathophysiology and Treatment of Sepsis,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2003, 348(2):138-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/12519925/pubmed\" id=\"12519925\" target=\"_blank\">",
"        12519925",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lawrence RA, &ldquo;Corticosteroid Effect on Lactation,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1991, 265(18):2409.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/2016840/pubmed\" id=\"2016840\" target=\"_blank\">",
"        2016840",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Liggins GC and Howie RN, &ldquo;A Controlled Trial of Antepartum Glucocorticoid Treatment of Respiratory Distress Syndrome in Premature Infants,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1972, 50:515-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/4561295/pubmed\" id=\"4561295\" target=\"_blank\">",
"        4561295",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McGee S and Hirschmann J, &ldquo;Use of Corticosteroids in Treating Infectious Diseases,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2008, 168(10):1034-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/18504331/pubmed\" id=\"18504331\" target=\"_blank\">",
"        18504331",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O&rsquo;Shea R, Dasarathy S, McCullough A, et al, &ldquo;Alcoholic Liver Disease,&rdquo;",
"      <i>",
"       Hepatology",
"      </i>",
"      , 2010, 51(1):307-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/20034030/pubmed\" id=\"20034030\" target=\"_blank\">",
"        20034030",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ost L, Wettrell G, Bj&ouml;rkhem I, et al, &ldquo;Prednisolone Excretion in Human Milk,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1985, 106(6):1008-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/3998938/pubmed\" id=\"3998938\" target=\"_blank\">",
"        3998938",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ostensen M, &ldquo;Optimisation of Antirheumatic Drug Treatment in Pregnancy,&rdquo;",
"      <i>",
"       Clin Pharmacokinet",
"      </i>",
"      , 1994, 27(6):486-503.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/7882637/pubmed\" id=\"7882637\" target=\"_blank\">",
"        7882637",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pradat P, Robert-Gnansia E, Di Tanna GL, et al, &ldquo;First Trimester Exposure to Corticosteroids and Oral Clefts,&rdquo;",
"      <i>",
"       Birth Defects Res A Clin Mol Teratol",
"      </i>",
"      , 2003, 67(12):968-70.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/14745915/pubmed\" id=\"14745915\" target=\"_blank\">",
"        14745915",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Report of a Workshop by the British Association for Paediatric Nephrology and Research Unit, Royal College of Physicians, &ldquo;Consensus Statement on Management and Audit Potential for Steroid Responsive Nephrotic Syndrome,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):151-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/8129444/pubmed\" id=\"8129444\" target=\"_blank\">",
"        8129444",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Salem M, Tainsh RE Jr, Bromberg J, et al, &ldquo;Perioperative Glucocorticoid Coverage. A Reassessment 42 Years After Emergence of a Problem,&rdquo;",
"      <i>",
"       Ann Surg",
"      </i>",
"      , 1994, 219(4):416-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/8161268/pubmed\" id=\"8161268\" target=\"_blank\">",
"        8161268",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      van Runnard Heimel PJ, Schobben AF, Huisjes AJ, et al, &ldquo;The Transplacental Passage of Prednisolone in Pregnancies Complicated by Early-Onset HELLP Syndrome,&rdquo;",
"      <i>",
"       Placenta",
"      </i>",
"      , 2005, 26(10):842-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/27/40376/abstract-text/16226134/pubmed\" id=\"16226134\" target=\"_blank\">",
"        16226134",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9913 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-89ED0DCEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40376=[""].join("\n");
var outline_f39_27_40376=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505542\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505543\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518574\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505639\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505638\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505640\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505641\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506803\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505545\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505655\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505546\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13844855\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505495\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505593\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505558\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505559\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505596\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505597\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505601\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505553\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505554\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505556\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505557\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505654\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9506885\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505657\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10962004\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505616\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9505618\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9913\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9913|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?30/0/30723?source=related_link\">",
"      Prednisolone (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?42/13/43220?source=related_link\">",
"      Prednisolone (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?36/49/37650?source=related_link\">",
"      Prednisolone (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/12/29894?source=related_link\">",
"      Prednisolone (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?1/54/1896?source=related_link\">",
"      Prednisolone (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_27_40377="Fetal limb body wall complex";
var content_f39_27_40377=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F81234%7EOBGYN%2F54368%7EOBGYN%2F55474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F81234%7EOBGYN%2F54368%7EOBGYN%2F55474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester vaginal ultrasound of fetus with limb-body wall complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 269px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAENAXwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDRn1PxBYi6iS2aR4r+2CTjSY2WNGVQI8GHdvbOC+XBHRhTxr/itU+yCwENqmrIBbpo6NHFNgfuFXZjHLHd97/ar5sGr3YAAuboADAAnbgfnSjWLwdLq7HGOLhun50AXb6WC28SXs15C81pHqEjXEKPtZk3neqt2OM4NetW/wAO/DFz420HQrO5vLmO8jbWLmZ28rZYMuYouTgSerZrw+S6BR/MTKkHdk9a9n0TwN4o1vw5a6nqvi3TtKh1bTBAtveMxkeyjwQjALgKBgjnNAGL428FWnhrRfG0zrI1zpWpWsVk4lyn2edSwB/vEDAz6ijxNoXhvR/hh4fv1iRvEOqWKXR3X8glUsxBZYNhQpgdS4PtWXqvinxZ4E8SajodtrswksUjsi8O0xvEgzGFDKflAbj61iT+Odfn8NnQJtSuH0UjH2RiuzG7djpkc89aAO4m8N+G7bwB4NuJIQ+u695W7N86zANPsJjgCFGXb3Lr9K2ZfDPgn/hb1l4St9PFzazSTQSS22sSu8ToCfnDRDDfL90Ej3rxyfXLy5TTFnnlkGmIEsst/wAe6htwC/jzWzqPxF8UalqVhqN9rFzNf2BY2s52BoiwwxBCjqOOc0Ad74U+H+neK/Bfi/XrS1lsJIpZI9It2u/M2eUu5yxODJnoOOoriPiHptjoTaAdNjmUXmh2+oTLM+T5r53Y9Bx0rIt/FWr2x0s297PGdLZ3scEf6OzklyvHGSSTVq/8deINR8PjQ7/U57jSBjFrIF2jByOcZ6k96AO01Twpotjbf2Gljq9xrraVBqi6xDIGtUaTB2yRkAJAAcGUsSDVTRvAMl5HrOlebY6h4je1S70oaZfpcxsFcLKjBDjOCCMkcCuRfxlrj+Gf+EeOp3h0PI/0Myny8A52+u3PO3OPaqWi67e6HqkGpaPPLZ38IYRzxEBlDDBHTuCRQB6HJ4X8Pv4+8UWdt9ql0Xw7pzXcsSTYkvJYwodVcg7V3E54JABrS0Hw74Qu7HW9cvtMvLDTIra0ntrbV76S2RTLncEmRGaVDj5WKDPf1ryrTdcvtM1SPUtPuJ7a/RmdbiOQh8t97nvnuDwa3LT4k+K7TVb/AFO31u8W/vtouZiVYyhfuggggAdgAMUAeg+F/h1oeuaf4WvVe4R7myuL/VLMzfMIAWEUsZxnAICt+eKj0zwx4U1i7+HFvbaReWreI/NmuZP7QaQIkRZWUAqMbiud3b0NeZQeMdbt7q2uINRuo57aGS3hdXAKRuSXTpjBJJwajs/FGq2s+kPaXdwk2khl08ocm33EkhBjuSeuaAPXfCnhDwdr2t+IBFDZNZWUtpa22NamFtLJKxB/fmEPv4wF2Yz3715Z4tsrPTvFutWWlG4bTbW7eGBrhcSbVOMMOOQcjoK2n1bxT4iupf7b1adRdiNpC+3dIYjujyqgcqeR0qKTSb3XdSnvtT1F5bq5mHnTumWZum49PSgDmYG23MBwTiRT+tehjw7okGk6NFe6frWp6x4gs5b+G40sh/shDkKggxiTp8xLDHtXOT+H4rHVhDJfAiNwwYR9SOnfjNTxatqmn6Ff6bba7d2mlXLsZ7JD8hVjzjuAe4GM96AOq8XfDrT4rbT18P3VvDcxztZ3sl7fokAkEYch3cKI5uf9Wu9cc7qboHwv8zwHr+tavPGJUljisLi1l822RRJskmd0BVxzwAe1ef8AiHX7/VTYWuq6pPfQ2MflWwkOViTtj1+p5qlZa1d2treWFveTw2F8giuYg3ySKDkAj0zzxigDvY/hq9r8R9F8K6vqSJNdxSXNysA/eRIgZgozkFnC5HXGeRmtjwd4U8KeKZdM1eLT77TdJaa8trmxub0uGMMXmLL5wQMq9mwDjtXAR3tzr/iBb+61i4fVVCst2eJBsGF2kEEYHTFdhLf+J59UsNbPiy9l1W2jZIZCo3Qq3DAD7vPfjnvQBuL8NdAutTzbzTJp2pW1o1hLDOZY0mlc7gjsqtIu1SPnVWBPQ1Usfhna+M49KuPCsEmi2zz3EF415eJdiNYjgOwG10kJ6oQAByDVLU9L1fWdLurubxVeXsv2lLueGWMx7ZVGFcEHggdMYFW7288WfbNLvL/xjdi7t1b7KzxgshYYOV6MSOpbNAGDN8OJYvDt1qA1uxkvIba5vEskjdjLDBL5buJPugZ5HrVN/BQPw0i8XJfm2yozZX8XkNcEkDNs2T5q8+g6Gt4aPrc0hhPiORYJIZLMkxqq+VI2+RMA/dZuTiqo+GqNapPJrBVB+6h3wE7gOyfN0oAl8G+DND8QaF4VlE18bu+1We0v3AC4WKEy+XEuT1AxuPPtWxF8IY/FD2994WvP7Ns7qzjuzp+oHzJrUNkctkblOCRxmq9rpGtQ6PDosPiu4g0mykWaCEQBNkqncCvO4HPvVqbRPFQlm1ZvFd02o3UiTy7ox5hZAQrHnA2qTgDjmgDJl+G9td6b4NuLHUoLNdYLWrT3LExzTq5DOvZFwOATljwK4DxBpzaP4g1HS3Z3aymMJeSIxM2O5Q8r+NemaPpWtxWiGHxbcWkenkNaxPAGVQCSGUEkA5J/xrHvPBf9oyy6nd6/Jc3N3Jvklkg3SSMe5y1AHnlW7EAxXQZZHQmPekYy7ru5C/7Xp/WvVdM+DC3ySSHxB5SCIPErWnzyt3ULu7etRp8IruB51ttSkcuUNvMINhLKc5X5uCD+VAEet/DzS9V1LwqnhOWa1OswecbR2e6+RGPmsH2qQ6gYKFfvfdyKtL4F8Ox/ETxR4YuLHUkEUHn6bI9yY2VRCHOAUxI5OTtYqNoOOan1DwX4q8Rz3IPiK/1W4uZEE22E/ejGFLEH5QPbGfeul034SfEq9ttXlv8AxTHatqSI8yFmdrlkACCTgbcAAZH45oA8y8LeHvDWq+D9fmc31xeaagukvoGMZuId4U+VbuoBAzgkvnOMCq/izw3pX/CZeHdF0AzWN5qjRw3On3MwnbT5HbCb5BjLMpDMn8PSu81HwJ8R9LL2+p61cizFyt/vsoTJEtx2c4Ax0+ntWXcaZq2oeKNM1zXPED6te6RMksaT2wUHa27aSpHBP40AY9v8KpJ9Yltk8QWX2BI3IvjBIFaVJfKeLYfmBDEc9DXPePfCD+D7uwik1K01BbyKR1kt1YKrI+xl+YAnB716BrGl+IdS1O/1pfE95LLdYRgIuUQPvWMAn7qnGD14rIvfBWta40X9qavPN9lLKvmwf6oO25iORwTyaAPLj0NekfDjQ9C1bT/EGo+KBEbbSrW08oz3j2kWZGIIZ0R2zxwNpq83whAllDeIIFhVMrKYOHb+6Pm5+tT3HgCa2sbzTYNdnWK6hhW5tltvlnKHKbju7Z4oA4HxLoUWmeHNE1mC5DS640slrpqozPDErlATJ0ck9BgE16X4w+Fei+FfBltqmoy6s93/AKFDLFFayBpJZDmRYw3GSPlAPQ+/FZEvw21rWEsdOj1G4vIdOiYW6eR8tsu7cyg5455xW3q+jeMrqW1urvxFMXt7oXsUsduo8mdlCgnBx0HTt6UAZ2neEvCL/EK30e/tryBLu3US2Rv8/wBmXBziN5lQh5CoBCHABOCayfG3w6fwp8NLDWLuK6GqTal5UzScRxQMDsXgbS3AyQSM8V2p8NeL7zUJ7y68bXS3tzam1mkWAAvCOdpwQOpPPUetcvceAdUTSm0dfEL3OlRv9sFuoLr5uMZALfex70AYHw30/Qr6x8TXHiTTpri20uyN39qiu2hMZ+6kQQA7yzd8jAqHwVZeGr3SGl1vTfF19e+awL6PbI8CDAwmTyWGcn6itZfBeoWujS2ker7NO1N4zcRiP5HZD8u/nqM1i3PxI8Y+H7+70y08RX0cdvKY/wB0VVWIAGcY9AKAOCpa91sfhPotxLpN2Irw6XPoSy3DfaMY1J0LIoPXaQM4wa5eb4R3VmbN9Q160trObTZNSluJbSUGERsquhjxvPLDBxz6CgDzIbcjeodQQSp6MAeh9q9J1H4zeJ9RsNQsLuPTTY3EPkW8KW+z7AmAMQMDkZAH3i3SsrR/DVppHxKbw/4xiM1vE6xOYLgwxgvjZI8gViqYYHgZyQDWN450mLQPGuuaPb+b5FldvDH5xBfaOmSOD9aALvjzxnN4yms57zStKsrm3TbJPZQlJLrgAGViTuIArlqKBQAUYpaKAExRilxRQAUYoOOtW7DT7i+kCxLtB6u3AH9TQBUp8UMkx/dIzY7joPxrpF8ORwrIs7GSUKSvZcjt710dtZfabS1jgRQrRCSPAAG4UAc7pfhR5JbaTUZCsEhGVi64+prsG0awsHltrKOJP4gerNjkZPWr2oTR3OnWs9uMSR8SIezDgisSEyTX8XmCRHLlo2PTGOh9qAK1ze25m81chWypx1jb3qW/1NbW0Mf3bhVDA44JHasTV7uGxummt0yTmOSI1gX2pTXbkyEkFdhHsOh+tAGr4i1ZrqaGeJ+XQo49fesKWd5QuWbgYOTUPWjmgA/Kg8Ud80uDj1PoKAHQyPDIJImKuvRhW1Za5LBbqoldZdxZ5epb2rDooA9T8Ja/LLazW/2xJZrsfPBjk47Cu2eWPXIZjpMEL3NvGpEWNxAHBOeteDaTfiyu1mKtkdHX7yn1Fej+AfEclrfibzUFy7F3c/Ksqf3frQB1NraSyRvHcrs8v5mGMFifQetOmW4t1hs3YH5wSGJO7PQj6dxXU2kemeIReXMEKWrgBhHI5G0jqUPf6VnSWSLGbiMCNmI+c5xIf5jigDPWa3Ns6ypGs8K5jnkO1WGeuKngukWeSaS4MiRxZUqCeT2GetZl7DDLHN5i/MHHygkhhngVTmkuAx06IKXlbJYnjj+XpQBp3Edx5gdh5RKbmtYvnDDsT/hVO2kCW7iBVjZyGZcfMuPT0oM15btBdq8dpJbt5KkHgZ6k+ufXmr1zd281xaytbwo6pteRRgStnqaALOk397eXqQQ3bfuzujLHALDvnuK7S11wyzSQ6rcKGKnezKAW/wB0DoB6jrXntk81xdJDtVXfKKkbgGRs8YPYVYlS6kv2hkVldAdxbGIwB29frQB7P8N/FlnOl3p87RQ+TIfKlICK6+h9/rXogO4AryD3FfL+kvAsNwsg8sTr5cipLksR3PYD2NX9J8SXUdh9hlluLa2gyVkExUbR6c9PpQB9D6hf2+nxb7l9ueigZJ/CvE30OHX9X1LU9VuTChmJLLhVfjgEdxisFfFyyXMryLNuuCDE6uXyvQ5J/TNV/wC34poLgrFuzHsWMtkKAeSR3oA2bjw9ax2jT2N4ItqFljcnfITxtCnp7VZ0jSLxI7nU72+mCC3EbeYuSV6BSOv4CuFh12aK5uCkkgihQMFkOc+g57e9dDpnjG1suZ0kaYguVLAjnoFoA3tI0eK/ltrXTpFt4WizvuwVIduvl+n0NJrMVvGlqGtQv2dDA864ZHA7nHJauC1Pxrd6fLcNYXBa1cbjFMMHP19RWdrXiRp4ba4+0y5Yhi3AKt/WgD2TTvEcNlZyHRggi+zCOR5MAq34cmudn1C30+2FlJKUgKiZQrYMkhPqfvEdhXmltrVzFNdsZPkljLFQwClh3+vtUFnqltfxzvf3kqNNDmDyl3K0meVfpsGO4BoA6/V/EMcl9O8ckn2Z0IeFiSQfXA/pWbYa3bwXIa1uCGRCc7eF98evvXG/avJunMuxUYfu3yfvdsjvn1rPacS3EiIcTAfKG4IGeeO4oA67U9QeR4ZIpzgOCFY/KxJ6ivIfE+f+Ek1TeQW89skevFd9baluvTHc5k8sAgFRtx+Fee62c61fFcAGZiBQB6XDpvimKbwmuoeLIbT+24/9DdA9x5Lxjyo4m8pT8+GwMZ29yDXR2EXjbSxrupN4is9SvbS0udN05pJmWZ44CpuJbcYxlOh38tg9eKwh4g1Pw54b8EahJ4Gu7Gz0LzDaajPPIYrh5lJ3crgHJ3Dk9MdKwvC/xNvdC0KO0Sys7nU7aSaTT9TkJ32vnMGmHl/dk3Ed+nNAG94Q8GeNo9X0/XYNWudF1bVILmfzpoZHuGiRQWYxqpMm4MMBQT7DismX4V6/Nq+rWz3dpJeW8sGXlZ1M/nAtvO4bkKqNzK4DAdq27f4oyx2NtqMfhd10aI3Vtcyx38qiae5AMm2bBMTcZAXoDVS6+JuuyXmkS2+iRwzS3aTWnmmSU3kKp5McJLfNJwSPMBySaAOJ8U+Hk0WOwnsNY07XLS93LHLYM24SK20o0bAOpz0JGGB4qbxx4O1DwZdaXbau8Jub6yS9MaBswBv+Wb5A+cd8Vra/cXkF7De6D4Nj8O2/hmdWuMxtcNHcM2R9okcZIzwqHgDiovGHinV/ibqekLHpULX9nZtEU0+LmcAl3k2gcADJwOBQBxVFT2VlcX86w2kLyu3AxwPxPQV1Ft4O8mRv7TnBIQSCOA8Ed8sfT2FAHIqC7BVBLHsBzWjp2ky3ku12EQwT0y3HtWm1lHbTKYVAZTvTH8S960NLjBuDJEPmYEhf6UAYVlaD7QY1iDZ+XzG5x/ga6bT9PMhQwOFuUGPr7GprGwjedGUYMo/75ata20e4huLi7QksgDFB6d6AIrOzk1K/EUsZRc4cZ5z04qxZWU9kZLQ5U28h2E/0rf0a0EqCcyBfMOdw/hbsau3yfa9Jkv2jxeQZjnVf4wOhHvQBzCW80MV0kzBXl/eRsBwGrK1rVkWwtJOY51Odyjoe4Nad9rUKW+y4IAZCpz2PY15tq9+ZXSL/AJZgckUAV7nzXlmdg5hkJPI7+1Ukid3KKPmAziugtSk9tA/mfLHwF9/eqN5A0UzXC/LJG3zIeOPagDMCExl/4AcE+hpWRlYjrjnI9KleZWkkO35X9OKhRihyPpg0AIeOtTQSm3kJ2g5XGG/nUJycZ5xxU0bxmCSOVSW6oR1z6fSgCH8aToKmJV0G/IkUYPFSfYy0UbxyK2/gL0OfSgCsP5VsaNe+RIsUmPJB27W9/Wsp42jIz0PQil3Ha6sev86APVvDevmwkW01J3ubFmyqr/D7Z65969Ni1mz1PQC1nMJ7XzB57sP3kYXsR6+9fNuk3MnmeSj5bG5S54J9K2bbVb23nM8BaISOFkQH5X+poA9WnlmvkulVWC7s5K5YL2HsKyZMw3eG/wBHLIQpHzeZn0/+vV+z8baZJF5MgSK7dArwsMA++f6itq8u7fV9LjMgghMW1FYqCcHvlecfXmgDlYXfz5La6YStCp3rt4HuvrSQXTRq3neVLvwsSYySPU46YrXvPDjB5LnSbiSZbddkskTbVGeoyetZGnQqbpbF91skcZbeq9WPagC5JL5cwHmRwyiXIkRSVIx0HfFWZb26Mwa4UqI1/dx7id69z7g1Us47pNV05zbPMiEl1Y/e9PamanIdR1KUljBgkkA/6te4A7D3oA0r65sYtNEtnZskl03zu3O32A9Kz7SLTtUt7+K/uZYvJ5UAfOx7de1VZ53+0xwbSY4pE8ve2CV/veuKsapfSrJO/kxNulDM+4bsCgCm959ns40tnyV+UyjG0j0PoRS/22VtxHAIBG4w7FMFvUg9qxru7dJCqDbDvMjRuOBnuRVKN4pSWtycsf3igZXjrgetAGnq2uSkx7kUGI7oSAMMvYE96pTalM87OYwQSrKkYGUPcg+1Vpjbrer9ljYxAZXf1Ge+P6UjMACVlO0rgEDOD6UAXLpLl3kaaWMMymQ8ghh/jWfeyBoopbcAjGAGGDk9cCl8sJGscYdd6glhyDinRXEHnozuBcAFkyOMD0FAFHzs2k0ZYoCpJZvvE/7NLHfyQ/Z4wjSRBMr8mGz3JxUk0TXcDgBZ0L7guMBPrVCdXithNCCrH5V46DvQBPDNturtZsNE8eEY547gc9KrQOWgnecRrKTlS2QzD096qG4KSKJiQx42jkbaczYt5W3eYiEBc87M0AaUN1LE6fZSruY9xZhgD/d7VzF44nvJ5RnDuT83WtC1fzrtVjYrFJ0P931/CsXV1xqEoDZAOM+tAHsusfEvR2l0fTI7FbvRJbHT7bXLgbxPcJCOYQjEIoDc7lAJx1q74o8ZeD5dU1d9Gt9HaG9vtPI3ae3lPbRg+bu/dqyHOMhACccZroNB8NLbah4Gi8Q+E9Otbu5jle0SKAGAJ9nJSKVmJ8+Z2Af5s7c4HXFcX4l0vSf7V8Bf8JrZ2mi6xd3LLrtraItuq2/mARvJGnEbFc5xg45x3oA6Ww8Z+AE8YavcPJavp0uoebDLcaZny4vI2kwose0EN93enPVh3rhvEfizTdWufhvL9qOzRW8u8U2ojaJVuNwb5Rhspg4Xoe1dvd+Ek1q+tdL8XaNp2iPca2lrpD6ZFHDJPZ4YvgrkOgUIQ7Z5P3j0qvF4I0TT9J8YWVvot9far9mtZ4bJrmNr6xzIysgYKVJIAckDpx70AXLv4h+DL2XVftlrcXNvq9yl1fw4P+kukpEZAKgKAm1iDnOMYNWYPGHgq18V65PYfZbN54Zo90OnM32zdCVj8ttimAqT82FAb360h8I6Xf6DqFnBBpdj4UjtLaSy1eS2UyCcsBKXuQwYShiVMbDBx0FS618O/Cuma/Kt1JrE1uJrC0hSOVYm8ydyhcs6fMgxnIX296APHfB0kgWNHXbNa4dV/vDuK6rUpzKi3EQLR5+QjqAeqmsi6sjp+vajFDJv+yXUtqXAxu2MQG/EVvWkJ/syR0UHB+YD1HQ0AY9jAhlaKUYeJiBntnpTjEqvE8JCFn+Vh0z3FaOo263F9Dcw/IHHlSKOzdjUNvbn+zriyfCXkcvmxE/xUAa2mWcDWMkrsFkOB175ro7WGey1GymdN1vODHL7ZFYdpYRzw2sjfKjShZ4m9e9d3dq9tZLaMNzwkNG5H317fjQByd/p8unStDGXEDBipHbnoaaty8OnSxq+5ZVJ56g+lb+rSh9RtSrgQTr8pboG9DXn+oTXA1i/0+E8MMxqex+tAHKeI72LUnRW+SdEIyP61z9lGslhcxyA+Znch7g/4V3dv4b86WR2ytxkbo27+oFP1LQbe3sfPtRsuIzyOhYdx9aAOE0zM0DwAlXX94mB/M1sRWwurSSaVGeWIbGHVcH0rtl06ysLeyvrUJPbzR7W6blPcGtOTQLSfR2u9CILSMBIi87W/wAKAPD5YmhfZIpVuoz6UyvYtY8ENJFE7xFvNwruRjyfqKwtT8D20FsxEhSeEfvF6g+jD2oA867UV0V94UvobVbm2HnRucAD71YdzaXFqcXEMkeTwWXANAEPvyaUHHQmpbSdrdnIAIcYIbkUTpH5mbfcYyO4796AHW9wItiyoJYVbcVPXNamgaOuuX93HbyLbxwW0t0zSDIARcgfi21fbNYfY19AeHfgT4pi8E6pd2N1pV1caxYwrbrFO4IiaRJjyygAkIg/E80AeCSxPCSGGMNjcD/KpYL2aGNow5MbclT3PrUVzDJbzy282PMiZkYBgwBBwcEcH6inGLdD5qc5+UjuD9KANSPZLb70dZHBGVP31z6V02ka1Pol4rWtxIkHAZZcESfWuDVvmUKxQDjjg/nWnNqszWhtpo0miP8AF3U+3vQB7Zpvi6wv45tNikXTHmXMhPzRP3x7Zrcl/su5tlupPOXUHwg4CxlOmA1eB2rwvp2I3LFxl1DYKEd/Wt3R/FV7YxxIZPtNohxKsrAjHY5oA9f1ayVdIkh01ppkZct5inehB6Lj+dchdWFxFdhZ7ST7Sy7mUk7mT3PetDSPGsELv9k8yF9m0JndEy/j0qrZeNzcx/NGxuH3RLLIcqmOoUmgCvqFvFb2skwfzVQBWEgIxnt+FULotY3KpEFe3aAli4yUNbxNnJDI967tdyoPLZmADnHvxiuZWOYW5M4WaMkkYYAqB2NAFeS9R7iQ3ayB0g2goNwI9M+tLbyW6XG6GPCtF5eFOOD3I/rT47WS5swzwPDOjb1lzwVPQkVFZ+Wl1dtcO26NAqhhkNjoQR0oAp3igypGs6kR42MR1I7U0s728UpSNdzlmQjB471cne2mDRmISXB/hU4AJ7iql0kgjQGVAqtkKT82B2B70AMw9xatLEVXb0QjhefSqt/GjQRxbVVs4dmGWrQspA1nc3JIO448rPIqlLcrHOioscq9SoO40AKgW3tpHyR5q7UIzhm+tUE+xXNzexa/fT2iQ2/7j7NCJvMk7A5Zdo/2hn6VsQRC6WSPa5VoiYVX7qHvmuR1nIkVGUs5H+t7MPagDpPDVtpl38LfGtxfrp/9uQS2xspp5wJ2Xd86xITzx1IGTmuUlmeVwqqsbFMSFRjI96qFQc5wCvIB61PZnfJsYEs/AJ7CgDW0aMz3NuI1Qvn5QBlW+vpXP+IVKa1dqequQa7Tw3pcX2u3EpEKyMAGJ+56nFcf4mRYfEGoRQuXjSZlVj/EPWgD1jXfhvpMVt4R03RrudvEWvR2zq1zfxeXEZE3MWt1TzVQAcNkisT4eeC9L1zxZ4k03V77z7bSrWSZZrS5S3juJFcIB5sq4VSTjLAVzv8AwlmtHxFpmu/ax/aumRRwWs3lL+7SMbUG3GDgHvVOw1q+sF1ZbWVUGqwtb3gKA+YjNuI56fMAcjFAHp0vw9vdD8Xajq3gzW44bbw/NCry3JLzWxfCyDcE8ttu4jtu6gUus/Cm8tbbxRqFjqFqNC065ZI765dgWGBvY7VPRjjHX0Brirn4h+KLjSrvTpNTP2W7CiUCFAx2gAYbG4E7Rkg845zW1c+OPEUltcC4u7e4W5cTSrNaROok2gEqCuF3ADOMZPJoA7fw58LLK9l8M3zPfjTb3SWn1CRGHyXWCYwp24CtjPzc47jNZQ+F2q3UekpLf2G+/SSW3xI652cvjcoztHJIyMdCawI/HPiCK1tbu0v8rGI1eHy0+UxghcDHYMa6iTxv4ivYLK6TUSxRB5TiJA+P4hkDOT0PqODmgDi8mxujbvIkysSglT7kuDgMuex7V0ejuLe2kSTIhkUYJH3TTDaR6zMWZVErOZkdVAByckADgc9hUqy+VHLaXMZMigjAoAmtAplntZseag6j+JD0P4VWliluVjjkXbMjHy5h047GmvA1tPbTzybQo2rLnseze1bduJGEzRRhlPJj/wADQBLpNvJeWtw8itHLw5jz6cEiukv7y5FmjRIJJY49rKe4HQ1lROy29tNbHCvlG45Rvf2NU7DXJgVW7jKTRSFBnpIvp9aAIi0s8IQjbBM+9N38J9M1XvLJPtjLMpW4jX5m747MK6V0tn0ueN/9Qx82J8cxN3U+gqrGBqVwIGxHfwRZjbqs8fp70AZ8kqXEcLnH2ggRyEfxejCn/wBn/Z1VdXTa27fHJjiRe/412uj6BpU2iwXauvku21yeTFIKl1q/tbexNlewI5TlW7q3qD3B9KAOYsPClhdXVy6fuEwJoGzmOUkcirvguaLw79rtmjjkVn3hW5DD+h96pa015YWSy6eVks5F5VB/qyfb0qlo2k6gPPmf576OMusW7iWM/wB33oA9G1TW9Ovn0yZbdE2ExzgEZKHsw7ketV/iL8OYG0D+2PDkzSxhNzrKc/Ie4IrzfTr2yv7SfyJpY71GwysPlJ9DXrXg7xRFoGhi21Zi8bp8sTtvVT6KT1B9KAPI4r2G48JXEflD7bEwZHHBjYcc1Wn8jUtHRLmCC58xScoMNkdcZr0b4i6Lpd3dLd+H4kErQ+beRxKUUZGcgdvpXB6dp8WoOt3bZxGmWVTjp3xQB5zq3hex8pJreZ7fK8owz81Yg0a+tw0nkmeFUO8qM7Pwr2G+02Wz0iWQWiXcE2WQDBPvXOWty9mszFhsxzGw7emaAPMWthJAHhIyh2uhPI96+lbn4nNoX7M+ipBMya5dxPpUODholjJVn/CPaAexZa86i0jTNSsXuSiRKwLyKqYcY7+/0rI1DRrW9hjsFvJpTEjTQbtvyxkDLcHGSQBt68dKAPOzQK0tZ0XUNGm8rULd4+AwfacYPI+lZtAFiKZBEY5YwVI4YD5gaiAKocE4yOR0/GmVJDJsJyodT1U0AIhwknIyeMetXJbxdiRgblC4bHA/Cq6wM8LTpgqv3gOq1FnnPGetAGjYX72uWMztkcAenvUlrq8saqpy6M+94+w9xWSep9TyaBnORQB6hBrFpcxLCgZlG0xCY/cY9fqKuaxaSAxyFg9tINsjIcbD7AdRXllreS28qyKQxDBssM9K7jTNXtdSYtIGjVl2yKHwdx75/wAKAL6XUktjIm5PJZ/Lw+SUH1HY1ShWV4bi2e5RUHBhjGGbHfPpS3LrFFH9hUum/bsReX9jn+dV4xc2jzyyyfLjEaZ5Ueh9aAI4nh+0GCWQRzxEMH/vDsAe9PvLeM3szM8TPwSuCcfT3qC4jJhVJZN63A3cLzn2A6VakiLWwJcExEf5PqaALbRNFbAefEIJMOoH8Jx0NMis7OdIxhWmYFuPkV8ehqf7OiQRvK7AE8Nt4JPbFX4YC8RtRCGcYJdnGxT/AHR3oA5+5SdPvM6JnvwPpWLfyCaUh2UED5AwwFFdbqek6gtq8c8bFDyMfMf/ANVc6LO2ubG+uLu4+zS2ygwq0ZY3L5xsBHC4HOTxQBzNxGYplJAAPOKuaOsCzK043Bz9ztj1FNktTMGlb53LbfLUEED1rRh04vbL5Cus4+9ggYFAHSeH9Me4lFtK/wC5T960xPO3PC1574nKv4h1Bo/lTzjtHoK9BGqpYQxhFjlmACMS3H04rzvWGdtUumlIMjSEtx3oAbRRRQAN0H1ro7xHiMfyGSCWMAkdcdj9RXOdCvPcV2duk7wtE8YwBvhbsw7igDP0iNXkS3kJXzCQGxjB966aHzbaxEZHMbZwP7w6/mKybWMpqMG+M7APnPp6Gu2t9PzbSugEj/fXP8QHb6igCCzDW8yTQHFtP84/6Zv6/SrDX6nUVe6iwykI5A/hP9KfpCefZum392D8px0zVad0M5WUBZMiM56Fh0/OgCx4ghZYbq127otu5HAyMe9aXh14oFtnbm0lQQyrn7jdiKNRVy1vLaFWRo9ksJ7eppmkxxwzG2lH+jSjY6HsexFAGvqKCO3kjgO6WM7jjrx3qvP9lntTJcAIJgCWPGxx0NMsg0OsCGSTzHUZic/xjuprH8cajDHp0kcZ2OhyOP4e4I9qAKt94qSF/s6sPPUbHz0dff8AxrOsdVuEu4CrMroSFXORg+hrM0+whnv4RI6iSRcJLnIPpTHjjtb1hiRJoG5TtQB6Tp17Pb2k1iWVJpjvZTwr57//AF62buN7nwxFcouLqKUebG3IcDuPf2rjQZrvTrFp8yRwOGRk4bHdTW7eat/ZSoltMJLSbDLv5we6mgDY1K3mOlNqMEbwTKPLnVehHYsK4uXW7ucJDZ3TpJbrgHHTPofSuyutYjvNNW/0+5QSRptngY5yvcH1FcM9xHpmrtvgItrhd2AMjnuDQBQsGdNZbzF8qTO846O3c/8A1q9WsJtN13R0SdkW5Rs4bgH0I9DWDoGkaP4q8PX0JnNtr8A3wSLz5yj+Ej1rnbPUbyxtpNKubfzLmOTkv8jKO9AHda5pV1oM0d7b3ov7B8YQPhk/2WHcVh3G9LyDV7Jd4lcRmKIbVHruHr71QkEtw8hW8ZYtvBcZx7E0nhi4uYriVNSk3adLIPmhGdn+160AdDcW4l1GCSKaWGOM/cRMlGPXIrQbQtBaaEa7AWgdyPtScRsD9OhB7VSghsZLuc3eoT+RtKR3cY+4e2R3qjZahf6aktiNs+nM2FH3lf3PoaAOe8beDdS0SGU6XMLrT5ZtsAVhlmPIwe3FcxpczaUgmsJma3EwZH27C04GHHrkdPQ17R4b1abRLyAT3saWQVnj8xVZVz/CRWhoGl6DbQS2WvWceo299O0i3gVRs3cgKV6DnvzQBy2jeLNM1SBbPxfbRTWl8nlvcsg3oOxPauY8Ufs+6n9gbVfBl5Bqdg2XS33/ALzb6A9Cfau68afCwz2czeFrmO/k2/LCTiRQP0NcxZeI9b8P28Wl2xutJ1SIDfnKhsdiOlAHgN/Z3On3ctrfQS29xEcPHIuCpqufWvcdc1S38TrdC/s4n1dfvXBj++D79M15rr/h+O0uD5KGMEZCbuKAOZV2QkoxB9qtSLHcxp9miIkUfOoPB96hW3dnITDYOM+tKIZo3BRW3A8FexoAiIx2we+aMjPtWnb6fNdxM6oxuF+cqR94VQkDySO3lbcdVUcCgCOrNhxIW+baByAM5qsQR1BH4U5C8ZDoSpB6+9AHc2krrp4itRNI4X5UKD86hlhltoElEkv2qQ7ZSw3fnnpWTousX0BjkjmDFWOdw+575rqJPMuoUvBeJ5bHEi46/iKAKNr5ccqNCjOynBaJiQPUfWr2pxzRou1RHC53BerH64qmIRpd5M1wGW1xlGX+Mn1H9a1bVEmJZpfMkC5UI3HPagBlxe3lytskkKoEXIRRn8SO1T/avssUbhHe4bKkDoAe59KsaHZyIXnbywBn5WGTmtG2s5ZXnItxIrJkySDGD/hQBVl1C7g0wphPLYbS4JJA9M965zULaIY3qSFHmAjgMa6FpJSu3y4I1QbRzwfpmsO4sTeAq8jM+fuLzj8aAMGK/ByTErz5+8eij0PrVlhD5a+dNunkO7yVb5R9aqalayIrYxH820qB1xVaOLZcboUTzG6BgcfWgDTCrNctNModUOERWwBXIavxqdyF+YbzzzXc6ZHDPmB5AsQOSwHzN9P8a4rXVCaxeIq4VZCACc4FAEeKKP50lACj7y56bhn869R8MWxZ5bCUh3A861c/xLjlfrXl3V07/MP5161oalbiIofnjIeI+hA5WgCFIQb+VgmUQZwP7p6iuitB9nsQ0BzC/QH+FqfeWuzUTcWwGy4HmKPf+Jau6Z9mma506T92zqJISfX0+tAGR4avzZan5d1D+4lJWRCOVz3HtTvF+k/2fdNPC3mWswDKeoPtUt0YVdN/y3EDY9x7fSruuxPqGlxNbP8AuZMCReu1h3H1oAzYJ0leJl3faY06DuPUetSW5W8aJmcByCEcdPofSo7PT3DNGhxNGu+CQ/dkHdfY1NpqRyzZkBRXPzKePm/oaALNiBFqhN+rYdeGB7+tcr4hjeXWHkbDiFsbh3B9RXc30Wy1Am+aWE7wR/GvqP6isy8sbe5QNa7fOK78dpEP9RQB51JZi31Em3ZvLB3AbuF9q6TQrKS/nlnuRvkGMrjkiq114dkiud4ncq7ENEfT0Fd/4esYLzSftFi4g1S1XBRuBIo7GgC02mW7aSTC/l3Cx9jxIOx+orzW5luJXuVaeNn/ALhHDY9uxrptcvXmmihRmt3zl4xxg+o9qqJosc9pJNcERXJJMUw6MR/C3oaAM/wrcPEqz26CSKZvKnjP8J/wrp38OzXFmyQCTzom3JCw+YfT1FYeiPLbSrcR2m6JjieDs/qV9/avTLS7SOyT7GrXKOu+EP8AfQjqh70AeY211d2WrW2pWam3ureXDkDow/vLXS+OfEsPi5rS+ezjsdShUiWROVn+lTePtA8mzOuaezH7SA0in5gvqMj+tcz4etmay/0lCY5CW256j1X/AAoAzrXULqHdbxBXeQkYz09q6O1tbew0Il59lwAS8RGAc/3T2pkNjpEjNBHEs0kuShBwwb09q0r3QrlbK2nmd/NTCS2cg+Yr7HvigB+j6XMNMTUo5Wns5Gw+G3L9HH8J96cSftQhVSkAP3Djn6NUklpfWrBfDt0ogkUedbyDnP0rkru01W2klEryQyxy79m0kY9RQBe1Of7bdyQvbPGyN5eMZ4/vZFbeiz+VYqtzOZxuwJkYDae25exrln1C+sp2uZdk87DaMDDfU1qaTJBqAf7R5UGoSEA4bCfj9aAO3trnV9Oitb6ynguHhm3M0LZAU/3v61p6x4s03WpVHiDS4TcRfLHPCfvZ77vb0Ncpe2VzpnmOJCYY1DK9sclD6EdxWXZeKYYneSeAv5nyhRFjn196ALHiHw1Jp0c2o2s8McUmTvjyxC9gR0Ncc0kbWQstSgJuJWxHx8rk+9d3Azujp9vuPsLruCyjaFJ/hzWVq1kp094XWHUHQ5hkRuV/LigDynWvDtzpyyXqxyRCM/MqnKp6YrnvPnSOOXzANw9f1NemX9xI0jW1wrFGXaUPGD71xfiDT0gl8yGHzI48b9h6UAZKXV0gV0kkJII+9k/h6CnRTT3EEi2+9pAvzjGeKqM8Zd2RCoPAAPSkt5ngk3RsyseCVOOKACSVmUKSdq9Ae1Rg8cfWti5srWey+12jMqnhlY5INZL43DHXvQAqng5yO3Bxmu68M29vNLDBNK4HRpI/m49BXBHlWHQda6jw3q88cUVtCkYaPncBjj396AOr8Q2yWckwhVhBHt+eYbvwNOgi8vT5UndCZOUdUwc+3oKuzXSX9h5t1HD5m35UQjc3ue1Yyym2mCuZBMU4QkgfSgDa8NTWpszZySE3JPLoS5/AVsX8/wBsthFZyy74z5ZVxgN6kAf1rjtNjuBLutnVZJSWkO75QPTNaul6k6XPlG8X5Thl2/eHp7UAVvJDXEiXsxgt1blQeSR3J9Klsra1a/u45dRTTbYReZDJJEzm4b+4u0HBPqcCrOsahbXGqQCOCLeBsKgAjB/rVbUozHcJ5w8uPsSeR6ZoA2Y/DVte/CLVteutGmFxGxW21Bbk7g27q0X3ViA4JOWJPGK818kMgMTbmU4JYZ59q6U2ltKCIpHmmc8k5/yKr3ekLbqZblwMfdRTQA7TbaMxRI7gMSCQvLE/0rzzxED/AG9qAc5YTHJHNeiaQq3V2sEC+SoIzj0rz7xIBF4h1KMZws7AZoAq8Uoo7UDrQAfxoR1DqR+detWYxereI2IZgNy/3Hx1ryXksvH8QP613tlqW+2DRuQm/DZHII65oA7m/uJI4oTjo+So/mKbqbuUS7hU+ZEPnA/iU9xWbBcPKsVqR5n8cTg849PerVtfSQHOA8cDY47A9QRQA2+C39lFdI53uMK3ckdRVmwu5Y4TGwwMAn29/pUkNvFbXpe3O60nYSbMfcbvitDxLpMf2iK6s3CGaPy3TPyk9j+PrQBpnSAdHluLR9xYBzH3Rv7y/wCFUri1gvtEWS5zFKGBZk4O4fxD+tP0HfLpT2iyyRXlsSE3HBI9D6itKOE3ehtDLGBdLllAOBMvcD0YelAHKm7GoTvp7S5dBujccYP+FVBOLSxM6MzGB9kqD7yH1HtWla21tsm+x/vNozIn8WP7w+lRoI4rg8CUOQSe+D3oAv3ktvJplreOiuUIYOvRh6H0Na+tQ2tvY/brSQGGZdwKn5oyR09xXNS2G+/ijhnEVvLw0Egx8/8AgfWptQ0+/VfsMsZWEgjepzj0NAHKNrG64RnX7SsJMcgJ6g9D9a1rLUY5re4hjPmoeGjJ+dfQj1rLuPD88FpNcWy56pIB/C3rUEFoqx7wweQrycbXVvcUAao1ZrdVEEbSROdrrjDIw71o+G/EM1nqC3N1ie2V8gKMED29DWBY6jIJ0lmQmP7knH5Eir8hY3YmtY1ZG+UqDwx7E0AdVquuG0+1Lpu9tMuvnXePuMeoxWTo5W7hu4NpRH5G3jB9Vre8LKJ9P+z39sIyTtYN0/OsfWtK+wLLaM5t7jfmF+gYdue1AGNFp9xb6xBAHhaWQHbKzbcntj3rqdVu7jUYrWLWpZIbmIhfOHfHTJHauROmag7Otyu6Ycr35Hce/vXS6BY3uuwMdjTyRrtlRPvD60AOur2a31SK0hImmCg+aD94f0NQ3Op6paaoHvgJonBG4jIA+vrXT2OgR3sSQK4S7iywWUbX/wCAsOv0rMl0Zrx5DbS+dMhxJA5wTj09TQBo+EPD8WuxTJhGcHdGysFZT9DWb4u8MW+nzJJYGS4uOjII8ZPcHHetbT9M1UxQ31tH5awkZlhHOB2YDpiu+j13Tby1IuJrea4VcK8RCSg49OjUAfPUd7LptwsjCdQ77Wjk5GO4BrdurODWLfbos8T2pw0sM7BXQ99tdv5OlahqwtNSMN1BIDhihDKffHIride8HLp+oTSWM/mjdgeU/wAwX0I9KAKugRagLz7Da+ZKUkwoc5LD37HFafilr7Tb8C4s4/NZOFi/dkD3HQ1BZJf3E9uNOREvYjy7LtJHcfWuk8QWC3cST317dXMroE8qLBeFvfPUUAcql00+nvFPabyyjbPsBYn0/wD11g3kJhPk3sEQhUdSuGA/DrW61m2hTrZXrTxR3J3DzVKbvx6CrmqXayWDJaWiNGo2MXi3fjmgDxLxXpkVnKLiyUm2mOQ2f6Vz9eu3ECXcTWdzZRN8pZNvf/CuJs9Gshqlxb6rJJbEZ2Ko4H496AMbSLlba7wyI6SDad4zj3qbWLYJcF4QPKYZLngE1Heaa0V1LHC4eNW4J4OPetXT3QW/kX8DysflR85VaAOdKnAyDToXYTIQx6+vX2rSv7KeI/LNGwHUrxj2rKY5OWwfpQB2eh3cXnxpGyRELhomGcD+9mtt/sksrSQu86DruO3NcZ4fmRpcMiMyjowJz+XWunxC6x7BJ5h+8uQAPwFAEdjexPfIkiMtur/KNhwfUZrUvHeFHNuoFuw+UrjI+grHW+Nm0cAZpcsc5Uf5/KtZtVhJiLKQoIGwrhc+lAEVtpVzPJbypE8mTuyxwQfU1YOoaXDcSrrcc58rgADhj9a3I7ufyyd0LK/RTxgfSsiHS7DUor261G9SNrf5lhJwZecYTH3jQBR07Ube6u5BGjQ2ynhfbtzVy7CSRSee5iibhD1Y1ZgW1cmPTbJYl248yUkk+9VZ1eYi3ii8yUdMcfiaAM/S3f7a3kfuowwUFzy3+FcD4hBbXtQLfe85snGa9FhjkSWSC4lBuFYEIn3VH+Nec642/Wb1jwTKeDQBBQKKB3oAXup9xXVWsInlMqf8e5IWUL1HvXKj76An+Ifzr0Hw3YyLqVxHPt2OcAr0YY6ketAG7o+nNHCUEh/dNmKT+6e351qTMvN6qAM6+XMgHVh2P+NR6dP/AGfdbblOFGyQHoyf4irN3CtveyJE4McmGX/aHb8aAGxI6LHcW5zATjHdD6VeuZIXSO3u2ZbaU4z3jPYj/CrVukcUCOybQ3yTp2YHowputWPm6WYJQoniYFHPSRexz60AWNPdtNQrqJFxGvytKOu3swqPR9RW3vruyupDPaSHfFIDgj0Kn1qpvYQKvmhZUGDFJ0cex9K5TT9TS18SSW3lsYiu5oiMgfQ0AdMtzBJfsrOY9QiJaO4UYEq+jVFmQ3qXUEYMTZWRR0U/0qKTbDqSNbYms7nnceGjPv71sPb77GZlULcLxIE43r649aAMvT5bfUdbW21FJI/J+6/9zPQj1rpi1zp18bXU8yQDBjuIzkEdmH+Fc/a20zQrIoLsvAdeq+h+nrW7b3wktVh1BlWVMptb7rj+lAGnDPEsf2xrdSrfJOg/jX1rzXxNbJa6hLPaN51qxwccOq/Tviul1RnNulpbOyqSGVWb73sDXM+LNPjjnt72zkZW3hZYJDyjEdvUUAVdNiS+1GKGKVpHk+XaRgvW9Jpb6axG7a7fdLcDPow9axdCFza3gfCtIrZwwx8vt3Brr74T3cnnSg3FscCRCfnQdiD3FAFS21qWxv0heMN5o+eFjw3+0prrNJ0dfEMrwasksVquGjdxlU9ieoFef6jHEl5F9qIZYzmKdeOPQjsa9t+H/jDTbUWmlakUZpV2xXBAOVP8LUAcf4v8I3Hh28t5Q7zwE7oZYn+UL6Gm+HNWW0u5Lq2ja31FjlbiMDbIP7rDp+Ner+JtP0QaNNcQwowhO7ykYgN9B6fSuP8ADmiWetrdLpLRpLGA/wBnl4bB9x/OgDNzcaot5cXyxbnbKNAdrxH+tc5NaXlq89ylzLhjiQuvzfU/410eoafJpklxZyu9tu5EhBzGfY1m2WrQ29tew3hllj5DSEBxnHXHYfSgDsvhv4p0m0tTHfRGGfGHvApKNj+93U1x3xMsIYdeF54furWYz4nQo6svuOO9Zvhu6upbGbyJBa/MdkjrlWHv/wDXqxpem24E99fQJPj7kkDDA5/unt9KAI4Zru4EbqILa8lAxIcgMR79jXRK6y2iTanD5eqRMA0quMSD8P51R1CK2iMUssPkiVcKjtkH3BquLQTullZ3EhdhuKbwSPp/9agDR8Qaabm6j1G1vmRQmC5i5T2OOv1rmrRrtHcyTWt44J5Hys4+hxXVzafezWX2SXV4GnTjbJ+7lUe3rTbOyli/0bUSZEwQsgjDMvvQBmPrthqem+XqqXBmQ+WgfqvoK5tLmHR9TNrqQkNs6niM4JP0rrLTSLG6WQwq63IypaVQFP49q53V7KO4gkMwlE9qcLJncB9D3FAGHrUMSyb7XEcDD5I2PLVy11p6bstsfeeY5M5H0rpLAvNJchBEY3H+tOSFb14raiXw1caOYtXa4j1Zf9XLCMq/5igDy7VrOCSORYYSJUGc5AIAqhpis8fmDc4Py4C/yrvtU09JLSIvbHz528tNoxu+tc5e6VdaIDaQQnznycuvI+metABceGLpLJ5Z7eSOGTmPI+Yn65rn5NLaEEz24VQwABp19qeoiCO3u57iF42+USSHH5VVu9Re8hQvIfOTjaM4A9z70AWbOK3guFcYSQZ+ZeOK0NP2G7RmkZWc7yScfL+NczaztJOFlO1v4Mc8+n0ruYdId9MhMqRGRyAoDfMR6AUAU9QitRNJMmXKkMMnrVm3vTd2wLOEZeieWBU2taeLZULiSKNAADgbifTNYu22mkKoHF2eF3H5fzoA6JVM8ao88e7g4Zf0zUPnRm7IVAVT5SVO1T7CqunLKkUkU0cTyJnLs+PyrQ01mKeZOY4wvA4B/EUAOOoSmNgFjhwMKAD+tJpyx+ZuaURFV+YgZLGpribzI2ZJF2jozDLGsrRre4vbsEHcyH597YAHagC2PIuJ9sCSyHcNwHT8a8z18bdcvxt24mIx6V7Xp72636hvLjjjOXk/hz6Ad68Z8VOs3ifVpYTuje5Yq3TIoApfzo7UZpR2oAbj5lHfcP516ZHO8MSvKNsqkBmH8Q9frXmuDvjxz868fjXrAWGRVSbHluo+bupx3FAHRwRtdLDMAsuFww7Op6ip9V05Y4o1hJKAZt29B3Q/Ssmztr2zuIZrGXdAPlaM9Kv6rfzSGNUHlHJ+RujH2PY0AaehXqXVube6XLAbcHjPt/8AXqe+mFla+TeDzrRziKX+JT/db0Nc9pt/am4UXBMe/gnoUPqKm1C8m2z212vmIeCf4ZB2PsaAKnic+bpbSxNkryDjr9fQ1zOk3RS+trh8tE/yu/U/WtC8vYm05oRMY5VO1ZTyD7OP61ycE7pe/Z5nWOB5Rubsp9vSgD0O1sXjvZGlmVWbmID7jDsa2INSH2cmRd0edm8fwN6H2qOx0OO6tBALrzYCAyfN88fupq/DpyRiSBmAnZe/3ZR6/WgC7o8KCVZLYkxTdU7q3tSau1rLceVqVmS0f3JohjB9CKk0uEpZCDPzfwMpxhvQf4VHc6mx2vcKrXUfyntvA7MPWgDmJ7SYXyW88zSWaPvUYwwB9D2qXxAYHe3FyBl/kEnQt6Z96t32o6dfvCwSWGRCeF447inXqpLpiLDm5WNsq+Msn1FAGXLc28SJaXqssmfklH30PYg9xWhfIG09ZLsPmHpPbnBI/wBoVmw2M0N2UmjE44kVCcgfT0+lep+FfD1vq+lvqFuXZ+jrjLRkdiP4loA8ds0/01xKTJBIuDu5P5Hr9a6vwdaWkmvxW+wz27EIytk7fz5FReNdJFncboWVIw3zxgcxn1HqvtUCC6sPst5YyEyZGHgYHcPXnv7UAfRUnhbT7XRri1W3E0IjJQEkMpxxg5rhvAeo22kXwh1ZBHMrMnnKCrR+zeorZ8J+N55NLBvZIbowKPMxlJgPUqev1Fcb8RZ7K9vk1DQrlrYTMEuBMNqk9mWgD2N7ay1bTZlvHt72xkGUckcA+/avBPGOkHw9rMVpaTkWkrYxIN5Rc+3UfSp9H1y80d7myaZkkUbgyy5DqfauG8R+I573UV86SRTGwxI3JX0NAHuMPhu90nQC1lBa32nyxFnjByye6HGfwrz25tL5LMSuJDZo+9Vg9j0rc0XxVc3elraXjXVvdIn7q4UnZKO2R3rDhbUZJJYJ1mhSViS8LfIT6/8A66ANaIS6iY7nTlyHA3xToCPqPSn3mhSp5cipHZXCtuWTHX1A7VXtEvLK8jGJZHxtUPjY4+vY1f1ee9NxGMvEg5YXByhHoD60AD3El2htZjDdTDgNIo3Y/p+BqCzum0OZkln8wv8AL5E3UfQ1Rt7Sa8M1zZFraNgS4nbcCR6egprPE9pGzxNI0fAZk3qT7P1H40AdR4dvoF1uO21a3kjW6/1Z39as+OPh+UWS80bz23DLKp3H8q5nw7HJPKbnzbmSWMkImzJiHfivRdK8UWVppL295fmzvIs7VkG/I7HofyoA8eksbzTrSUmxkhlBw0ittyPXBHNcxLLJdMzbRIsLY38Bs/T0r1vWPiDp95btZ3jLIrttkmMY+VfUe1eZXU2j3GqzJplyZkQcO4GG+goAr319NLHbyLflxbNvUBApQ+o9azLjVZtWLT3t6bkAHBXqv1qDW7aSwv8AzL2zJtZBhfJYYU+pFLaaFNewyC0gM1xIOBGc/SgDznU55JtQuOJJFLbUJ54qnYzSW9wVyE/hO4ZH0rt4/AfiASSx3Vg8ZJ3BSQv5VzF/p11azS293AFUPgnv9M0AUbqQIf3hJ+bOUwAK7K0v3GlpK8MrhBkPkAKfauOvY2EojEOxduBuOfxrStEddLZQ+5h6cAGgCzqerG+W3IcsVf7hOC1aVubeaRDcCNQDg4bDVzXkqY1PLSH+FP8ACtG1nWFU3wlpd20HBytAHTXZtIZI2jVtnYN3rY0Ozt7y3vZDdWcDRQ+bm5l8tZP9iPI+ZvauMvFvBcpLclXHQLv6D6UsQ2SD5pHPXBbhaAPQNF8OQ3/w01TXZbbU0vbSNp4rg4FvJ84XYBjnA6ksDnoprl9LgL3KxD5lblirck+hNWrNrqS1e2SW5W2Zg7x7iY2PqV+7n361U/s0vd7bQvPMx+bnCoKAOhvAlrbmJBGzD0OQteMasc6reEEDMpNeo63dWekRxxGMyXBxwOQT9K8tv3Ml/cyFQC8hOB2oAhNFFKfagABxJFzg+Yv8xXs1/Yw+YXi+SaHEhUHOQR1HtXjIALoPVwP1rvrfUJU1FfMkffbfKH7qMdGHcUAdvpq3CRmayxIuMtA3ce39Kn1W/glsNzRlmPAzxnH8mFVLLUoJoVmgcRSrxIg6D3HtVW+vFnmAciMscOP4W96AMpg0sgk5MAbDOByh9TXQWV0Y5DC/zRgABj8yke9UoLIxF4X4SQYI7GnafciDfE2W8rgMRz9GoAw/GduY2BijADZYsh6j+tYi2onsvMjfz45PlZAPmFbXixRdWcqxyFGB3ID/AAn0+lcnpk9xp8kdwu4ng465IoA6zwRrCWtw1lezTeTG+EfkNH9K9gstHvtV0k6jpAN5AjYyRyGH+etcnJ4V034geFBe6RMtj4jtwGkizt87H9a2vhX4xl8Jag1rfxvErgJPA3AJH8Q96ANr+w/P02a+0ouk6c3lg3LKf7yjuPpXN3iSzXMbbPPhK5EoOGGO3v8AQ16r44m0fWdJOraFcqt9GMsYTiTHuO9eQ2812k81wrxzmQZMTfLuPrj+9QBWaa3km5h3xodsqoO3rjqDRd23lxefp2obWB+Uk8OPQ+9SmQ2X/EzihEc5XBzyrj+6fesnUNQgnVpYohA8nVP4JPp2z+tAFzRr2ee/K3fzMn3lQ4YD1HqK9Gj8TWmh2MVzpMuWYYYqcYPuO1eONqUNuEe2QCdRj8PQ+lZTa0ZdUMK5WFx8wyQyn6dxQB63411q28U6LHfJaCDVlbaTG3yyj39DXFJcSWUSCIuHH3o5Bgn/AD61RF4IU8mNmYleWzwfqKpT6pd2ww8qXLIM+XIPmA9jQB2EPiCBwJ55CHjGBNGMNH/ssO4rL1DV49jbZka1Q78eYdv5dq5WWa2njNyZGjLj70Z5U+h9RXP6ndysyjaJI+m4cBhQB2dxr7RyvNgssgGJSd236+1YjXcl9M6zB2ccsY2GwjscGuYe6ndfOtxtAO0KOv8A9erNheG1d5AitLJ8pUjp/hQB7f4Q8Q6dc6THZX6yRleI5lbcv0Ipt9DJb3Uj2k0k1vId3ySkgn6Z4ryXTLw6bceejNHHnLx4ztPrj0rvLLxHDcFEaKJlYZWZOo+uOaAO1uJohZRqskqPt+ZM4P4/4itC28QRPpvkToSQMeW5PzD2PNcDPeG7vIFluBJCB8vHNKbtLcEI6SFT1XO4fhQB1MJvra4SbTWEsMjf6rd936ipLi7u9NR8SfZJpm/1LKGjI9RWQL540iuyzzKnEik4Kj1GOtSalrdteotuJPLDciQEt+Y7UAWrqe5cQk3rx3ZOBhSA34itOxtbKB1TVQzXTDIkyWz+BrjBqQF+LaOSaRhxgLwfpWotp5rKiNcPdZ3YlYjb9CKAOv1HSPDOrWboZ/slyB93Z9+uJvtMgimVNMt1M0fHYZp+qgwTQSzxPFOp2vI8nygeua6uy8GDV4YrxdXtbcBflYk8++TQB5Xrq3r3KLJE0Ey8AMwKtV3wzPcJcNDBFLDOvVkbdz7Gu3v9CstMaVUvory+dgWdW3DHsK0vClmr3Ly6ZbSp5fM+W54/MUAYNxo2r+X9v1aa+Nox5laQYX2qG606yitZXhsQW258+f5s16JqerQXlgIYrNbdX4Ll9zHHop4rAuTaWcUaIvnu5wu9MAH3oA+etZspDM8qIqhicyuMH8qfpVlKLOTEyyBuFIjLNXtXivw1Zy6ZJfSXcavt3FcDaPbArg4rSRdMBMzvE3IZQFGPagDD0HT7q0GWt0ZicCQsM/r0rL8QBmvWDhRj+MZ4P9a3Lto7SSIQI3PJaU/17ViatNJf6tEsDxEr12mgCHQ4d2bi6MjRBto3Ejd/9auye1tBYLsiGw8ko3WublW4iiBa2WTJxhO3ua3tNltZNNvJEh3GwRZZd7hQATgbQcF+ewzQBC8wMLQ2+7aOgJwPzq7pY2Q5e2AAPXpuqCPM6m5uoiF/hbp+QrRSGWe086dZBGBkMflAFAHLeK52MwD7EXOMIM/rXB3R/wBJl2nC7jgV1ur3cEt8Y0Xeq9WLVyV6d15OcY+Y8CgCPNJmjtR24oAOjxnGfnU4/EV6z/Z0N7qjGKVA8sYMLH/loMco3uK8mHLJzg7h/Ou6McrLHuZlmhcOCp6+4oA04LJY5miuXe0lRioc9PoakjuEguGs9SQN/Dkdx2Iqc3J1VQlxhZV+Usw4Ye9CaOwCnlvK6K3JUf1FAGlZloYzG8guIB68tt/+tTPLEd2biCTzEPytnnHsfb3qOWExyRm3ZsMNykHkEdqTzMFZlwjt8rDHyt7Ef0oAp6vYpcwyqoMbqCUx1U+nuK4yxCMWtrtvImB2q38OfevTLeWC4Ro50KMBk+3/ANavOfGECW2obQ3D9GHOPx70AaFrrl1pEgG4xzxkZCn76+oNepXWueGvHGhQQ3B+x6rGAqXa9c4/i9RXgc07lkSZ1bYflY+lAnksLlntZWRh8wA6GgD0G7vdY8L3xS8lIgIwJk5RvQ5rZ07U5tbtlvJrdZJ4uMZwXX2I7+9czpHiH7VbGO6+ZGG1kflf/rVPZRy6dvk0uTMXUwt2+ntQBtrqXlNJbXTu1lcdnOWjb0P+Ncpd3UtvcSQvKkkQOAsh4kXtz6ipdUvortg02+Nh1KHJU+o9qz9V0xUtpJ45xJ5gyd33T/gaAK93c7ZS8UjxyJ3JyV9j6ikEz3LROdqyL1I6EevtWQrBomikkY4GVPcU9JHliDedtEYwdvGaAOwtXMoCz5inj4UvwHH1qO9t1S5j/dsrv0G79RWZY37GyVZSHROm7t9DWxa3FsyxTo6TYOPLYc/SgDGvS8UEkZjkUE4LIMgf4VQgtb6WNYreIyB/lBxwfrXpVlotrrd7HDblLaZuo38EV2sPwu1jRnjgt7Qyrc/dkY/Ip7fMM4/GgDwaDQ9SRZomh8tk+YBzg/hVzS9Lt5omW9uGiu2PWRetetav4T1XSVMmrwSHYPmUDLL7+49xWFNp9ndRhrYqYj95WTIz/SgDzW98uCUw5MkkfQp3FSWko8wmFy0vBH8JX2PrWh4msLWxuVeEKR1ZMkEfSsiY2zzJ5S/NjOc4zQB2FneTJb+TcSjcTuDog/XvXdeG0jvAJVjtdyj5ged307ivKba8aGEKypMi8qX4df8AEV32geMdIFikN/p0Rlx/rEbHNAHUyQaTcvJ80sEkQy6RE5/I9awNX0u1cLJZTGWJuihdp/H0NPsfFFhBf7XtfNhkOBLuIK+xNd1qtn4Wk8PSX1lHdC927gqyBkb2NAHk1wZNMnjePzkwchiuSPavQdEvBctb3QeMXKjLJISu8e/rXMvch7ULZSoVI+aNskofTB61o+GtQFvIEvLK2uTyP3mYz+GaAO9MFtOZZYbOMrIvzoxWXH05rFeWGG0kieGbCHO1XxgemBSXUNpqyiKCZtGA5yW3DPt2rndYvp7C6SJL22uSvAkTAz9aALay6NeOEjWaKQnaWfJGfritbw1a3sNxdWVi7JH3MkhQsP8AZ9a5c6rPdWrxWqRGQ8kJg8+vSjT7jVPOihuw01wBhQzbSaAOt1pTpzxwTs10zn/Vuwzn2xWDqENx9tLi1lWQgCOPzchT6kCrjvcJa4n8q3YclBhn/M1miSSRx5KTKO8jNsH+JoAsatq19a6ObSewh8yVdpdieR9K5K4tpoLAOyuyoMqrEKorXvpraa/WNEaSaLrPITx9B3qj4muLmazeJrmNIwuMiIA0AcnfObu5kMpjbeoACHO36DtWRc27xzjySsTL1LkMCPU4q1H9nWBHlnV9oxk9/wAKobba683yyVzwZHO0fgKANmHUgLZopbkIpHJjXk/SodMuIJLl44i0kfQho8tmudcR2jlXO3HAcZJNaulzQhkZJJUIOc8DP4UAdXponW5k2wlgBlC/b8Kg8T63diEQSNnPGeoH0FW7fUljjzEpA/iZ8AmuW8WX32qPZEhL5zknn8qAMW4uTH90FnJ5yOT/AIVkSEvI7OMMTkgVYaWaMJufLE545qtJ80js2QSeQKAEopKWgAOdyY67l/nXsFja/a4WE0WTtHI4ZWA714+ceZFnp5iZ+m4V9OX3ht4khu9OcMdisrLyHGBQBxVjpyxTBy6vHJ8uT0z6H0q4Wnsb+BRGXhLYIJ+ZPofSp9SthJcEsjQPJxKg+6T2ZfepbdXjdbLU8SIR+7nH9fegB95pcMyfaE3CBjkmPrG/qPT3FZHkiTzrS6RWL8iVBwT2bHb6V1NjbvFLJ5cuJUGJVxnK9mI7iob3S40jlkx5U2N6MvIH09RQBh29rLpkAaV98a/xHnb+PcVyfjawgkgNzEhRSdxA5X6j0rumuDd6WUcoJHBCsDmOQ/0PtUWlxQ3GnG21G2V4X/dllGSh9xQB4ZPGPl2fMrfdYfyqPgOMkHA6Guk8VaHdaTqk8MMLGBTlWA6iucaNihlXkj7w7igCS0mkjd2h3jHXaa6PTtbS7CwTjZKv3JBxn2NcyzGEgxthmHOO4pGYIUYAkkc56GgDZ1GNhcvucqD0J6j/ABFPFwYrLCnD4xsblWrN+3v9mKybZOwB6ipoJ0kiUupx0bHagBIYo1dWyYmJ5VuQP/rVNf2jQ4EHlmM8kjpTpLqGMCF1WRCPlk7j2qWyMjQssbo6Hqp6/hQBnW7MeMjYwwR6GtaxvbcRLDexBZk+5Ih2mqNxCJHREkEbA/dYYzUd3a3cJwBkDkgc0Adt4c1ZGmbzdzHIxMvDJ719M/DvVNSvtPghh1eNgo4WZVdXHpnqK+MdMeaC6WSOQqXH3Fr0/wAEa/PY25Fy0hRupibDL+FAH07rulxXljcRaheOWj+dYdo3ReuPVfpXzx4uhFvOx0yZPLUksBwTVDxl43vmgj+xak0wjOFySsifjXOXuuw3EPmswnkcDzFbhwfUUAc94jinu5vMVjIo53Kc4PuKxt0ibWkUgJ1UCulvLmKSGOSzYw8YIcAbvbisG4EsmGkXA6YHegCKK6keRWaESKh6jIwK6OzntBDh7SRHYcHOaw1WFQpiiZT0ODXS2ipJaoLkK4x244oAmsVS3IDESW7dfn2kfhWw6QW8Al06a4D4/wBXKu5fwIrIeKLcFwTCe7c7frVu0VLaQIjKqt/GjnFAE2lz3Z1CItKiZbLL6iuxn1mzMQU273Ew6j2rz67jA1KO4S98pk6bWHNaUviC+ltWgkW0uW24VzHtegDQ1DXFE/k2sMsMbdmlAWqrtGY23PCm49+pPtXMW1208wSeE7kOHrrBYx20QuFL7dmdpAYflQBNpenyRRmeLzIm9MkA/iKlvEljZb6S7xJGMAo+5l/OmadrEb24iVUklOQVfIxVuNZyds0MEET8bwhIoAteGNbup3KzS29xB3d8b/oa09U1vy5NkNjNcIBy0WBisi28PR6UnmLco6vzkJxV+01C3trmNLm6YwsQJGjQYjXuQD1+lAGRbMb2aeZrGUkjrJLgD61SvrSDyHIjLPjlUf5f8a9Uufh1fQ2Rv7G+/tCxmXzI5LYEhkPQlevT0zXGatHbafb7VcPKvXaMfhQB5PqGRanzECAPjcV4FUJ7aSJQC0fldeep/CtO9ke31OVeqTvuII3bay5tjStEnDE46cmgBsF48+4OsRWM8sw5/KtnSdOl1eS5k0u3V3s4jcTF5o4VCDuN5G4/7IyfauUuovs52kKB/dHf60sc+VUSqTHnjBxQB6rpeiNL8JdU8arFKyW8yxwx7QQ67grux/hAJ6V57d3fnylpXXaeuBUH9pT21pdWNpcTpZ3m37TCshEcu05XcO+D0qk7nd8hB45JOaAGMxVygcqueMioW+8e+D19akYZUsxJbtUR6nGaADtR+FJRQA5BmaADqZUH/jwr6l0G8fT7mXTbrdGgxtweEbA5X0+lfLcPN1bDP/LaP/0IV9meMdDa4nN3FDsu40j8wovDDaMMR2+tAGRf20FywFzCpP8AEUHDD++v9RWTfeHpSki2g85kXzBFnPmL6qfX2rd02J9SjMMP7nUouQh6Pjv9feoFTULqCSWLNvqFq+XjP8xQBw0t+1qkNzuP7o7UmH3l9Ucela6apDc2uAA8TfNtU/d91P8ASr3ibRxqNpLqtpEsdx0uokGUY+pHbNcBY2rQXJ+wszLnc1vn5kPt6igDe8gLFLDbiN1l+bYRhZf8GrntL1OSw1iWGV5Iw/8ABJ69uf61sxpKtrI1pmVOrRHhkPqKrGOK+iVw6SuOqvww/wDr0AdBLHaeIIFaRFiv4xtVs4Vx6fWvJvFPh1k1GR7dfKuFJ3xkY3j2966NLy+sr1pYkeNYztdHXKOPf0rcENr4qIaOUJOg/wBS5+ZT6qe4oA8QuozE+MZVfUdPakSQeUVxlf7p7fQ13PirwtcWlw+yNmx/rFAzx6iuO1LTZLN0KZKN0Y9M0AUsrtxj8acs7Im1eMdxTCDvwflPvTmiIXcCDxyM0AAZh1PynmrUMzxQDcuY2OVZexqr5TAZxkY7UsczRxug5VuoNAF64mDGG4ZSxU4YEcY9a1Y2hba8dyyqR91+fw9xXOb22+W7EL3I5re0W3h2hZtu1jxIpyv4jtQALFFl2SMkdQU9a1LW8Sa0KeYwnUcEcHNajeGkSAXNm+GIydjZDVliyJdnkRSBxkHDD/GgDnr+aecuJG/eDqD1P+NZwl+TlTuHfNejWukbYfOgiimA+YBsE1i309k10fOtGiKDDqg4/KgDl2upGiMS8hvU5x9Ks5aa3WMRSK3TJORXRRy6FGu+GOOUHkqwx/8AqpkmvaS0RjitZIiOhxnFAFWxhNkhiuvmiYfeHIH0rWTULeO18r92SeBkZP5iuXutVkmYLuIQHggYNRpM8c6vcxeaAcq3Q0Ad/Y3drJBtMQVSOpB61O1pK9vlZo3VuqLg4/HrXNWWqBW/eMYkbqepq+ZUsw09pMk6OckFs8/SgDT0u0sYDtvcEqeGfnNR601tLA/2GbaRxxwKyhf/AGtd0ljsB/iXvWRqd2YZiqRSMuODJ2oAWCUQXJEp8zPXb/ga3TqltDZgecZlbjCuQR+Fcfcak0ygFBnvVZlaTHlq2KAOqtdQFvc+aPntyflDcla6OHxNbSXEMb+c6Y5A7fhXn1i0gLRxsqyN/e/xrXsYdxLXSyAj/lopHH4igDvNY1KxuIUUNfRdCCzcH2xU3hK3ae+aQxyyq33VYcH8643TGukuVWfzJkJ4kUHhfQ16voQsDbxGKciUc7YwefYmgD1DwD4ij0Jo9M1WaO3tbhv3Ct0icnpnoFP6H6mmfGPT7LUtOv5NN8P22ralaYW6eGcxXFtlQyuVC5kXB9/0OOA8Q3Q/s4xywxEkYO5yxri7zxprNnqsWp2eoeVqMSLGswALMqgAKw6MMAZz1oA5AQBWZr6UCY9FVwM01r2C1gMiRRFvVgSTXo0+naP8UHN9okdtofjVVzLYSHZbaie7RE/cf2/PPLV5drEd1p91LZarZTQXiMUeKYFWQ+hFAGJqV2164crGo/ur3+tQgP5LlliJAzknp9Kdc25hiP7vapOSQeTRBpt9fWt3cWlvI9tZRiW4K8iFScBm9ATxQBQIDFDxhuvtTo0D3McS7naRgihRksScAAd+ajGVPTnoM103w38Sx+EPHOma5NYQ6hFbP88MwztB4Lp2DjqDQBjX9lPpN7PaX0EkN5A+ySCUbWQ9cMOxqpITJIzgAAnOBXS+PNRsNc8a67qlhIws768kuIy6lWwxzyMnmuYfAdgCSAeD0oASlras9Ign0SW6e6iSTcp80l/Kg6/upMIT5jY+XGR6kViDnnB/GgBUx58GRlfNTIH+8K+5o/7RtbWK7sLg39hGF8uRhmWD5RmOQfxLXwyOGVhkFSGB9COQa7C2+J3ja1kke38S38bOAGxt+YAYGRtoA+stWsINTtF1jQV8jUbf55bbp06lfaqLaxDrdkL21iEeqx/LND93zAO4968a+E+ra34gt5r3WvFGvKp1K30m0WxMYaOefOJnJHKLj7o6561l6TqerXGj+Orm58UapNruiyIkSwoiRsPPERduMsxzwgxz3oA9psTC2+WGR4rxusbD5Zl9PqK5XXdAH9oGSOMwXi/PGwG0SD09jWV4t0PW0MT6X4wuYLW2Lx6te3ciyxWzIBhpNiBopSxx5IDbRyWrL0vSvHuv6Xp93J4+sYo52PlJPISwQSGNXBVDkMwwO5zQB0YuIpAq38f2e7HCzrxk/wC1WLe2MyX3ny25ilYfM6fdcdmx/WvJ9R8TeJIb66tL3Vbgz28zwyDKkblJB7e1Rp4x8RJGI11i6CAYC5HH6UAeq6jD5kI2uYJl691YeuK524sLiznFxC7RhudyHK59vSofCl5NqXhqO51G7eWf7S8f7w4yvsakurWeJlMV1KdpPyv3U9vegDrNG8VQFoYfEkQcfdjulGGHsas+IvB1veZurFoZ7CQZZkHMZ/2l/qK4u1V2hYMBJD/FHIOlWdN1+70XUYkhmZoJOAr8rj0z/Q0AZHifwHc2cHmwL+7P3XHzJ9M9q4V7aWC4MU8JVhwVP9K91bxB5s6xQqIC/wB6JhmOQelW7fQNC1eVFvYkj3dUcYz9D2oA+e2Z0bYGOF6UzOWyRn1r3fxf8HIZIJLjwxdC6CctCzfvE/xFeL6xpF1pV39nuomRgcEkYoAoPjPygj2rTsLWTy/Ot3DrjDKP6iqE8LRbchgre1SxEwHzIHaN8evB+tAF8atdWhKQStH/ALJYlavWniKcQs0wViB2+bNczLI8j7pOWojkKk8A5oA7C31ISTCSQ+SrLwAcVmawrhy7sHjb+IP1rKNz5kRjcsPQjmmxTtsKO2f7pPagB0axLhnVnQngg4IqK4ULLxkKematLMHj2Ox47AClNp5vAkfb2yORQBRCFmwBn3pyHqrk4/h+taNt5UbFdwWZejDo1OuZpXUr5COvfK4P50AU4kWR18zdnuCcflXYaHokGoWzi0vI2cDDIQNwNcS0uZFO0hR29KsWtzLbxtJHzz97PIoA19Ssb3SLgwyHamflbceargRXrBZr7yD3DjiqM1/dXeVdt/8AsnmolTPDgI46A0AXbjSTCw8q7t5k9Q2DTrKUWM219k6N1DKflqha273EpCtgg/eFb1npckt5EI0eRwPu54NAEf22znuAot1Qeq5rU8uxhtt8MdwcnlcnaTWvZ6Dm8j8zy4pMZ2zDP5EV1Oi+FlmmBuv9KiznEYIAFAFLw1bWd9AscqSZPq+0V1V08WkWO2zFssmeSSCf5Vak0i0tYvNsrGZSnG2RTtNY9/qM1yrRCyQY4LIBx+dAGPqeufaIykk8iMf1rFdTsYuY2yOo4rdttODKzS20bOT37VkXlpLGzK8R65AXgCgDLeQ26I4ISRWBjZR8ynsRjkV1+p+LNM8UeGzZ+ObSe61yzgP2HVrWILKxA4jmycMv+1+PXJPIXTNHKNnloT3fDN+FZV8JrmUJJNKR02rwKAM2+8hHMrtvReAvYGsl7gmRzGoRW42qcf8A660tQ09owFQFR6HvWY0G3IdgG/nQBHIScZbdj1pgJHA71KIwvJ5PYU51CqrFVBz0oAasbOw8pSSOpz0qObKyuOuD1rVsIN8g+dcMRkZrOv1Vb+4VfuhyBjpQBEHYIUDNsJyVzwSOhIopO9LQAUUn1paANjw34n1vwyb06BqVxY/bYjDcCIj51/How7MMEdiKuWnjnxDZ2eoWtrfJHBqEKwXQFtETKijCgkrnIz1HOec55rmutL2FAHUR/EDxVHeafdrrVx59hH5UDFUIC/7QK4c/7Tgngc8VFB428QwJGsepSDyyCrFVJz5nmZJI5+fmucpKAJbqeS7u57qdi888jSyN/eZjkn8TUdJRQB6X8NoXk8KSeaqy2bXTgqf4SO9bkukKJStvdOFdciKTkfhVH4US7PCG2WFvKN3JiVeOfT/9ddKIGnuGgh/eRYJU7c/p/hQBREFm6C1uC1tcAcMw+Vj9eoqCWz25SWGOUrwWU/e+vv71JqwksYB9sjMsGcLIvO38ev502zukYbZJWhbHEjJlSPegCK1sVCv5cc0lu3zDHzNH+FOt9VNkDA7M+05G7kMPr1BqeaK4tlDLkBz8s1u24Z7Z9qqXdtdzzx3XIvYzzuAG4eo7GgDp7e+W6hi1DSr2SG7jH3ozg+4I6GphJa6ukkurWUV07j95hcH647GsjQnt7i4aO6VYZ+7Qnb+JFas+ny27faLO7WYp/d4P4igDj9d8HWUqStojsYupgfqv0B6VzqeEHu7RxAqvMvGzdtb6EGu6vr8Xr7vMVJc4yVxz7kVBYzPaamJJ7FJg3Eqh+T/tD1/CgDyG+0e5tGKyRukgODG4wRVBkZAwdSrD1FfVGpeHdF1yzSe3jwxXJgnGGHurf0rz+++HdsLxjaFwzfwFsr9OelAHigIyMjinEdxnFeh638PdSs5hJbwqqPyE6nPtVOLwpqhUNJZFkH3iqYP5UAcUgKtux+YzmrMd4UHAVPQrXWT+Dbkp5kakqeQuCD9PrVGfwffwqs32S6EJ4YFOR/8AWoA5wiKUliz7yeanmMsMa4dCuOoOQa3f+EOv54w1mrSr6Y5FSR+Ebkx7JQ6sOqk7cGgDmWheQpsHX34oWznecKFySccHrXWWPhhmZ43zuQc7Dx+tW7fw357jAb5fT5T+dAHJvp8wI2R5b07itS18OXD2cckq7tzYPqK9K8N+F9GtiWuruUSt1WQZ/WulbTLRVAtvnRemFOKAPKrfwNPKB5CuT3JPFdro3g6K2RGvfNcDHzK4BFdJBJcwMBBtaMH5hG+0r7kEVPeWzTSby0VzGeCqMNw/OgCSGx06KDELwzN6M+4027i1GCIm3iKQ9hG2P1qvLawWRzaAo/XDtn+lVLq6v3TDTfuu/b+lAEMmpzXEbxTahNF2I31hy2qSTfLdGUnqxBwPyp95bwPMA0ltvPrkn9KnkZLS2LG7QED7oU/yoAyriO2jcxRGSWc9GjBwPrVS/mawRHcFmPduB+taltcPMXdpAF7HycVnavcWoG94zI39514oAy28u+UyyuRjoIx1rHniEUjSCU4/hDnBFXY/tEl0XjLkf7AwPpinzeaJlSa3QgjqR0oA5e7bcTtDvI3VjkfzpNI8Parr1zJa6Hp15qV3GvmSJbxl2Rc4yQO2eKta8drgLIVPTAFZpuHRAULIwGC0fGfxoA6eLwBdj4f6r4ju7o29zp8zQy6YIN80e1tpMvzAxDPqpHvzXGRuxZCcEE455rYs/E+rWfh690W3uVTTr0/6QBCnmyjIO0y437cgfLnFZcVz5Y+WJB2zjmgDWhSGMDPLt3Pb6CsW6AF1KF6bjjNTG7PJQfvD/ETVfnJyMnPJoAbS0nfFL2oAKKSlxQAnajFHrQDzigBaKKSgBc0UDvSUAe+/AXb/AMK+uFkt1mR76Thu+B2rbvbKOTfcaMWgmQ4Knpn0rmfgTqctp4PaEKrp9udhnscV3N9qT/aDe28UcNyvLFRlZB6Mvf60AZiNHcWf+nR4m+7Ku3B+uO9R2mm2k6MtjJG5HWGQ4yP9k1txahHqcaQ3FpEI5x/CcFD7GrK+GrN9KS9jZ45lcpuHU47mgDmItHkgZtkBSLPQHp9aV1ZIWt7qAtH/AAkjO36EV2/hyAX4azujuO0lJQMMuPX1HtU3hzT7PVdXOl38G4ndsuI22OuPXsaAPJBYqLl1u1/eZyky5U47c96jPnWc+5d/sSco4+o6GvVvF3hKHSrxYI7l5FxuBKgEVx2oaXCsckkJMUqcMU+6/wBV6ZoA5qQW14XcIYy331Rsj8RUd7o+oR2KTWm66tEOcLyy/QipZnT7SkUkSFm6SL8rD8qvaVdz6Xcs0EjMjD5kfkGgCvoni/ULYtZ3Jklsj2ZMuh+hrpJ9TW48lbdlnlI4bbsf6Z6GoW0+11syOYjBKq7tynIP4VyEd5PZXrIkhaMNt2sM4oA7Z3khgWS9V5VBzsZdrp7+9K2uzRqotZxJE3QkYK/Wqlvq9wkK78Sof4H5AqSfUIZI2iexg9dy8GgC5Z6mykrqC2siP/z0AUn8RwamF7MQBZW8gh7bGEif41hwu7WrPG5RV42YyD+dWIYpba2+0RzbSR0VduPxFAFfVbyOT5o1AnBwyo20g1lyzyzoBdIVkHQsCM/0q5pl2GuniuYI5jIeWPBqXVv9DkiWAnypOsbHIH0oAyzBCuGQOso6rtyGpun2rW9890lwsSEf6oZ4PvV+8skEAubd2jYDO0/MKxoLj7W7RyoAy/xKSKAOog1BGIE0KYP/AC0MeRWratLszZzQMeyo+P0NU9Mt3isRGsx2kd1GRVS8urmwTYszSFjwxAyP0oA0l3XE5W/hjRx0JIVj+PesrWoLW3mUhZlyequD/KsySW5m/fyXDNt/hxVqO/2QqZYhMMZwzUARvcQRN5tvdTB/Q5qNdRmlk2Snzx6edippJLaaDetoqewYkVm2sMUh+1GJAy8AYoAlaztGl3ulrA56EsWP6UxbKOGR5jcRuo56HH602aWOU8W8ahTg9Tmnw3cEy+VJZoQOMlj/ACoApHVLiWdlVR9jHCsnU1WnZJid9q7r6vIBWn9ltWcO0Ax0Cg4ApLrT7aVlDx8Y6A4oAxhcxRYQuUB/hjyaY/kLl1jkPfMjba15rC3gizGmDjrXMahA0Ujyea546dqAMjXZgQXhCEk8gf8A16xroqpDZyMevT6Cp7rPmEliT6ntWdcOXyGx8tAEUhDNnk/Wmlj+A6U6JPMkCZxmmvw5HpxQALjPOfwoPU46UlBoA//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long arrow points to herniated abdominal contents/umbilical cord extending beyond amniotic membrane. Short arrow points to measurement of nuchal translucency.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendy Shaffer, RDMS and Joshua A. Copel, MD, Yale University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester vaginal scan of fetus with limb-body wall complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Arrow points to herniated abdominal contents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendy Shaffer, RDMS and Joshua A Copel, MD, Yale University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    First trimester vaginal scan of fetus with limb-body wall complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 256px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note that the spine is twisted out of the plane of the image at the left side. Arrow points to herniated abdominal contents.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Wendy Shaffer, RDMS and Joshua A. Copel, MD, Yale University School of Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40377=[""].join("\n");
var outline_f39_27_40377=null;
var title_f39_27_40378="Carotid endarterectomy";
var content_f39_27_40378=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carotid endarterectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Ronald M Fairman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/27/40378/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/27/40378/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H93838457\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment aimed at carotid atherosclerotic lesions may be beneficial for symptomatic or asymptomatic patients. This topic will review the preoperative evaluation and surgical technique of carotid endarterectomy (CEA). The indications for carotid revascularization and perioperative stroke risk assessment for patients with carotid atherosclerosis are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Carotid artery stenting is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=see_link\">",
"     \"Carotid artery stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838464\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid endarterectomy (CEA) is most commonly performed for symptomatic or asymptomatic high-grade (&gt;60, 70 percent, respectively) internal carotid artery stenosis. The effectiveness of CEA has been established by large randomized clinical trials. The indications for CEA in patients with significant carotid atherosclerosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link&amp;anchor=H2#H2\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Carotid endarterectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592415\">",
"    <span class=\"h2\">",
"     Special considerations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83591930\">",
"    <span class=\"h3\">",
"     Bilateral carotid stenosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some patients have varying degrees of bilateral carotid disease. No randomized clinical trials have evaluated the effectiveness of bilateral CEA for such patients. However, bilateral carotid occlusive disease appears to increase the risk for complications during and after unilateral CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, in one study of 700 patients undergoing CEA, 15.4 percent had contralateral disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/2\">",
"     2",
"    </a>",
"    ]. The combined death and stroke rates in these patients were almost twice that of matched patients with unilateral disease (5.6 versus 2.4 percent).",
"   </p>",
"   <p>",
"    The impact of severe contralateral carotid artery stenosis or occlusion on the benefit and risk of unilateral CEA in patients with symptomatic and asymptomatic disease is discussed separately in the appropriate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of symptomatic carotid atherosclerotic disease\", section on 'Contralateral carotid stenosis or occlusion'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link&amp;anchor=H12#H12\">",
"     \"Management of asymptomatic carotid atherosclerotic disease\", section on 'Contralateral carotid stenosis or occlusion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When the extent of contralateral carotid disease is significant enough to warrant bilateral CEA, most surgeons stage the approach, with a delay of at least one to two weeks between operations.",
"   </p>",
"   <p>",
"    The risk of respiratory compromise secondary to neck hematomas or laryngeal nerve injury, frequent difficulty with blood pressure control after manipulation of the carotid sinus, concerns about cerebral hyperperfusion syndrome and the unknown effect of bilateral cerebral ischemia (although temporary) generally contraindicates a combined approach. (See",
"    <a class=\"local\" href=\"#H93838577\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83593145\">",
"    <span class=\"h3\">",
"     Prophylactic carotid endarterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic carotid intervention in patients with severe carotid artery stenosis prior to another surgery is rarely needed and a decision to proceed should be individualized depending upon the risk of perioperative stroke.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838471\">",
"    <span class=\"h4\">",
"     Coronary artery bypass surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic complications are second only to heart failure as a cause of morbidity and mortality following cardiac surgery. New stroke or transient ischemic attack occurs in about 3 percent of patients following CABG. As a result, carotid endarterectomy (CEA) is often considered in conjunction with coronary artery bypass grafting (CABG) in patients with significant carotid stenosis. However, there have been no trials examining the use of CEA in patients having CABG. In addition, it is not clear if CABG should be combined with CEA or should be staged (ie, performed before or after CEA). Whether to offer prophylactic CEA before or after CABG is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6617?source=see_link&amp;anchor=H12#H12\">",
"     \"Coronary artery bypass grafting in patients with cerebrovascular disease\", section on 'Prophylactic carotid intervention'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838478\">",
"    <span class=\"h4\">",
"     General surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of stroke appears to be lower following general (nonvascular) surgical procedures than following cardiac surgery, with a reported incidence in patients undergoing general anesthesia of less than 0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. The risk may be slightly higher (1 percent) in asymptomatic patients with a carotid bruit who undergo general surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There have been no randomized trials examining the use of prophylactic CEA in patients with carotid stenosis prior to general surgery. A retrospective review suggests that prophylactic CEA is probably not warranted in most patients with asymptomatic carotid disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/8\">",
"     8",
"    </a>",
"    ]. This study was a chart review of 284 patients who had undergone nonvascular surgery requiring general anesthesia and had preoperative carotid ultrasound. While a previous history of stroke or TIA, a carotid bruit, or both were present in 250 patients, all were considered to have asymptomatic carotid stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/9\">",
"     9",
"    </a>",
"    ]. Ten of 284 patients (3.5 percent) had perioperative ischemic strokes within 30 days of the index procedure, and 8 of 224 (3.6 percent) with &gt;50 percent carotid stenosis had an ipsilateral perioperative stroke (bilateral lesions were present in three patients). While this stroke risk exceeds that of the general population and of patients with carotid bruits, the increased risk appears to be insufficient to mandate prophylactic CEA for asymptomatic carotid stenosis in the general surgical population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83593195\">",
"    <span class=\"h4\">",
"     Vascular procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no trials of prophylactic CEA prior to abdominal aortic aneurysm repair or other major peripheral vascular procedures, many vascular surgeons support performing prophylactic CEA in anticipation of a major vascular procedure that may involve significant hemodynamic fluctuations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592089\">",
"    <span class=\"h3\">",
"     Endarterectomy in patients with intracranial aneurysm",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ipsilateral intracranial aneurysms that are distal to a cervical internal carotid artery stenosis may be susceptible to sudden hemodynamic changes associated with CEA leading to aneurysm rupture. On the other hand, surgical clipping of an aneurysm distal to a severe internal carotid stenosis may increase the risk of ischemic stroke.",
"   </p>",
"   <p>",
"    Unfortunately, data are too sparse to allow firm conclusions as to which problem should be treated first. However, caution is advised if CEA is performed in this setting, especially if the ipsilateral aneurysm is &ge;7 mm in diameter or if there is a history of subarachnoid hemorrhage from another aneurysm. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=see_link\">",
"     \"Unruptured intracranial aneurysms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592452\">",
"    <span class=\"h2\">",
"     Relative contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although there are no absolute contraindications to cervical carotid endarterectomy (other than the absence or complete occlusion of the carotid artery), the following conditions may increase the risk of local or systemic complications and may support the use of alternative treatments such as medical management",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carotid angioplasty and stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      History of prior neck irradiation resulting in &ldquo;woody fibrosis&rdquo; of the skin and subcutaneous tissues.",
"     </li>",
"     <li>",
"      Concurrent tracheostomy",
"     </li>",
"     <li>",
"      Prior radical neck dissection with or without radiation",
"     </li>",
"     <li>",
"      Contralateral vocal cord paralysis from prior endarterectomy",
"     </li>",
"     <li>",
"      Atypical lesion location, either high or low that is surgically inaccessible",
"     </li>",
"     <li>",
"      Severe recurrent carotid stenosis",
"     </li>",
"     <li>",
"      Unacceptably high medical risk (eg, unstable cardiac status) (see",
"      <a class=\"local\" href=\"#H93838506\">",
"       'Perioperative risk assessment'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with these conditions may be candidates for carotid artery stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=see_link\">",
"     \"Carotid artery stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough vascular history and physical examination are essential components of the evaluation of a patient being considered for CEA. A search should be made for evidence of atherosclerotic disease elsewhere, including abdominal aortic aneurysm and peripheral artery disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=see_link\">",
"     \"Screening for abdominal aortic aneurysm\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=see_link\">",
"     \"Noninvasive diagnosis of arterial disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Cardiac evaluation should be considered selectively since patients undergoing CEA are most likely to have morbidity that is related to coronary heart disease. This evaluation may be performed with exercise stress testing,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/57/25494?source=see_link\">",
"     dobutamine",
"    </a>",
"    echocardiography,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    imaging, or, when warranted, coronary catheterization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/11\">",
"     11",
"    </a>",
"    ]. However, there is no evidence that immediate cardiac intervention alone reduces perioperative procedural risk of stroke or death for carotid endarterectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=see_link&amp;anchor=H27#H27\">",
"     \"Estimation of cardiac risk prior to noncardiac surgery\", section on 'Noninvasive cardiac testing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838506\">",
"    <span class=\"h2\">",
"     Perioperative risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of risk factors for morbidity and mortality associated with CEA is important in order to avoid surgery in patients who may face unacceptably high risk for endarterectomy.",
"   </p>",
"   <p>",
"    However, the data are conflicting regarding risk factors for morbidity following CEA. One or more of the following characteristics have been associated with an increased risk of poor outcome (stroke, myocardial infarction, or death) at 30 days after CEA in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/12-18\">",
"     12-18",
"    </a>",
"    ], but not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/19-23\">",
"     19-23",
"    </a>",
"    ] studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Age 80 years or older",
"     </li>",
"     <li>",
"      Severe heart disease",
"     </li>",
"     <li>",
"      Severe pulmonary dysfunction",
"     </li>",
"     <li>",
"      Renal insufficiency or failure",
"     </li>",
"     <li>",
"      Stroke as the indication for endarterectomy",
"     </li>",
"     <li>",
"      Anatomic issues, including limited surgical access, prior cervical irradiation, prior ipsilateral CEA, and contralateral carotid occlusion (see",
"      <a class=\"local\" href=\"#H83592452\">",
"       'Relative contraindications'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As already noted, a number of reports have NOT confirmed the independent association of these proposed risk factors with poor outcome after CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/19,20,22,24,25\">",
"     19,20,22,24,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest studies queried the database of the National Surgical Quality Improvement Program of the American College of Surgeons and analyzed a sample of 3949 patients who had CEA as the primary procedure in 2005 and 2006 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/25\">",
"       25",
"      </a>",
"      ]. Patients with one or more \"high risk\" factors (age &gt;80 years, major cardiac disease or chronic obstructive pulmonary disease) made up 30 percent of the population. Neither the indication for CEA (symptomatic versus asymptomatic disease) nor anatomic risk factor status (eg, prior neck radiation therapy) was available in the database. The following observations were reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/25\">",
"       25",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The 30-day stroke rate was similar for patients with and without \"high risk\" criteria (1.4 versus 1.7 percent). In contrast, the 30-day mortality was significantly higher for patients with \"high risk\" criteria (1.3 versus 0.4 percent). However, when individual \"high risk\" criteria were analyzed, only major cardiac disease was associated with a higher 30-day mortality; age &gt;80 was not.",
"     </li>",
"     <li>",
"      In multivariate analysis, independent risk factors for stroke at 30 days were intraoperative transfusion, baseline hemiplegia, longer intraoperative anesthesia time, and shorter height (likely a surrogate for smaller artery size). However, from other studies, there is no convincing evidence that female gender is a significant risk factor for adverse outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/26-30\">",
"       26-30",
"      </a>",
"      ]. Independent risk factors for 30-day mortality were baseline critical limb ischemia and poor functional status.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective review of 625 patients compared patients with high-risk (anatomic and pathophysiologic) with normal risk patients and found no differences in perioperative outcomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/10\">",
"       10",
"      </a>",
"      ]. Two-year survival was worse in high-risk patients.",
"     </li>",
"     <li>",
"      A single center series of 2236 consecutive isolated CEA operations reported a 30-day stroke and death rate of 1.4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/24\">",
"       24",
"      </a>",
"      ]. No single clinical variable was significantly associated with perioperative complications.",
"     </li>",
"     <li>",
"      Another single center study of 1370 consecutive CEAs found that patients with two or more risk factors had significantly higher mortality compared with those who had no risk factors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Advances in perioperative management have led at least some surgeons to conclude that the proportion of patients with unacceptable risk is extremely small and continues to shrink [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/19,31\">",
"     19,31",
"    </a>",
"    ]. Others have challenged the concept of a high-risk group of patients for CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/22\">",
"     22",
"    </a>",
"    ]. Modifications in surgical practice, refinement of anesthetic techniques, refinement and use of vasoactive medications in the perioperative period and the declining use of routine preoperative contrast angiography may all be driving a reduction in the perioperative complication rates for CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/24\">",
"     24",
"    </a>",
"    ]. In the series of 2236 CEAs discussed above, the investigators noted that morbidity and mortality in the last five years of the study compared with the previous five years had declined by 36 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients deemed unfit for general anesthesia can undergo CEA with regional anesthesia, a technique that has shown equally good perioperative outcomes after CEA in patients with and without risk factors such as advanced age, diabetes, coronary artery disease, and contralateral internal carotid occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H83592649\">",
"     'Choice of anesthesia'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592219\">",
"    <span class=\"h2\">",
"     Preoperative imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients suspected of having carotid atherosclerosis are typically evaluated with carotid duplex ultrasound as the initial test to assess the severity and extent of carotid stenosis. Other useful noninvasive methods to assess the degree of stenosis of the internal carotid artery include computed tomography angiography, magnetic resonance angiography (MRA) and contrast enhanced magnetic resonance angiography. The utility of these noninvasive methods and cerebral angiography in the initial evaluation of carotid stenosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31033?source=see_link\">",
"     \"Evaluation of carotid artery stenosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a hemodynamically significant atherosclerotic lesion identified on duplex ultrasound, it remains controversial if further imaging is needed prior to endarterectomy in asymptomatic patients to verify the degree of stenosis or further evaluate arterial anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592226\">",
"    <span class=\"h3\">",
"     Duplex ultrasound",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some surgeons may feel the sensitivity of carotid duplex at their institution is not sufficient to reliably determine the degree of internal carotid artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. In support of this point of view is a lack of uniformly applied, prospectively-validated criteria in some settings for quantifying the degree of internal carotid artery stenosis with duplex ultrasound. Against this point of view are the risks and costs associated with catheter-based angiography, the known tendency of MRA to overestimate the degree of stenosis, and CTA to potentially underestimate the degree of stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Experts in carotid ultrasound addressed this issue and developed consensus recommendations for using duplex-derived velocity and imaging parameters to quantify internal carotid artery stenosis with duplex ultrasound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recommendations are by consensus and it is suggested the utility of the recommendations be verified in individual vascular laboratories, and that these parameters should not replace duplex parameters that are locally well documented as providing accurate assessment of carotid stenosis. As such, it may be reasonable for the surgeon who has access to a certified vascular laboratory with ongoing quality assurance programs and staffed by registered vascular technologists to use duplex ultrasound as a sole imaging modality of the cervical internal carotid artery prior to performing carotid endarterectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592233\">",
"    <span class=\"h3\">",
"     Other imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the symptomatic patient, the preoperative evaluation should also include computed tomography (CT) or magnetic resonance imaging (MRI) of the brain to assess the degree of cerebral infarction, if any, and to exclude other disorders that might be responsible for symptoms (eg, subdural hematoma, tumor).",
"   </p>",
"   <p>",
"    The added risk and costs of catheter-based arteriography probably outweigh the benefit of obtaining more anatomic detail. The Asymptomatic Carotid Atherosclerosis Study (ACAS) found a 1.6 percent incidence of stroke associated with routine arteriography, although the risk was less in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/39\">",
"     39",
"    </a>",
"    ]. However, arteriography is the gold standard for evaluating intracranial atherosclerotic disease, which is present, to some degree, in 20 to 50 percent of patients with stenosis of the extracranial internal carotid artery.",
"   </p>",
"   <p>",
"    In an analysis of a subset of patients from NASCET, the relative risk of stroke associated with intracranial atherosclerotic disease in medically-treated patients was 1.3 for extracranial stenosis &lt;50 percent, and 1.8 for extracranial stenosis 85 to 99 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/40\">",
"     40",
"    </a>",
"    ]. CEA reduced this risk, suggesting that detection of intracranial atherosclerotic disease, particularly in those with moderate extracranial carotid stenosis, may help stratify patients into a group that is more likely to achieve benefit from CEA. Of the available noninvasive tests (ie, transcranial Doppler, CTA, MRA), CTA may be more accurate for identifying intracranial large artery stenosis. The diagnosis of intracranial stenosis is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=see_link&amp;anchor=H3#H3\">",
"     \"Intracranial large artery atherosclerosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101623404\">",
"    <span class=\"h2\">",
"     Laryngoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Otolaryngologic examination, which may include laryngoscopy, should be performed in patients who have a residual vocal disturbance (tone change, hoarseness) after a prior neck surgery (eg, CEA, thyroid surgery). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16009?source=see_link&amp;anchor=H22#H22\">",
"     \"Hoarseness in adults\", section on 'Neurologic dysfunction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592460\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medication management",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838520\">",
"    <span class=\"h3\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    reduces the risk of stroke of any cause in patients undergoing carotid endarterectomy (CEA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. In addition, lower-dose aspirin (81 to 325 mg daily) is more effective than higher-dose aspirin (650 to 1300 mg daily).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, controlled trial involving 232 patients,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      75 mg daily or placebo treatment was started preoperatively and continued for six months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/43\">",
"       43",
"      </a>",
"      ]. Patients assigned to aspirin had significantly fewer strokes at one month and six months than those assigned to placebo. However, this study was likely underpowered [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The ACE trial randomly assigned 2849 patients scheduled for endarterectomy to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      at doses of 81, 325, 650, or 1300 mg daily [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/45\">",
"       45",
"      </a>",
"      ]. Aspirin was started before surgery and continued for three months. At three-month follow-up, the primary end point (stroke, MI, vascular death) was significantly reduced in the lower-dose (81 or 325 mg daily) aspirin group compared with the higher-dose group (6.2 versus 8.4 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Consensus guidelines from the American Academy of Neurology (AAN) and the American College of Chest Physicians (ACCP) recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for symptomatic and asymptomatic patients undergoing CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/44,46\">",
"     44,46",
"    </a>",
"    ]. We recommend starting aspirin (81 to 325 mg daily) prior to CEA and continuing indefinitely in the absence of contraindications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients taking extended release",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"      dipyridamole",
"     </a>",
"     /",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"      aspirin",
"     </a>",
"    </span>",
"    combinations (eg, Aggrenox, Asasantin), the need to continue combination therapy depends upon the original indication. One study of 102 patients undergoing CEA found no significant difference in perioperative bleeding in patients taking",
"    <span class=\"nowrap\">",
"     dipyridamole/ASA",
"    </span>",
"    (n = 39),",
"    <span class=\"nowrap\">",
"     dipyridamole/ASA",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    (n = 30) or",
"    <span class=\"nowrap\">",
"     dipyridamole/ASA",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (n = 33) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/47\">",
"     47",
"    </a>",
"    ]. There was also no difference in the number of postoperative microembolic signals as detected by transcranial Doppler. Given these results, it may be reasonable to allow patients who are placed on dual antiplatelet therapy for other indications to continue on these throughout the perioperative period. However, for patients on triple oral antithrombotic therapy (ASA, thienopyridine, oral anticoagulation), the management of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is individualized. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=see_link\">",
"     \"Management of anticoagulation before and after elective surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=see_link\">",
"     \"Triple antithrombotic therapy in patients with cardiovascular disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who are allergic or sensitive to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    can be used as an alternative agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=see_link&amp;anchor=H4#H4\">",
"     \"Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease\", section on 'Aspirin sensitivity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=see_link\">",
"     \"Antiplatelet therapy for secondary prevention of stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838527\">",
"    <span class=\"h3\">",
"     Statins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of statins in symptomatic patients undergoing CEA may be associated with improved outcomes. In a retrospective observational study of 3360 CEAs, statin use was associated with reduced in-hospital mortality and combined in-hospital ischemic stroke or death (adjusted odds ratio 0.25, 95% CI 0.07-0.90 and 0.55, 95% CI 0.32-0.95, respectively), but in-hospital cardiac outcomes were not significantly improved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/48\">",
"     48",
"    </a>",
"    ]. In contrast, statin use by patients with asymptomatic carotid stenosis was not associated with significantly different outcomes.",
"   </p>",
"   <p>",
"    Similar results were reported in another retrospective study involving 1566 patients with symptomatic and asymptomatic disease who received statins for at least one week before CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/49\">",
"     49",
"    </a>",
"    ]. These findings require confirmation in randomized clinical trials.",
"   </p>",
"   <p>",
"    Evidence is also emerging that statins may be of benefit in the perioperative period, and that this benefit might be lost if statins are discontinued. This issue is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H9#H9\">",
"     \"Perioperative medication management\", section on 'Non-statin hypolipidemic agents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592851\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend administration of antibiotics prior to carotid endarterectomy to control surgical site infection due to the frequent use of prosthetic material (",
"    <a class=\"graphic graphic_table graphicRef87206 \" href=\"mobipreview.htm?34/1/34844\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link\">",
"     \"Overview of control measures to prevent surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592468\">",
"    <span class=\"h1\">",
"     SURGICAL ANATOMY AND PHYSIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592483\">",
"    <span class=\"h2\">",
"     Carotid artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The left common carotid artery (CCA) originates from the aortic arch, whereas the right CCA originates from the innominate artery (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"mobipreview.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    ). The CCA divides into the internal carotid artery (ICA) and external carotid artery (ECA) at the level of the superior border of the thyroid cartilage corresponding to the",
"    <span class=\"nowrap\">",
"     C3/C4",
"    </span>",
"    disc space. The vagus nerve is located posteriorly to the common carotid artery in most individuals, although it may be located anteriorly in 5 to 10 percent of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441529762\">",
"    <span class=\"h3\">",
"     External carotid artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECA has multiple branches that supply the face and scalp and provide collateral circulation to the brain (",
"    <a class=\"graphic graphic_figure graphicRef50495 \" href=\"mobipreview.htm?31/61/32728\">",
"     figure 2",
"    </a>",
"    ). These branches include (caudal to cranial) the superior thyroid, lingual, facial, ascending pharyngeal, occipital, posterior auricular, maxillary, and superficial temporal arteries. The ascending pharyngeal artery arises very near the bifurcation of the carotid artery. In one anatomic study, the ascending pharyngeal artery originated from the ECA in 80 percent of specimens (56 percent medially, 44 percent posteriorly) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/50\">",
"     50",
"    </a>",
"    ]. In the other 20 percent, the ascending pharyngeal artery originated from the internal carotid artery (5 percent), carotid bifurcation (5 percent), occipital artery (5 percent), and a trunk common to the lingual and facial arteries (5 percent). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441529769\">",
"    <span class=\"h3\">",
"     Internal carotid artery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ICA normally has no branches in the neck (",
"    <a class=\"graphic graphic_figure graphicRef63286 \" href=\"mobipreview.htm?4/48/4874\">",
"     figure 3",
"    </a>",
"    ). The cervical segment of the internal carotid extends from the carotid bifurcation until it enters the carotid canal anterior to the jugular foramen. The internal carotid artery runs cranially within the carotid sheath and lies posterior and lateral to the external carotid artery beneath the medial border of the sternocleidomastoid muscle. In its distal (cranial) course, it passes beneath the hypoglossal nerve, the digastric muscle, the stylohyoid muscle, the occipital artery and the posterior auricular artery. More cranially, the styloglossus and stylopharyngeus muscles, the tip of the styloid process and the stylohyoid ligament, the glossopharyngeal nerve and the pharyngeal branch of the vagus nerve separate the internal from the external carotid artery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H441529887\">",
"    <span class=\"h2\">",
"     Carotid baroreceptor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Baroreceptors are stretch-sensitive mechanoreceptors that respond to alterations in blood pressure. The carotid sinus baroreceptors are located within the adventitia of the origin of the internal carotid artery and are innervated by the sinus nerve of Hering, which is a branch of glossopharyngeal nerve. In response to low blood pressure, the nerve fibers decrease their firing rates stimulating the sympathetic nervous system and inhibiting of the parasympathetic nervous system via a centrally-acting mechanism. Carotid sinus reactivity may be altered in patients with carotid atherosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology of symptoms from carotid atherosclerosis\", section on 'Impaired vasoreactivity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients display varying degrees of heart rate or blood pressure alterations during manipulation of the carotid bifurcation, carotid clamping, or postoperatively following CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/51\">",
"     51",
"    </a>",
"    ]. Endarterectomy, removal of atheromatous debris, and reconstruction of the carotid artery may increase tension on the carotid sinus baroreceptor, increasing its activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/52\">",
"     52",
"    </a>",
"    ]. The opposite is also possible if damage to the carotid sinus or sinus nerve occurs. As an example, eversion endarterectomy requires division of the carotid artery, and as a result, the longitudinal fibers of the carotid sinus nerve are transected. A study that measured baroreceptor sensitivity following CEA found increased sensitivity with conventional CEA and decreased sensitivity with an eversion technique [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/53\">",
"     53",
"    </a>",
"    ]. Correspondingly, postoperative blood pressures were significantly increased for eversion compared with conventional CEA (systolic: 127, diastolic: 64, mean: 86, versus systolic: 111, diastolic: 55, mean: 75). Compensation over time occurs due to intact baroreceptor mechanisms from the contralateral side and aortic arch. (See",
"    <a class=\"local\" href=\"#H83592621\">",
"     'Conventional versus eversion endarterectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592649\">",
"    <span class=\"h1\">",
"     CHOICE OF ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of general anesthesia for CEA or performing awake carotid surgery with local anesthesia (with or without cervical block) is generally decided by individual surgeon preference and patient characteristics and preference. Ideally, surgical and anaesthetic teams should be competent in both techniques because a patient might prefer, or there might be a medical reason to choose, one rather than the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/54\">",
"     54",
"    </a>",
"    ]. An analysis of 26,070 cases in the American College of Surgeons (ACS) National Surgical Quality Improvement Program (NSQIP) database identified the use of general anesthesia in 84.6 percent and regional anesthesia in 15.4 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The available evidence suggests that the choice of anesthetic technique has no significant impact on clinically important outcomes after CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/54,56-58\">",
"     54,56-58",
"    </a>",
"    ]. Blood pressure in the perioperative period is affected by the method of anesthesia. General anesthesia reduces blood pressure during anesthesia induction and may require the use of pressor agents. Overall, the use of local anesthesia appears to be associated with fewer alterations in blood pressure compared with general anesthesia. (See",
"    <a class=\"local\" href=\"#H83592525\">",
"     'Labile blood pressure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Local/regional&nbsp;anesthesia",
"    </span>",
"    may be more beneficial for some patients, but mandates&nbsp;a &ldquo;dedicated&rdquo; anesthesiologist with refined skills in regional anesthetic techniques. Anesthetic techniques are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of anesthesia and anesthetic choices\", section on 'Types of anesthesia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=see_link&amp;anchor=H4#H4\">",
"     \"Peripheral nerve block: Techniques\", section on 'Superficial cervical plexus block'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review and meta-analysis of randomized trials comparing locoregional with general anesthesia identified ten trials that included 4335 operations of which 3526 were from the General Anesthesia versus Local Anesthesia (GALA) trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/54\">",
"     54",
"    </a>",
"    ]. The primary outcome measure of the GALA trial was a composite of stroke (including retinal infarction), myocardial infarction (MI), or death between randomization and 30 days after surgery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the primary outcome between the local and general anesthesia groups (4.4 versus 4.8 percent). However, 9.5 percent of patients randomized to one arm received the opposite treatment. An as-treated analysis was performed removing the crossovers for the composite outcome (no differences) but individual outcomes (stroke, death, MI) were not assessed.",
"     </li>",
"     <li>",
"      There was no difference between the groups (intention-to-treat analysis) in the risk of postoperative stroke within 30 days of surgery, but locoregional anesthesia was associated with a trend towards decreased mortality, odds ratio (OR) 0.62 (95% CI 0.36-1.07). No significant differences were found for other measures, including myocardial infarction, postoperative bleeding, pulmonary complications, or length of stay. In the NSQIP study above, adjusted analysis identified general anesthesia as a risk factor for postoperative myocardial infarction (odds ratio 2.18, 95% CI 1.17-4.04) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A post-hoc analysis of the GALA trial found that local anesthesia may be more cost-effective than general anesthesia [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/59\">",
"       59",
"      </a>",
"      ]. The difference in cost was primarily due to differences in the length of intensive care unit stay and the use of consumables, with a mean cost difference of ���178 ($285 US). Two other nonrandomized studies have similarly suggested a cost difference between the two anesthesia techniques [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/57,60\">",
"       57,60",
"      </a>",
"      ]. The larger of these evaluated 24,716 patients from National Surgery Quality Improvement Program (NSQIP) database finding modestly shorter operative and anesthesia times, and a larger proportion of patients discharged on the first postoperative day in the local compared with general anesthesia groups (77 versus 64 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/57\">",
"       57",
"      </a>",
"      ]. We do not feel that these modest differences translate into any meaningful clinical advantage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838534\">",
"    <span class=\"h1\">",
"     SURGICAL TECHNIQUE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592614\">",
"    <span class=\"h2\">",
"     Endarterectomy procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carotid endarterectomy (CEA) is performed through a neck incision, either bordering the sternocleidomastoid muscle, or with a transverse incision in a skin crease at the level of carotid bulb. For the latter incision, preoperative imaging and palpation of the neck will guide the surgeon to the optimal placement of the incision. No significant differences between these approaches have been identified in terms of stroke, wound complications, or nerve complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying platysma muscle and subcutaneous tissues are divided, the carotid sheath exposed, and the internal carotid artery (ICA) is carefully identified and dissected. The extent of exposure of the artery is dependent upon the distribution of disease determined by intraoperative findings. Typically, dissection is needed from the common carotid artery (CCA) to a point distal to the bifurcation of the ICA and ECA that is beyond palpable ICA plaque to allow for clamping of normal soft artery.",
"   </p>",
"   <p>",
"    After proximal and distal control of the artery is obtained, the patient is given a bolus of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , intravenously. Monitoring of the activated clotting time (ACT) is not usually needed owing to the short duration of carotid clamping, typically less than an hour. The internal, common, and external arteries are then clamped sequentially; the internal carotid artery is usually clamped first to prevent embolization. A longitudinal arteriotomy is performed below the level of the bifurcation and extended proximally and distally.",
"   </p>",
"   <p>",
"    With general anesthesia and mandatory shunting, the shunt is placed after the vessel is opened and prior to the endarterectomy. For patients who are undergoing general anesthesia, some surgeons routinely place a carotid shunt while others use cerebral perfusion monitoring to guide the need for selective shunt placement. For these patients and those undergoing awake carotid endarterectomy using local anesthesia (with or without cervical block), the endarterectomy is often completed prior to the need to place a shunt, as indicated by brain monitoring. (See",
"    <a class=\"local\" href=\"#H93838563\">",
"     'Carotid shunting'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H93838556\">",
"     'Assessing brain perfusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The carotid plaque, which is consistently found at the carotid bifurcation and the origin of the internal carotid artery, is then freed and removed through a dissection plane developed in the layers of the deep media. Great care is taken to create a smoothly tapered transition between the endarterectomized portion of the artery and its normal distal extent. This maneuver avoids intimal flaps that might lead to arterial dissection after flow is reestablished.",
"   </p>",
"   <p>",
"    After meticulous inspection of the endarterectomized surface to remove any residual plaque or debris, attention is directed at repair. Some surgeons choose to repair primarily, while others patch the artery with saphenous vein or prosthetic material such as polyester (eg, Dacron), polytetrafluoroethylene (PTFE, eg, Gore-Tex) or bovine pericardium. (See",
"    <a class=\"local\" href=\"#H93838549\">",
"     'Patch angioplasty versus primary closure'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Just prior to completion of the arterial closure, the carotid clamps are sequentially briefly released and re-clamped to back bleed (ECA, ICA) and forward flush (CCA) the vessel which is then irrigated with heparinized saline and suctioned of any residual debris. After the suture line is completed, flow is restored first to the ECA, then to the ICA.",
"   </p>",
"   <p>",
"    A topical hemostatic agent may be used over the suture line to slow any oozing of blood. In a retrospective analysis of 4587 patients in a regional registry, reversal of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with protamine was associated with a lower incidence of serious bleeding requiring reoperation (0.64 versus 1.7 percent) compared with no reversal, without increasing the risk of MI, stroke, or death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/62\">",
"     62",
"    </a>",
"    ]. Although a small Jackson Pratt drain can be placed, drains are generally not required if heparin is reversed. The platysma and skin are closed and the wound dressed.",
"   </p>",
"   <p>",
"    A completion study to assess integrity of the repair can be performed using duplex ultrasound, contrast arteriogram or angioscopy, depending upon resources and operator preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/63-75\">",
"     63-75",
"    </a>",
"    ]. A retrospective review that categorized surgeons as rarely, selectively, or routinely using completion imaging found no significant differences in perioperative stroke or death after adjustment for patient characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/67\">",
"     67",
"    </a>",
"    ]. A small but significant reduction in restenosis (&gt;70 percent) was found for surgeons who performed completion imaging.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83596031\">",
"    <span class=\"h3\">",
"     High access",
"    </span>",
"    &nbsp;&mdash;&nbsp;More distal (cranial) access may be needed. As the internal carotid artery is dissected, the hypoglossal nerve will be seen to cross anteriorly. The nerve is isolated and gently retracted.",
"   </p>",
"   <p>",
"    The ansa hypoglossus nerve, which innervates the strap muscles of the neck, is typically seen coursing along the carotid sheath. The ansa can be divided without clinically significant consequence when dissection needs to be carried more cranially. The posterior belly of the digastric muscle can also be divided. Subluxation of the jaw is rarely warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592621\">",
"    <span class=\"h3\">",
"     Conventional versus eversion endarterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eversion endarterectomy is a variant of carotid endarterectomy. The internal carotid artery is transected horizontally at its origin at the carotid bulb and then the artery is everted, or turned inside-out, which creates an exposure not seen with vertical arteriotomy. Eversion endarterectomy is particularly appealing in small arteries and in patients with significant carotid redundancy as a means to eliminate carotid kinks and coils. However, in our opinion, the bulk of the evidence does not favor one technique over the other.",
"   </p>",
"   <p>",
"    The largest and best designed trial comparing eversion endarterectomy with conventional endarterectomy (EVEREST trial) was a multicenter trial that included 1342 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/76\">",
"     76",
"    </a>",
"    ]. No significant differences were found for the primary endpoints (perioperative stroke and death, carotid occlusion) or secondary endpoints (any stroke, ipsilateral stroke, transient ischemic attack, cranial nerve injury, neck hematoma, myocardial infarction). For eversion CEA compared with conventional CEA, the odds ratio for a combined endpoint of perioperative major stroke or death was 1.0 (95% CI 0.4-2.9), and for any perioperative stroke, 1.2 (95% CI 0.5-2.7). Compared with CEA performed without a patch, eversion CEA and conventional patched CEA each had a lower risk of carotid restenosis (hazard ratio [HR] 0.3, 95% CI 0.2-0.6, and HR 0.2, 95% CI 0.07-0.6, respectively). A metaanalysis that included the EVEREST trial and five other smaller trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/76-82\">",
"     76-82",
"    </a>",
"    ] identified a trend toward a reduced risk of perioperative (30-day) stroke for eversion CEA compared with conventional CEA (OR 0.56, 95% CI 0.33-0.96) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/83\">",
"     83",
"    </a>",
"    ]. Among the included randomized trials, one single center trial found a significantly reduced risk for perioperative stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/79\">",
"     79",
"    </a>",
"    ]; the other trials found no significant differences between the techniques. In this trial, perioperative stroke occurred in 2.9 percent of patients undergoing conventional CEA and no patient undergoing eversion endarterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/79\">",
"     79",
"    </a>",
"    ]. Two of the four strokes involved the contralateral hemisphere, not necessarily related to endarterectomy technique, and the other two strokes were related to angulation at the interface of the artery and the patch material.",
"   </p>",
"   <p>",
"    Randomized trials and other observational studies that have evaluated conventional versus eversion CEA have included patients with asymptomatic and symptomatic disease. A post hoc analysis of data from the Stent-Protected Angioplasty versus Carotid Endarterectomy in Symptomatic Patients (SPACE-1) trial found no overall difference between the techniques; however, perioperative outcomes were better for conventional CEA, while later outcomes favored eversion CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/84\">",
"     84",
"    </a>",
"    ]. Ipsilateral stroke or death &le;30 days was significantly reduced for conventional versus eversion CEA (9 versus 3 percent), but the risk of ipsilateral stroke &gt;30 days was significantly lower for eversion compared with conventional CEA (3 versus 0 percent). Interestingly, eversion CEA was not found to have a significantly lower incidence of restenosis in contrast to other studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/83,85\">",
"     83,85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proponents of eversion CEA feel that once the technique has been mastered, it may be easier to perform than conventional CEA. Although this may be so, advocates of conventional CEA point out that shunt insertion during eversion CEA can be more difficult since the plaque must be completely removed before the shunt can be inserted. In addition, eversion CEA is less commonly introduced during vascular surgery training, and for those who adopt it later the technique may be associated with a learning curve. A retrospective review at an academic medical center compared the outcomes of the first 100 patients on whom they performed eversion endarterectomy with 100 patients who underwent conventional endarterectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/86\">",
"     86",
"    </a>",
"    ]. The rate of perioperative neurologic deficits and deaths were not significantly different. One case of amaurosis occurred after eversion CEA, and one case each of transient cerebral ischemia and retinal infarction after conventional CEA; one cardiac death occurred with each. No significant differences were seen in the rate of critical (&gt;80 percent) residual or recurrent stenosis, late stroke, or late carotid occlusion at 36 months follow-up. However, eversion endarterectomy had a higher rate of &gt;50 percent recurrent stenosis (38 versus 6 percent) compared with conventional CEA in spite of similar residual stenosis rates. The significance of this late mild to moderate stenosis is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838549\">",
"    <span class=\"h3\">",
"     Patch angioplasty versus primary closure",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, some surgeons choose to repair to the carotid artery primarily, while others patch the artery with saphenous vein or material (eg, polytetrafluoroethylene, Dacron, bovine pericardium) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/87-90\">",
"     87-90",
"    </a>",
"    ]. We recommend patch closure for all patients undergoing carotid endarterectomy (non-eversion).",
"   </p>",
"   <p>",
"    The trials that have been performed suggest two benefits from use of a patch: a marked reduction in the frequency of &ge;50 percent restenosis and a lower rate of ipsilateral stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/91,92\">",
"     91,92",
"    </a>",
"    ]. A systematic review of patch angioplasty versus primary closure during CEA identified ten eligible randomized controlled trials involving 1967 patients undergoing 2157 operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/92\">",
"     92",
"    </a>",
"    ]. Many of the trials were limited by significant methodological flaws; most were small, and none could be analyzed on a true intention-to-treat basis because of losses to follow-up. The use of a patch is associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A reduction in the risk of ipsilateral stroke in the perioperative period (odds ratio (OR) 0.31, 95% CI 0.1-0.63 and long-term OR 0.32, 95% CI 0.16-0.63).",
"     </li>",
"     <li>",
"      A reduced risk of perioperative arterial occlusion (OR 0.18, 95% CI 0.08-0.41).",
"     </li>",
"     <li>",
"      Decreased restenosis during long-term follow-up in eight trials (OR 0.24, 95% CI 0.17-0.34). These results are more certain than those of the previous review since the number of operations and events have increased. However, the sample sizes are still relatively small, data were not available from all trials, and there was significant loss to follow-up.",
"     </li>",
"     <li>",
"      No significant correlation was found between use of patch angioplasty and the risk of either perioperative or long-term all-cause death rates.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A separate systematic review identified 13 trials involving 2083 operations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/90\">",
"     90",
"    </a>",
"    ]. Seven trials compared vein closure with PTFE closure and six trials compared Dacron with other synthetic materials. No significant differences were found comparing synthetic grafts versus vein graft for stroke, stroke or death, arterial occlusion, arterial rupture, nerve palsy, wound infection or recurrent arterial stenosis during perioperative or one-year follow-up. The review identified one high-quality trial that compared Dacron with PTFE and found that Dacron was associated with an increased risk for perioperative stroke and an increased risk for both perioperative and late, recurrent carotid stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. Using a synthetic patch was found to decrease the risk of pseudoaneurysm relative to using a vein patch (odds ratio 0.09, 95% CI, 0.02-0.49). However, the studies that examined pseudoaneurysm outcomes were older [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/93-95\">",
"     93-95",
"    </a>",
"    ], using saphenous vein, jugular vein or other vein sites; the technical aspects of vein handling were not included. In one of these studies, the incidence of pseudoaneurysm was 17 percent using jugular vein, 9 percent using saphenous vein or PTFE, and 5 percent with primary closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/93\">",
"     93",
"    </a>",
"    ]. The use of vein during initial open carotid endarterectomy has declined, but when vein is needed (eg, graft infection, re-do carotid surgery), we prefer to use proximal saphenous vein harvested from the groin.",
"   </p>",
"   <p>",
"    Very few arterial complications, including hemorrhage, infection, cranial nerve palsies and pseudo-aneurysm formation have been evaluated with patch compared with primary closure but the available data suggest no significant differences [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838556\">",
"    <span class=\"h2\">",
"     Assessing brain perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit derived from CEA is partially dependent upon low perioperative morbidity. Although 80 to 85 percent of patients tolerate clamping of the carotid artery without consequence, assessment of the ability of the collateral circulation via the circle of Willis should be performed in all patients who do not undergo mandatory shunting. Assessing cerebral perfusion in selectively shunted patients can be accomplished with a variety of methods that are determined in part by the type of anesthesia chosen. Methods that have been studied include awake monitoring, transcranial Doppler, somatosensory evoked potentials, raw electroencephalographic (EEG) monitoring, processed EEG monitoring, carotid stump pressure, jugular venous oxygen saturation and others. The most commonly used methods are discussed below. The author prefers EEG monitoring. (See",
"    <a class=\"local\" href=\"#H83592649\">",
"     'Choice of anesthesia'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H93838563\">",
"     'Carotid shunting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Data from randomized trials on which neurologic monitoring method should be used to select patients for shunting are limited. A trial comparing EEG to carotid stump pressure monitoring showed a benefit to EEG monitoring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/97\">",
"     97",
"    </a>",
"    ]. A trial that randomly assigned 200 patients undergoing CEA under general anesthesia to routine or selective shunting (carotid systolic blood pressure &lt;40 mmHg), found no significant difference in perioperative stroke rate between the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/98\">",
"     98",
"    </a>",
"    ]. Other methods of assessing brain perfusion have not been evaluated in randomized trials.",
"   </p>",
"   <p>",
"    A review of the literature reported mean perioperative stroke rates for CEAs using the various techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/99\">",
"     99",
"    </a>",
"    ]. These are tabulated below and the more commonly used techniques are discussed in the next sections.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Routine shunting &ndash; 1.4 percent,",
"     </li>",
"     <li>",
"      Routine non-shunting &ndash; 2 percent",
"     </li>",
"     <li>",
"      Selecting shunting &ndash; 1.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Cervical block anesthesia (awake endarterectomy) &ndash; 1.1 percent",
"     </li>",
"     <li>",
"      Electroencephalogram &ndash; 1.6 percent",
"     </li>",
"     <li>",
"      Stump pressure &ndash; 1.6 percent",
"     </li>",
"     <li>",
"      Somatosensory evoked potentials &ndash; 1.8 percent",
"     </li>",
"     <li>",
"      Transcranial Doppler &ndash; 4.8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592875\">",
"    <span class=\"h3\">",
"     Awake endarterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who undergo",
"    <span class=\"nowrap\">",
"     local/regional",
"    </span>",
"    anesthesia can be followed clinically throughout the procedure by monitoring mental status, speech and extremity function. A disadvantage of awake surgery is that it is frequently uncomfortable for the patient and may necessitate urgent conversion to general anesthesia or urgent shunt placement.",
"   </p>",
"   <p>",
"    A neurologic assessment is performed at the beginning of the procedure and repeated every ten to fifteen minutes during carotid dissection, immediately prior to carotid clamping and continuously during carotid clamping. Agitation, slurred speech, disorientation, and extremity weakness are indications for shunt placement. (See",
"    <a class=\"local\" href=\"#H93838563\">",
"     'Carotid shunting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Clinical assessment of the patient undergoing awake carotid endarterectomy is consistently associated with the lower rates of shunt use. With awake carotid endarterectomy, a carotid shunt is needed in &lt;5 percent of patients. In a metaanalysis of ten trials, five evaluated shunt use and found significantly less use for local anesthesia compared with general anesthesia (odds ratio 0.27, 95% CI 0.23-0.31) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/56\">",
"     56",
"    </a>",
"    ]. However, there were no significant differences in the rates of stroke or death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592882\">",
"    <span class=\"h3\">",
"     EEG monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;When general anesthesia is used, raw EEG monitoring is more commonly used. A neurologist monitors the tracings during the course of the procedure for cerebral ischemia as indicated by the presence of theta and delta waves or disorganized rhythms that indicate the need for shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/100\">",
"     100",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H93838563\">",
"     'Carotid shunting'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Processed EEG monitoring (eg, bispectral index) has been used to correlate cerebral ischaemia with processed EEG monitor values [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/101-103\">",
"     101-103",
"    </a>",
"    ]. Bispectral index monitoring for depth of anesthesia and normal BIS values during general anesthesia are presented elsewhere (",
"    <a class=\"graphic graphic_table graphicRef81084 \" href=\"mobipreview.htm?21/31/22014\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=see_link&amp;anchor=H15#H15\">",
"     \"Awareness with recall following general anesthesia\", section on 'Brain monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one study, bispectral index (BIS) monitoring used during awake carotid endarterectomy found that the percent reduction in BIS values from baseline was significantly greater in patients shunted on the basis of clinical neurologic status compared with non-shunted patients (14 versus 4 percent). No trials are available using processed EEG prospectively in patients undergoing general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592896\">",
"    <span class=\"h3\">",
"     Stump pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although stump pressures have been used to determine the need for carotid shunting in the past, EEG monitoring is more commonly used in patients undergoing general anesthesia when mandatory shunting is not chosen.",
"   </p>",
"   <p>",
"    <br/>",
"    Carotid stump pressures are obtained after clamping the proximal common and external carotid arteries. A needle attached to a transducer is introduced into the common carotid artery to obtain a waveform. Mean pressures greater than 30 to 50 mmHg imply adequate collateralization via the circle of Willis down the ipsilateral carotid artery. Lower stump pressures are an indication for shunt placement and higher pressures are associated with stroke rates &lt;0.5 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/104\">",
"     104",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    Critics of this technique caution that pressures are only obtained after initial clamping, and, therefore, represent a \"snapshot\" in time. In addition, the above criteria should be used with caution in patients who have suffered prior ipsilateral strokes since there is a poor correlation between adequate perfusion pressures and outcomes in this setting. The accuracy of the pressure in the face of a preocclusive (string) lesion may also be questionable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838563\">",
"    <span class=\"h2\">",
"     Carotid shunting",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any patient who demonstrates evidence of cerebral ischemia by any of the monitoring techniques discussed above, shunting should be performed expeditiously. A temporary shunt is placed beyond the proximal and distal extent of the arteriotomy from the common to the internal carotid artery. Blood flows through the shunt providing continuous cerebral perfusion during the procedure. Neurologic reassessment is then performed.",
"   </p>",
"   <p>",
"    Studies targeted at defining the best approach (mandatory shunting, selective shunting) have been equivocal with respect to demonstrating any difference in important clinical outcomes, and given that there is no consensus, neurologic monitoring with selective shunting versus routine shunting has been largely a matter of surgeon preference [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/105-108\">",
"     105-108",
"    </a>",
"    ]. A key question is whether shunting results in lower overall rates of perioperative stroke or other morbidity. A systematic review that identified three trials involving 686 patients found no significant differences in the rates of all stroke, ipsilateral stroke or death up to 30 days for patients that were routinely shunting compared with",
"    <strong>",
"     no",
"    </strong>",
"    shunting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/108\">",
"     108",
"    </a>",
"    ]. Similarly, there are insufficient data to support one type of carotid shunt over another [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/107\">",
"     107",
"    </a>",
"    ]. Many shunts are available for use (Argyle&trade;, Pruitt-Inahara, Brenner, Burbank, Sundt) and each have their advantages and disadvantages. The features (stiff versus flexible, inline Doppler, balloons for occlusion), and use of these shunts can be found on proprietary websites. The selection of a particular shunt by a vascular surgeon is based on their experience. Most vascular surgeons become comfortable using one particular shunt.",
"   </p>",
"   <p>",
"    Although some surgeons prefer to use carotid shunts routinely to avoid the need for intraoperative neurologic monitoring, it should be recognized that shunting is unnecessary in approximately 90 percent of patients and exposes patients to the risks of shunting that may include the following: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Formation of an intimal flap during shunt insertion, resulting in arterial dissection",
"     </li>",
"     <li>",
"      Dislodgement of plaque emboli during vessel manipulation",
"     </li>",
"     <li>",
"      Air embolism due to bubbles in the shunt",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Surgeons who routinely shunt feel that shunt complications are less likely to occur if shunting is routinely performed. The advantages of routine shunting may include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Familiarity of the surgeon and surgical team with the technique. Data from the Vascular Study Group of New England (VSGNE) database found that surgeons who routinely shunted had lower stroke rates during carotid endarterectomy in patients with contralateral carotid occlusion compared with those who selectively shunted [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/109\">",
"       109",
"      </a>",
"      ]. The higher rate of stroke amongst practitioners who selectively shunted may be attributable to a lack of familiarity with the procedure. Other groups have also reported a higher rate of shunting in patients with contralateral carotid occlusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/110,111\">",
"       110,111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cerebral flow is assured with a properly placed shunt without need for neurological monitoring (EEG, stump pressure, awake neurological examination).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592498\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Upon recovering from anesthesia, a neurologic assessment is performed and repeated every hour during recovery.",
"   </p>",
"   <p>",
"    Because blood pressure lability is common in the first 12 to 24 hours postoperatively, it is standard care for CEA patients to be placed in a monitored setting with an arterial line in place.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592525\">",
"    <span class=\"h2\">",
"     Labile blood pressure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Manipulation of the carotid bulb during carotid endarterectomy not infrequently results in hemodynamic instability intraoperatively and in the early postoperative period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/112\">",
"     112",
"    </a>",
"    ]. Adequate cerebral perfusion pressure should be maintained during periods of hemodynamic instability to avoid low cerebral blood flow and cerebral ischemia.",
"   </p>",
"   <p>",
"    Systolic blood pressure should be maintained between 100 to 150 mmHg in the postoperative period. Hypertension may increase the likelihood of neck hematoma or suture line disruption, while relative hypotension compared with the patient's baseline value will increase the likelihood of inadequate cerebral perfusion and potential thrombosis of the endarterectomy site. Hypotension is more likely to result in cerebral ischemia and neurologic deficits in those patients who also have intracerebral small vessel disease. Patients may require pressor or antihypertensive drips to maintain the target blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=see_link&amp;anchor=H4#H4\">",
"     \"Drug treatment of hypertensive emergencies\", section on 'Nitroglycerin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A systematic review identified nine trials that recorded blood pressure during and after carotid endarterectomy. Blood pressure dropped significantly in the general anesthesia group after induction of anesthesia and in one trial, more patients in the general anesthesia group had significant hypotension during or after the operation (25 versus 7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/108\">",
"     108",
"    </a>",
"    ]. The GALA trial found that more patients undergoing general anesthesia required manipulation of blood pressure compared with patients receiving local anesthetic (72 versus 54 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/54\">",
"     54",
"    </a>",
"    ]. However, blood pressure responses intraoperatively and postoperatively are highly variable with hypertension and hypotension reported for local and general anesthesia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83592832\">",
"    <span class=\"h2\">",
"     Bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative bleeding, resulting in neck hematoma, occasionally occurs after CEA. It is easy to underestimate the size of a neck hematoma and the patient can rapidly lose their airway. There must be a low threshold to reexplore the neck and search for a surgically correctable source of bleeding.",
"   </p>",
"   <p>",
"    Close observation and judgment are critical in deciding when to open a neck wound and drain a hematoma. The airway may be lost if clinical signs such as hoarseness and stridor are relied upon. Diagnostic studies are generally not helpful in making this clinical decision. If there is any question about the significance of a hematoma, the patient should be returned to the OR for re-exploration",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838577\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a number of controlled trials have highlighted the patient population most likely to benefit from carotid endarterectomy (CEA), this operation is not without risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/113\">",
"     113",
"    </a>",
"    ]. The perioperative mortality associated with CEA ranges from &lt;0.5 to 3 percent. Mortality rates may be higher when this procedure is performed at non-tertiary care centers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. Surgeons are encouraged to keep accurate records of their individual stroke rates to ensure that standards are upheld. Low patient volume (&lt;3 CEAs performed every two years) and a greater number of years since licensure of the surgeon are associated with worse outcomes following CEA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American Heart Association (AHA) consensus statement states that indications for surgery are proven in symptomatic patients in whom morbidity and mortality rates associated with CEA are less than 6 percent and in the asymptomatic patient when the rates are less than 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. These recommendations are, however, more than 10 years old and based upon data that are up to 20 years old. The AHA recommendations are under revision. Two large randomized trials likely reflect more accurately the contemporary risk of stroke or death following carotid endarterectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The European trial (International Carotid Stenting Study [ICSS]) randomly assigned patients to receive carotid endarterectomy or carotid stenting for treatment of symptomatic carotid stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/120\">",
"       120",
"      </a>",
"      ]. The 120 day all-cause mortality for the 857 symptomatic patients in the endarterectomy group was 0.8 percent. The 120 day combined any stroke or procedural death rate was 4.2 percent.",
"     </li>",
"     <li>",
"      In North America, the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) reported combined results for symptomatic and asymptomatic patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/121\">",
"       121",
"      </a>",
"      ]. In 1240 patients assigned to endarterectomy (47.3 percent asymptomatic), the 30-day death rate was 0.3 percent and the rate of any periprocedural (30-day) stroke or death or postprocedural ipsilateral stroke was 2.3 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H709631791\">",
"    <span class=\"h2\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of deaths following CEA are due to cardiac events, placing emphasis on the appropriate cardiac workup and perioperative management in these patients. (See",
"    <a class=\"local\" href=\"#H93838506\">",
"     'Perioperative risk assessment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=see_link\">",
"     \"Perioperative myocardial infarction after noncardiac surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838584\">",
"    <span class=\"h2\">",
"     Postoperative stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stroke is the second most common cause of death following CEA. The rate of perioperative stroke (30 day) associated with CEA ranges from less than 0.25 to more than 3 percent, with the experience of the surgeon again being important.",
"   </p>",
"   <p>",
"    Multiple factors can contribute to postoperative stroke in patients who have undergone CEA. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Plaque emboli",
"     </li>",
"     <li>",
"      Platelet aggregates",
"     </li>",
"     <li>",
"      Improper flushing",
"     </li>",
"     <li>",
"      Poor cerebral protection",
"     </li>",
"     <li>",
"      Relative hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, neurologic changes in the patient after CEA must be considered secondary to thrombosis at the operative site until proven otherwise. Technical errors must be ruled out.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838591\">",
"    <span class=\"h3\">",
"     Evaluation and treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the CEA patient with new neurologic deficits varies among surgeons. Some advocate recovery room or intraoperative ultrasound to assess potential thrombosis, while others immediately return to the operating room and open the endarterectomy site for direct visual inspection.",
"   </p>",
"   <p>",
"    The optimal time to heparinize the symptomatic postoperative patient is also controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/122\">",
"     122",
"    </a>",
"    ]. Some surgeons heparinize immediately upon suspicion of the diagnosis, while others first obtain a head CT to rule out hemorrhagic stroke. Head CT performed immediately after an embolic event is frequently normal; follow-up CT in a few days may reveal injury.",
"   </p>",
"   <p>",
"    Percutaneous transluminal carotid angioplasty with stenting is an alternative therapy for elective treatment of carotid artery disease. Carotid stenting may also be effective for managing perioperative stroke after CEA, particularly if the cause is a flow-limiting dissection. As an example, one study evaluated 13 patients with major or minor neurologic complications after CEA who underwent emergency carotid angiography and stent placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/123\">",
"     123",
"    </a>",
"    ]. The angiographic success was 100 percent and 11 patients had complete resolution of neurologic symptoms. In contrast, only one of five patients undergoing surgical reexploration had neurologic recovery. Stenting, however, is not considered standard for treatment of acute complications of carotid endarterectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=see_link\">",
"     \"Carotid artery stenting and its complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intraarterial thrombolytic therapy, in highly selected cases, may be another treatment option in patients with a postoperative stroke proven by arteriography to be due to distal emboli that, presumably, occurred during the course of the endarterectomy. The rationale for the administration of tissue-type plasminogen activator (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    ) in this setting is based upon trials in acute stroke in which benefit has been demonstrated if therapy is initiated within 4.5 hours in highly selected patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=see_link\">",
"     \"Reperfusion therapy for acute ischemic stroke\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the incidence of intracranial hemorrhage in patients treated with thrombolytic therapy for acute stroke has been in the range of 6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/124\">",
"     124",
"    </a>",
"    ]. Furthermore, it is not known if the results obtained from the intravenous systemic administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/41/11929?source=see_link\">",
"     alteplase",
"    </a>",
"    can be extrapolated to localized intraarterial therapy.",
"   </p>",
"   <p>",
"    Intraarterial thrombolysis for patients with postoperative stroke has only been described in case reports and retrospective studies and is, currently, experimental. There are, as yet, no controlled trials. Some neurologists advocate searching for distal thrombosis via arteriogram and, if found, proceeding with intraarterial thrombolytic therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838598\">",
"    <span class=\"h2\">",
"     Hyperperfusion syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cerebral hyperperfusion syndrome is probably the cause of most postoperative intracerebral hemorrhages and seizures in the first two weeks after CEA. The clinical manifestations of hyperperfusion occur in only a small percentage of patients after carotid revascularization (from less than 1 to as high as 3 percent in various reports) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/125-128\">",
"     125-128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of hyperperfusion is related to changes that occur in the ischemic or low-flow carotid vascular bed. To maintain sufficient cerebral blood flow, small vessels compensate with chronic maximal dilatation.",
"   </p>",
"   <p>",
"    After surgical correction of the carotid stenosis, blood flow is restored to a normal or elevated perfusion pressure within the previously hypoperfused hemisphere. The dilated vessels are thought to be unable to vasoconstrict sufficiently to protect the capillary bed because of a loss of cerebral blood flow autoregulation. Breakthrough perfusion pressure then causes edema and hemorrhage, which in turn results in the clinical manifestations.",
"   </p>",
"   <p>",
"    The hyperperfusion syndrome is characterized by the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Headache ipsilateral to the revascularized internal carotid, typically improved in upright posture, may herald the syndrome in the first week after endarterectomy.",
"     </li>",
"     <li>",
"      Focal motor seizures are common, sometimes with postictal Todd's paralysis mimicking post-endarterectomy stroke from carotid thrombosis.",
"     </li>",
"     <li>",
"      Intracerebral hemorrhage is the most feared complication, occurring in about 0.6 percent of patients after CEA, usually within two weeks of surgery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/129\">",
"       129",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Neuroimaging studies, including head CT and MRI with T2 or FLAIR sequences, typically show cerebral edema, petechial hemorrhages, or frank intracerebral hemorrhage. Post-revascularization ipsilateral cerebral blood flow (CBF) is markedly increased compared with preprocedure flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/130\">",
"     130",
"    </a>",
"    ]. Ipsilateral CBF after revascularization may be two to three times that of homologous regions in the contralateral hemisphere [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/131\">",
"     131",
"    </a>",
"    ]. However, hyperperfusion syndrome may develop in the presence of only moderate (20 to 44 percent) increases in ipsilateral cerebral blood flow, as measured by perfusion magnetic resonance imaging, and in the absence of increases in middle cerebral artery flow velocity, as measured by transcranial Doppler (TCD) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/132\">",
"     132",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The hyperperfusion syndrome appears to be more likely with revascularization of a high-grade (80 percent or greater stenosis) carotid lesion, and it may be more likely when CEA is performed after recent cerebral infarction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/133\">",
"     133",
"    </a>",
"    ]. Reduced CBF or cerebral vasoreactivity prior to CEA may also be a risk factor for postoperative hyperperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Transcranial Doppler techniques have been used to monitor flow velocities of the middle cerebral artery in order to predict the occurrence of hyperperfusion syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/135-137\">",
"     135-137",
"    </a>",
"    ], but the utility of these methods for this indication is not clearly established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838605\">",
"    <span class=\"h3\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best remedy for cerebral hyperperfusion is prevention. Strict control of postoperative hypertension is paramount. Systolic blood pressure must be maintained at or below 150 mmHg. Aggressive measures including intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35544?source=see_link\">",
"     labetalol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21302?source=see_link\">",
"     nitroprusside",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    may be necessary to achieve this goal. Therapy should begin at the time of restoration of internal carotid flow and be maintained vigilantly during the hospital stay and for the first 10 to 14 days postprocedure. Fortunately, most postoperative blood pressure lability resolves in the first 24 hours. (See",
"    <a class=\"local\" href=\"#H83592525\">",
"     'Labile blood pressure'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Seizures related to hyperperfusion are usually successfully treated with standard antiepileptic drugs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/138\">",
"     138",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intracerebral hemorrhage from hyperperfusion is often devastating. Hypertension must be strictly controlled and anticoagulant and antithrombotic drugs should be discontinued. For patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , platelet transfusions may be useful to reverse the antiplatelet effect. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=see_link&amp;anchor=H323385#H323385\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Platelet function defects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838612\">",
"    <span class=\"h2\">",
"     Nerve injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nerve injuries can complicate CEA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The vagus nerve, which usually lays posterolaterally in the carotid sheath, is identified during dissection of the carotid from the internal jugular vein and is at risk for injury.",
"     </li>",
"     <li>",
"      The recurrent laryngeal nerve branches of the vagus are distal to the area of carotid artery dissection; injury to this nerve may result in unilateral vocal cord paralysis. The occasionally nonrecurrent nerve places this branch at even higher risk.",
"     </li>",
"     <li>",
"      The facial nerve exits the stylomastoid foramen and courses along the inferior portion of the ear. The most common branch affected during CEA is the marginal mandibular branch, which may be damaged during improper or prolonged retraction. The resulting paresis of the lateral aspect of the orbicularis oris muscle may be exacerbated during bedside examination with a revealing asymmetric smile.",
"     </li>",
"     <li>",
"      The glossopharyngeal nerve is more cephalad than the extent of the typical neck dissection during CEA. A branch of this nerve, the nerve of Hering, has great clinical significance since it innervates the carotid sinus and is responsible for the bradycardic and hypotensive responses that may be seen with manipulation of this structure. Some surgeons anesthetize the carotid sinus with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      to avoid this complication, which is typically manifested intraoperatively.",
"     </li>",
"     <li>",
"      Damage to the hypoglossal nerve, also identified routinely during a CEA, is the complication with which most are familiar. Injury to this nerve may result from inadvertent retraction or, rarely, transection; it results in tongue deviation to the side of injury.",
"     </li>",
"     <li>",
"      Branches of the trigeminal nerve may be transected during dissection, resulting in sensory loss in the area of distribution",
"     </li>",
"     <li>",
"      The ansa hypoglossus nerve innervates the strap muscles of the neck and is typically seen coursing along the carotid sheath. Unlike the other nerves, this nerve may be divided without clinically significant consequence.",
"     </li>",
"     <li>",
"      The superior laryngeal nerve is rarely injured during CEA. The internal branch supplies sensation to the larynx, while the external branch innervates the cricopharyngeal muscle. Changes in voice quality may result from nerve injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The vast majority of cranial nerve injuries associated with CEA resolve over the first few months after surgery, and the risk of permanent cranial nerve deficit is very low. Among the 1739 patients who had CEA in the European Carotid Surgery Trial (ECST), immediate motor cranial nerve injury occurred in 5.1 percent, all ipsilateral to the side of the operation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/139\">",
"     139",
"    </a>",
"    ]. By hospital discharge, the cranial nerve injury rate had declined to 3.7 percent, and the involved cranial nerves included hypoglossal (n = 27), marginal mandibular (n = 17), recurrent laryngeal (n = 17), accessory (n = 1), and Horner syndrome (n = 3). The rate of persistent cranial nerve injury at four-month follow-up declined to 0.5 percent. Duration of surgery longer than two hours was the only independent risk factor for cranial nerve injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838633\">",
"    <span class=\"h2\">",
"     Parotitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parotitis is an unusual complication after CEA that results from manipulation of the parotid gland during the procedure. For this reason, most surgeons use this landmark as the cephalad extent of their dissection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20417841\">",
"    <span class=\"h1\">",
"     FOLLOW-UP CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following carotid endarterectomy, patients are typically discharged within one to three days. The most common delay in discharge is due to difficulties controlling blood pressure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20417848\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;The postoperative dressing is removed on the first postoperative day. If a drain has been placed, it should be removed as soon as possible in the postoperative period (day one or two) to decrease the potential for wound infection provided there is no significant drainage. Antibiotics are limited to perioperative prophylaxis. (See",
"    <a class=\"local\" href=\"#H83592851\">",
"     'Prophylactic antibiotics'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20417855\">",
"    <span class=\"h2\">",
"     Duplex surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repeat duplex ultrasonography should be obtained three to six weeks following carotid endarterectomy to establish a new baseline for future comparison. Duplex surveillance is performed at six months and annually. More frequent intervals may be warranted if a contralateral stenosis is being observed. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H93838640\">",
"    <span class=\"h1\">",
"     CAROTID RESTENOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical rates of carotid artery restenosis after CEA were as high as 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/140\">",
"     140",
"    </a>",
"    ]. Lower values (2.6 to 10 percent at five years) are reported in more contemporary series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/1,141,142\">",
"     1,141,142",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathology of the restenotic lesion is related to the time of presentation after initial surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/143\">",
"     143",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    \"Early\" restenosis is that which occurs within two to three years after CEA. Patients with early restenosis frequently have highly cellular and minimally ulcerated intimal hyperplasia, similar to that which occurs after angioplasty or with stent placement. As a result, there is a low likelihood of symptomatic embolization.",
"   </p>",
"   <p>",
"    \"Late\" restenosis occurs more than two to three years after CEA and generally results from progression of atherosclerotic disease. It is frequently associated with irregular plaques that may serve as an embolic source.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at increased risk for restenosis include those below age 65, smokers, and women, probably due to the smaller size of their carotid arteries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. Elevated creatinine has been associated with the development of early restenosis, and elevated serum cholesterol with late restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/141\">",
"     141",
"    </a>",
"    ]. Lipid lowering drugs may be protective for both early and late restenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/141\">",
"     141",
"    </a>",
"    ], although this finding requires confirmation.",
"   </p>",
"   <p>",
"    The cellular features of the atheroma at the time of CEA may predict the occurrence of restenosis. In a prospective study of 500 patients that examined target lesion atherosclerotic plaque composition from specimens obtained at carotid endarterectomy, both low macrophage infiltration and a small or absent lipid core were associated with an increased risk of restenosis at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/145\">",
"     145",
"    </a>",
"    ]. In another study of 150 patients, an abundance of smooth muscle cells and a scarcity of macrophages were seen in the primary lesion of those who had neointima development six months after surgery; in those who did not develop neointima, the lesions were rich in lymphocytes and macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patch angioplasty appears to be associated with a decreased risk of long-term recurrent stenosis compared with primary closure (see",
"    <a class=\"local\" href=\"#H93838549\">",
"     'Patch angioplasty versus primary closure'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/147\">",
"     147",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Reoperation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the diagnosis of restenosis has been made, a decision has to be made about the need for reoperation. This decision is not one to be made lightly since reoperative CEA may be associated with a significant incidence of complications, although the evidence is retrospective and conflicting. The following studies illustrate the range of perioperative complications reported for redo CEA:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An earlier series described 69 patients (48 percent men, 66 percent symptomatic) who had 82 reoperative CEA procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/148\">",
"       148",
"      </a>",
"      ]. Nine patients had two reoperative CEAs and two patients had three reoperative CEAs for either bilateral recurrence or a second recurrence on the same side. The average time to presentation with recurrent carotid stenosis was 6.5 years. The incidence of postoperative stroke (4.8 percent), transient ischemic attack (7.3 percent), and hematomas (7.3 percent) was nearly twice as high as reported for a first CEA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/148\">",
"       148",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series of 401 reoperative CEAs in 10 states in the United States, the 30-day combined risk of stroke or death from mid-1998 to mid-1999 was 5.7 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A subsequent series described 145 patients (56 percent men, 36 percent symptomatic) who had 153 reoperative CEA procedures [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/150\">",
"       150",
"      </a>",
"      ]. The incidence of perioperative stroke (1.9 percent) and death (O) was very low. While the average time from primary to reoperative CEA was 6.1 years in this series, 41 percent of the cohort were patients with early (&lt;2 years) restenosis, which is typically due to intimal hyperplasia and carries a low risk of symptomatic disease compared with late restenosis (see",
"      <a class=\"local\" href=\"#H31\">",
"       'Pathology'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      A study of 31 patients who underwent carotid surgery for a secondary recurrent carotid stenosis required resection of the carotid and placement of an interposition graft in about 30 percent of the patients. No perioperative strokes were reported and peripheral nerve injury occurred in 10 percent of the patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/151\">",
"       151",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An additional major concern is that there are no controlled studies establishing the efficacy of reoperative CEA in patients with restenosis. The presumed benefits of surgery in this group of patients are an extrapolation of the results of trials performed on patients at initial presentation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     PREDICTORS OF LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The predictors of long-term outcome after surgical therapy for atherosclerotic occlusive disease of the carotids were evaluated in one study of 1982 patients who underwent surgery at a single center and were followed for &ge;25 years. Predictors of mortality included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/152\">",
"     152",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Age, with a relative risk of 1.51 for each 10 year increase in age",
"     </li>",
"     <li>",
"      Male sex, relative risk 1.58",
"     </li>",
"     <li>",
"      Diabetes mellitus, relative risk 1.48",
"     </li>",
"     <li>",
"      Systemic hypertension, relative risk 1.31",
"     </li>",
"     <li>",
"      Cigarette smoking, relative risk 1.13",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predictors of recurrence of symptoms or progression of disease were established by analysis of a subset of 886 patients who underwent one or more postoperative angiograms; these included [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/27/40378/abstract/152\">",
"     152",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Total cholesterol, with a relative risk of 1.13 for each 50",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (1.3",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      increase",
"     </li>",
"     <li>",
"      Systemic hypertension, relative risk 1.42",
"     </li>",
"     <li>",
"      Cigarette smoking, relative risk 1.47",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=see_link\">",
"       \"Patient information: Carotid artery disease (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H83591810\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The effectiveness of carotid endarterectomy (CEA) for moderate to severe asymptomatic or symptomatic carotid artery stenosis has been established in large randomized trials. Prophylactic carotid endarterectomy in patients with asymptomatic carotid stenosis prior to cardiac or general surgery has no demonstrated benefit. For patients with indications for bilateral carotid endarterectomy, a staged rather than combined procedure is performed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link\">",
"       \"Management of symptomatic carotid atherosclerotic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=see_link\">",
"       \"Management of asymptomatic carotid atherosclerotic disease\"",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H93838457\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H93838464\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to carotid endarterectomy for asymptomatic carotid stenosis, duplex ultrasound may be sufficient to reliably determine the degree of internal carotid artery stenosis and assess local anatomy when performed in a certified vascular laboratory using validated criteria. If these standards cannot be met, additional imaging to verify the degree of stenosis should be performed. (See",
"      <a class=\"local\" href=\"#H83592226\">",
"       'Duplex ultrasound'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to carotid endarterectomy, we recommend starting",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (81 to 325 mg daily) and continuing treatment indefinitely (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). For patients who are sensitive to aspirin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      is an alternative agent. (See",
"      <a class=\"local\" href=\"#H93838520\">",
"       'Aspirin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with symptomatic carotid stenosis, we suggest initiation of statin therapy prior to carotid endarterectomy (or maintenance in patients already being treated) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). The use of statins in symptomatic patients is associated with reduced morbidity and mortality following CEA. For patients with asymptomatic carotid stenosis undergoing CEA, statin therapy has not shown the same benefit but may be indicated for other medical reasons. (See",
"      <a class=\"local\" href=\"#H93838527\">",
"       'Statins'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend antibiotic prophylaxis prior to carotid endarterectomy to reduce the risk of surgical site infection due to the frequent use of prosthetic material (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Antibiotics should be discontinued within 24 hours. (See",
"      <a class=\"local\" href=\"#H83592851\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carotid endarterectomy can be performed using general anesthesia or local anesthesia (with or without cervical block). Statistically significant differences for major endpoints (perioperative stroke, myocardial infarction, and death) have not been consistently shown for differing anesthetic approaches. The choice of anesthesia technique is largely dependent on the preferences of the patient, the anesthesiologist and the surgeon. (See",
"      <a class=\"local\" href=\"#H83592649\">",
"       'Choice of anesthesia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No one technique for plaque removal has been found to be superior over another with respect to the incidence of stroke, death or other morbidity. As with many surgical techniques, one technique may be preferable to another for specific circumstances and the choice of technique is largely dependent on the preferences and experience of the surgeon. (See",
"      <a class=\"local\" href=\"#H83592614\">",
"       'Endarterectomy procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prior to carotid artery clamping, the patient is systemically anticoagulated. At the completion of the procedure, we suggest reversal of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      with protamine over no reversal (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H83592614\">",
"       'Endarterectomy procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following carotid plaque removal, we recommend patch closure of the carotid artery over no patch (non-eversion technique) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). With conventional CEA, carotid patch techniques are associated with decreased rates of stroke and carotid restenosis. No one patch material (synthetic, vein, bovine pericardium) has been shown to be superior over another.",
"     </li>",
"     <li>",
"      After the completion of the procedure, the patient&rsquo;s neurologic status and blood pressure are carefully monitored. We keep the systolic blood pressure between 100 and 150 mmHg. Hypotension and hypertension are both associated with adverse outcomes. (See",
"      <a class=\"local\" href=\"#H83592498\">",
"       'Postoperative care'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complications following CEA include perioperative stroke, myocardial infarction, cerebral hyperperfusion syndrome, cranial nerve injury and parotitis. The cerebral hyperperfusion syndrome is probably the cause of most postoperative intracerebral hemorrhages and seizures in the first two weeks after CEA. The mechanism of hyperperfusion is related to loss of cerebral autoregulation. Patients complaining of severe ipsilateral headache (same side as CEA) within two weeks of CEA should be evaluated for hyperperfusion syndrome. (See",
"      <a class=\"local\" href=\"#H93838577\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/1\">",
"      Counsell CE, Salinas R, Naylor R, Warlow CP. A systematic review of the randomised trials of carotid patch angioplasty in carotid endarterectomy. Eur J Vasc Endovasc Surg 1997; 13:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/2\">",
"      da Silva AF, McCollum P, Szymanska T, de Cossart L. Prospective study of carotid endarterectomy and contralateral carotid occlusion. Br J Surg 1996; 83:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/3\">",
"      Gasecki AP, Eliasziw M, Ferguson GG, et al. Long-term prognosis and effect of endarterectomy in patients with symptomatic severe carotid stenosis and contralateral carotid stenosis or occlusion: results from NASCET. North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. J Neurosurg 1995; 83:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/4\">",
"      Parikh S, Cohen JR. Perioperative stroke after general surgical procedures. N Y State J Med 1993; 93:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/5\">",
"      Landercasper J, Merz BJ, Cogbill TH, et al. Perioperative stroke risk in 173 consecutive patients with a past history of stroke. Arch Surg 1990; 125:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/6\">",
"      Larsen SF, Zaric D, Boysen G. Postoperative cerebrovascular accidents in general surgery. Acta Anaesthesiol Scand 1988; 32:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/7\">",
"      Ropper AH, Wechsler LR, Wilson LS. Carotid bruit and the risk of stroke in elective surgery. N Engl J Med 1982; 307:1388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/8\">",
"      Evans BA, Wijdicks EF. High-grade carotid stenosis detected before general surgery: is endarterectomy indicated? Neurology 2001; 57:1328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/9\">",
"      Ballotta E. High-grade carotid stenosis detected before general surgery: is endarterectomy indicated? Neurology 2002; 58:1442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/10\">",
"      Marcucci G, Accrocca F, Antonelli R, et al. High-risk patients for carotid endarterectomy: turned down cases are rare. J Cardiovasc Surg (Torino) 2012; 53:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/11\">",
"      Eagle KA, Boucher CA. Cardiac risk of noncardiac surgery. N Engl J Med 1989; 321:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/12\">",
"      Hsia DC, Moscoe LM, Krushat WM. Epidemiology of carotid endarterectomy among Medicare beneficiaries: 1985-1996 update. Stroke 1998; 29:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/13\">",
"      Ouriel K, Hertzer NR, Beven EG, et al. Preprocedural risk stratification: identifying an appropriate population for carotid stenting. J Vasc Surg 2001; 33:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/14\">",
"      Reed AB, Gaccione P, Belkin M, et al. Preoperative risk factors for carotid endarterectomy: defining the patient at high risk. J Vasc Surg 2003; 37:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/15\">",
"      Mozes G, Sullivan TM, Torres-Russotto DR, et al. Carotid endarterectomy in SAPPHIRE-eligible high-risk patients: implications for selecting patients for carotid angioplasty and stenting. J Vasc Surg 2004; 39:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/16\">",
"      Piepgras DG, Sundt TM Jr, Marsh WR, et al. Recurrent carotid stenosis. Results and complications of 57 operations. Ann Surg 1986; 203:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/17\">",
"      Miller MT, Comerota AJ, Tzilinis A, et al. Carotid endarterectomy in octogenarians: does increased age indicate \"high risk?\". J Vasc Surg 2005; 41:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/18\">",
"      Halm EA, Hannan EL, Rojas M, et al. Clinical and operative predictors of outcomes of carotid endarterectomy. J Vasc Surg 2005; 42:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/19\">",
"      Gasparis AP, Ricotta L, Cuadra SA, et al. High-risk carotid endarterectomy: fact or fiction. J Vasc Surg 2003; 37:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/20\">",
"      Jordan WD Jr, Alcocer F, Wirthlin DJ, et al. High-risk carotid endarterectomy: challenges for carotid stent protocols. J Vasc Surg 2002; 35:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/21\">",
"      Hill BB, Olcott C 4th, Dalman RL, et al. Reoperation for carotid stenosis is as safe as primary carotid endarterectomy. J Vasc Surg 1999; 30:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/22\">",
"      Flanigan DP, Flanigan ME, Dorne AL, et al. Long-term results of 442 consecutive, standardized carotid endarterectomy procedures in standard-risk and high-risk patients. J Vasc Surg 2007; 46:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/23\">",
"      Jackson RS, Black JH 3rd, Lum YW, et al. Class I obesity is paradoxically associated with decreased risk of postoperative stroke after carotid endarterectomy. J Vasc Surg 2012; 55:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/24\">",
"      LaMuraglia GM, Brewster DC, Moncure AC, et al. Carotid endarterectomy at the millennium: what interventional therapy must match. Ann Surg 2004; 240:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/25\">",
"      Kang JL, Chung TK, Lancaster RT, et al. Outcomes after carotid endarterectomy: is there a high-risk population? A National Surgical Quality Improvement Program report. J Vasc Surg 2009; 49:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/26\">",
"      Baracchini C, Saladini M, Lorenzetti R, et al. Gender-based outcomes after eversion carotid endarterectomy from 1998 to 2009. J Vasc Surg 2012; 55:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/27\">",
"      Dorigo W, Pulli R, Marek J, et al. Carotid endarterectomy in female patients. J Vasc Surg 2009; 50:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/28\">",
"      Rockman CB, Garg K, Jacobowitz GR, et al. Outcome of carotid artery interventions among female patients, 2004 to 2005. J Vasc Surg 2011; 53:1457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/29\">",
"      Yavas S, Mavioglu L, Kocabeyoglu S, et al. Is female gender really a risk factor for carotid endarterectomy? Ann Vasc Surg 2010; 24:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/30\">",
"      den Hartog AG, Algra A, Moll FL, de Borst GJ. Mechanisms of gender-related outcome differences after carotid endarterectomy. J Vasc Surg 2010; 52:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/31\">",
"      Brott TG, Brown RD Jr, Meyer FB, et al. Carotid revascularization for prevention of stroke: carotid endarterectomy and carotid artery stenting. Mayo Clin Proc 2004; 79:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/32\">",
"      Magnadottir HB, Lightdale N, Harbaugh RE. Clinical outcomes for patients at high risk who underwent carotid endarterectomy with regional anesthesia. Neurosurgery 1999; 45:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/33\">",
"      Johnston DC, Goldstein LB. Clinical carotid endarterectomy decision making: noninvasive vascular imaging versus angiography. Neurology 2001; 56:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/34\">",
"      Qureshi AI, Suri MF, Ali Z, et al. Role of conventional angiography in evaluation of patients with carotid artery stenosis demonstrated by Doppler ultrasound in general practice. Stroke 2001; 32:2287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/35\">",
"      Silvennoinen HM, Ikonen S, Soinne L, et al. CT angiographic analysis of carotid artery stenosis: comparison of manual assessment, semiautomatic vessel analysis, and digital subtraction angiography. AJNR Am J Neuroradiol 2007; 28:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/36\">",
"      Kahlon B, Sundb&auml;rg G, Rehncrona S. Comparison between the lumbar infusion and CSF tap tests to predict outcome after shunt surgery in suspected normal pressure hydrocephalus. J Neurol Neurosurg Psychiatry 2002; 73:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/37\">",
"      Patel SG, Collie DA, Wardlaw JM, et al. Outcome, observer reliability, and patient preferences if CTA, MRA, or Doppler ultrasound were used, individually or together, instead of digital subtraction angiography before carotid endarterectomy. J Neurol Neurosurg Psychiatry 2002; 73:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/38\">",
"      Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis--Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003; 229:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/39\">",
"      Johnston DC, Chapman KM, Goldstein LB. Low rate of complications of cerebral angiography in routine clinical practice. Neurology 2001; 57:2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/40\">",
"      Kappelle LJ, Eliasziw M, Fox AJ, et al. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The North American Symptomatic Carotid Endarterectomy Trail. Stroke 1999; 30:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/41\">",
"      Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/42\">",
"      Engelter S, Lyrer P. Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev 2003; :CD001458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/43\">",
"      Lindblad B, Persson NH, Takolander R, Bergqvist D. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. Stroke 1993; 24:1125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/44\">",
"      Chaturvedi S, Bruno A, Feasby T, et al. Carotid endarterectomy--an evidence-based review: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2005; 65:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/45\">",
"      Taylor DW, Barnett HJ, Haynes RB, et al. Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy: a randomised controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators. Lancet 1999; 353:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/46\">",
"      Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/47\">",
"      de Borst GJ, Hilgevoord AA, de Vries JP, et al. Influence of antiplatelet therapy on cerebral micro-emboli after carotid endarterectomy using postoperative transcranial Doppler monitoring. Eur J Vasc Endovasc Surg 2007; 34:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/48\">",
"      Kennedy J, Quan H, Buchan AM, et al. Statins are associated with better outcomes after carotid endarterectomy in symptomatic patients. Stroke 2005; 36:2072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/49\">",
"      McGirt MJ, Perler BA, Brooke BS, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005; 42:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/50\">",
"      Cavalcanti DD, Reis CV, Hanel R, et al. The ascending pharyngeal artery and its relevance for neurosurgical and endovascular procedures. Neurosurgery 2009; 65:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/51\">",
"      Demirci M, Sariba�� O, Ulu&ccedil; K, et al. Carotid artery stenting and endarterectomy have different effects on heart rate variability. J Neurol Sci 2006; 241:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/52\">",
"      Demirel S, Attigah N, Bruijnen H, et al. Changes in baroreceptor sensitivity after eversion carotid endarterectomy. J Vasc Surg 2012; 55:1322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/53\">",
"      Demirel S, Macek L, Bruijnen H, et al. Eversion carotid endarterectomy is associated with decreased baroreceptor sensitivity compared to the conventional technique. Eur J Vasc Endovasc Surg 2012; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/54\">",
"      GALA Trial Collaborative Group, Lewis SC, Warlow CP, et al. General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. Lancet 2008; 372:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/55\">",
"      Leichtle SW, Mouawad NJ, Welch K, et al. Outcomes of carotid endarterectomy under general and regional anesthesia from the American College of Surgeons' National Surgical Quality Improvement Program. J Vasc Surg 2012; 56:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/56\">",
"      Rerkasem K, Rothwell PM. Local versus general anaesthesia for carotid endarterectomy. Cochrane Database Syst Rev 2008; :CD000126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/57\">",
"      Schechter MA, Shortell CK, Scarborough JE. Regional versus general anesthesia for carotid endarterectomy: the American College of Surgeons National Surgical Quality Improvement Program perspective. Surgery 2012; 152:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/58\">",
"      G&uuml;rer O, Yap��c�� F, Yap��c�� N, et al. Comparison between local and general anesthesia for carotid endarterectomy: early and late results. Vasc Endovascular Surg 2012; 46:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/59\">",
"      Gomes M, Soares MO, Dumville JC, et al. Cost-effectiveness analysis of general anaesthesia versus local anaesthesia for carotid surgery (GALA Trial). Br J Surg 2010; 97:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/60\">",
"      McCarthy RJ, Walker R, McAteer P, et al. Patient and hospital benefits of local anaesthesia for carotid endarterectomy. Eur J Vasc Endovasc Surg 2001; 22:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/61\">",
"      Marcucci G, Antonelli R, Gabrielli R, et al. Short longitudinal versus transverse skin incision for carotid endarterectomy: impact on cranial and cervical nerve injuries and esthetic outcome. J Cardiovasc Surg (Torino) 2011; 52:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/62\">",
"      Stone DH, Nolan BW, Schanzer A, et al. Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke. J Vasc Surg 2010; 51:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/63\">",
"      Sharpe R, Sayers RD, McCarthy MJ, et al. The war against error: a 15&nbsp;year experience of completion angioscopy following carotid endarterectomy. Eur J Vasc Endovasc Surg 2012; 43:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/64\">",
"      Walker RA, Fox AD, Magee TR, Horrocks M. Intraoperative duplex scanning as a means of quality control during carotid endarterectomy. Eur J Vasc Endovasc Surg 1996; 11:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/65\">",
"      Padayachee TS, Brooks MD, Modaresi KB, et al. Intraoperative high resolution duplex imaging during carotid endarterectomy: which abnormalities require surgical correction? Eur J Vasc Endovasc Surg 1998; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/66\">",
"      Panneton JM, Berger MW, Lewis BD, et al. Intraoperative duplex ultrasound during carotid endarterectomy. Vasc Surg 2001; 35:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/67\">",
"      Wallaert JB, Goodney PP, Vignati JJ, et al. Completion imaging after carotid endarterectomy in the Vascular Study Group of New England. J Vasc Surg 2011; 54:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/68\">",
"      Ricco JB, R&eacute;gnault de la Mothe G, Fujita S, et al. Impact of routine completion angiography on the results of primary carotid endarterectomy: a prospective study in a teaching hospital. Eur J Vasc Endovasc Surg 2011; 41:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/69\">",
"      Ascher E, Markevich N, Kallakuri S, et al. Intraoperative carotid artery duplex scanning in a modern series of 650 consecutive primary endarterectomy procedures. J Vasc Surg 2004; 39:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/70\">",
"      Mullenix PS, Tollefson DF, Olsen SB, et al. Intraoperative duplex ultrasonography as an adjunct to technical excellence in 100 consecutive carotid endarterectomies. Am J Surg 2003; 185:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/71\">",
"      Ott C, Heller G, Odermatt M, Furrer M. Intraoperative duplex ultrasonography in carotid endarterectomy: the impact on indication for immediate revision and intermediate-term outcome. Vasa 2008; 37:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/72\">",
"      Zannetti S, Cao P, De Rango P, et al. Intraoperative assessment of technical perfection in carotid endarterectomy: a prospective analysis of 1305 completion procedures. Collaborators of the EVEREST study group. Eversion versus standard carotid endartectomy. Eur J Vasc Endovasc Surg 1999; 18:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/73\">",
"      Lingenfelter KA, Fuller BC, Sullivan TM. Intraoperative assessment of carotid endarterectomy: a comparison of techniques. Ann Vasc Surg 1995; 9:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/74\">",
"      Jain KM, Simoni EJ, Munn JS. Routine completion study during carotid endarterectomy is not necessary. Am J Surg 1994; 168:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/75\">",
"      Ricotta JJ, O'Brien-Irr MS. Completion angiography, is it really necessary? Am J Surg 1997; 174:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/76\">",
"      Cao P, Giordano G, De Rango P, et al. A randomized study on eversion versus standard carotid endarterectomy: study design and preliminary results: the Everest Trial. J Vasc Surg 1998; 27:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/77\">",
"      Markovic DM, Davidovic LB, Cvetkovic DD, et al. Single-center prospective, randomized analysis of conventional and eversion carotid endarterectomy. J Cardiovasc Surg (Torino) 2008; 49:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/78\">",
"      Ballotta E, Renon L, Da Giau G, et al. A prospective randomized study on bilateral carotid endarterectomy: patching versus eversion. Ann Surg 2000; 232:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/79\">",
"      Ballotta E, Da Giau G, Saladini M, et al. Carotid endarterectomy with patch closure versus carotid eversion endarterectomy and reimplantation: a prospective randomized study. Surgery 1999; 125:271.",
"     </a>",
"    </li>",
"    <li>",
"     Balzer, K. Eversion versus conventional endarterectomy. In: Perioperative monitoring in carotid surgery, Horsch, S, Ktenidis, K.  (Eds), Steinkopff Spinger, Darmstadt 1998. p.159-165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/81\">",
"      Cao P, Giordano G, De Rango P, et al. Eversion versus conventional carotid endarterectomy: late results of a prospective multicenter randomized trial. J Vasc Surg 2000; 31:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/82\">",
"      Vanmaele RG, Van Schil PE, DeMaeseneer MG, et al. Division-endarterectomy-anastomosis of the internal carotid artery: a prospective randomized comparative study. Cardiovasc Surg 1994; 2:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/83\">",
"      Antonopoulos CN, Kakisis JD, Sergentanis TN, Liapis CD. Eversion versus conventional carotid endarterectomy: a meta-analysis of randomised and non-randomised studies. Eur J Vasc Endovasc Surg 2011; 42:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/84\">",
"      Demirel S, Attigah N, Bruijnen H, et al. Multicenter experience on eversion versus conventional carotid endarterectomy in symptomatic carotid artery stenosis: observations from the Stent-Protected Angioplasty Versus Carotid Endarterectomy (SPACE-1) trial. Stroke 2012; 43:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/85\">",
"      Cao PG, de Rango P, Zannetti S, et al. Eversion versus conventional carotid endarterectomy for preventing stroke. Cochrane Database Syst Rev 2001; :CD001921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/86\">",
"      Brothers TE. Initial experience with eversion carotid endarterectomy: absence of a learning curve for the first 100 patients. J Vasc Surg 2005; 42:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/87\">",
"      AbuRahma AF, Hannay RS, Khan JH, et al. Prospective randomized study of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated Dacron (Hemashield) patching: perioperative (30-day) results. J Vasc Surg 2002; 35:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/88\">",
"      AbuRahma AF, Hopkins ES, Robinson PA, et al. Prospective randomized trial of carotid endarterectomy with polytetrafluoroethylene versus collagen-impregnated dacron (Hemashield) patching: late follow-up. Ann Surg 2003; 237:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/89\">",
"      Kim JH, Cho YP, Kwon TW, et al. Ten-year comparative analysis of bovine pericardium and autogenous vein for patch angioplasty in patients undergoing carotid endarterectomy. Ann Vasc Surg 2012; 26:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/90\">",
"      Rerkasem K, Rothwell PM. Patches of different types for carotid patch angioplasty. Cochrane Database Syst Rev 2010; :CD000071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/91\">",
"      AbuRahma AF, Robinson PA, Saiedy S, et al. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: long-term follow-up. J Vasc Surg 1998; 27:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/92\">",
"      Rerkasem K, Rothwell PM. Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev 2009; :CD000160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/93\">",
"      AbuRahma AF, Khan JH, Robinson PA, et al. Prospective randomized trial of carotid endarterectomy with primary closure and patch angioplasty with saphenous vein, jugular vein, and polytetrafluoroethylene: perioperative (30-day) results. J Vasc Surg 1996; 24:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/94\">",
"      Gonz&aacute;lez-Fajardo JA, P&eacute;rez JL, Mateo AM. Saphenous vein patch versus polytetrafluoroethylene patch after carotid endarterectomy. J Cardiovasc Surg (Torino) 1994; 35:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/95\">",
"      Hayes PD, Allroggen H, Steel S, et al. Randomized trial of vein versus Dacron patching during carotid endarterectomy: influence of patch type on postoperative embolization. J Vasc Surg 2001; 33:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/96\">",
"      Ho KJ, Nguyen LL, Menard MT. Intermediate-term outcome of carotid endarterectomy with bovine pericardial patch closure compared with Dacron patch and primary closure. J Vasc Surg 2012; 55:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/97\">",
"      Fletcher JP, Morris JG, Little JM, Kershaw LZ. EEG monitoring during carotid endarterectomy. Aust N Z J Surg 1988; 58:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/98\">",
"      Aburahma AF, Stone PA, Hass SM, et al. Prospective randomized trial of routine versus selective shunting in carotid endarterectomy based on stump pressure. J Vasc Surg 2010; 51:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/99\">",
"      Aburahma AF, Mousa AY, Stone PA. Shunting during carotid endarterectomy. J Vasc Surg 2011; 54:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/100\">",
"      Blume WT, Ferguson GG, McNeill DK. Significance of EEG changes at carotid endarterectomy. Stroke 1986; 17:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/101\">",
"      Deogaonkar A, Vivar R, Bullock RE, et al. Bispectral index monitoring may not reliably indicate cerebral ischaemia during awake carotid endarterectomy. Br J Anaesth 2005; 94:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/102\">",
"      Kodaka M, Nishikawa Y, Suzuki T, et al. Does bilateral bispectral index monitoring (BIS) detect the discrepancy of cerebral reperfusion during carotid endarterectomy? J Clin Anesth 2009; 21:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/103\">",
"      Estruch-P&eacute;rez MJ, Ausina-Aguilar A, Barber&aacute;-Alacreu M, et al. Bispectral index changes in carotid surgery. Ann Vasc Surg 2010; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/104\">",
"      Hertzer NR, Beven EG, Greenstreet RL, Humphries AW. Internal carotid back pressure, intraoperative shunting, ulcerated atheromata, and the incidence of stroke during carotid endarterectomy. Surgery 1978; 83:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/105\">",
"      Halsey JH Jr. Risks and benefits of shunting in carotid endarterectomy. The International Transcranial Doppler Collaborators. Stroke 1992; 23:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/106\">",
"      Whitney DG, Kahn EM, Estes JW, Jones CE. Carotid artery surgery without a temporary indwelling shunt. 1,917 consecutive procedures. Arch Surg 1980; 115:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/107\">",
"      Bond R, Rerkasem K, Counsell C, et al. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev 2002; :CD000190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/108\">",
"      Rerkasem K, Rothwell PM. Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev 2009; :CD000190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/109\">",
"      Goodney PP, Wallaert JB, Scali ST, et al. Impact of practice patterns in shunt use during carotid endarterectomy with contralateral carotid occlusion. J Vasc Surg 2012; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/110\">",
"      Kretz B, Abello N, Astruc K, et al. Influence of the contralateral carotid artery on carotid surgery outcome. Ann Vasc Surg 2012; 26:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/111\">",
"      Tan TW, Garcia-Toca M, Marcaccio EJ Jr, et al. Predictors of shunt during carotid endarterectomy with routine electroencephalography monitoring. J Vasc Surg 2009; 49:1374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/112\">",
"      Demirel S, Attigah N, Bruijnen H, et al. Eversion carotid endarterectomy is associated with impaired postoperative hemodynamic stability compared with the conventional technique. Ann Vasc Surg 2012; 26:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/113\">",
"      Matsumoto GH, Cossman D, Callow AD. Hazards and safeguards during carotid endarterectomy. Technical considerations. Am J Surg 1977; 133:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/114\">",
"      Wennberg DE, Lucas FL, Birkmeyer JD, et al. Variation in carotid endarterectomy mortality in the Medicare population: trial hospitals, volume, and patient characteristics. JAMA 1998; 279:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/115\">",
"      Brott T, Thalinger K. The practice of carotid endarterectomy in a large metropolitan area. Stroke 1984; 15:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/116\">",
"      Barnett HJ, Plum F, Walton JN. Carotid endarterectomy--an expression of concern. Stroke 1984; 15:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/117\">",
"      O'Neill L, Lanska DJ, Hartz A. Surgeon characteristics associated with mortality and morbidity following carotid endarterectomy. Neurology 2000; 55:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/118\">",
"      Moore WS, Barnett HJ, Beebe HG, et al. Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. Circulation 1995; 91:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/119\">",
"      Biller J, Feinberg WM, Castaldo JE, et al. Guidelines for carotid endarterectomy: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation 1998; 97:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/120\">",
"      International Carotid Stenting Study investigators, Ederle J, Dobson J, et al. Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet 2010; 375:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/121\">",
"      Brott TG, Hobson RW 2nd, Howard G, et al. Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med 2010; 363:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/122\">",
"      Chamorro A, Vila N, Saiz A, et al. Early anticoagulation after large cerebral embolic infarction: a safety study. Neurology 1995; 45:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/123\">",
"      Anzuini A, Briguori C, Roubin GS, et al. Emergency stenting to treat neurological complications occurring after carotid endarterectomy. J Am Coll Cardiol 2001; 37:2074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/124\">",
"      Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 1995; 333:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/125\">",
"      Youkey JR, Clagett GP, Jaffin JH, et al. Focal motor seizures complicating carotid endarterectomy. Arch Surg 1984; 119:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/126\">",
"      Reigel MM, Hollier LH, Sundt TM Jr, et al. Cerebral hyperperfusion syndrome: a cause of neurologic dysfunction after carotid endarterectomy. J Vasc Surg 1987; 5:628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/127\">",
"      Naylor AR, Ruckley CV. The post-carotid endarterectomy hyperperfusion syndrome. Eur J Vasc Endovasc Surg 1995; 9:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/128\">",
"      Coutts SB, Hill MD, Hu WY. Hyperperfusion syndrome: toward a stricter definition. Neurosurgery 2003; 53:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/129\">",
"      Piepgras DG, Morgan MK, Sundt TM Jr, et al. Intracerebral hemorrhage after carotid endarterectomy. J Neurosurg 1988; 68:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/130\">",
"      Sundt TM Jr, Sharbrough FW, Piepgras DG, et al. Correlation of cerebral blood flow and electroencephalographic changes during carotid endarterectomy: with results of surgery and hemodynamics of cerebral ischemia. Mayo Clin Proc 1981; 56:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/131\">",
"      Kidwell CS, Saver JL, Mattiello J, et al. Diffusion-perfusion MRI characterization of post-recanalization hyperperfusion in humans. Neurology 2001; 57:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/132\">",
"      Karapanayiotides T, Meuli R, Devuyst G, et al. Postcarotid endarterectomy hyperperfusion or reperfusion syndrome. Stroke 2005; 36:21.",
"     </a>",
"    </li>",
"    <li>",
"     Clagett, GP, Robertson, JT. Surgical considerations in symptomatic disease. In: Stroke: Pathophysiology, diagnosis and management, Barnett, HJM, Mohr, JP, Stein, BM, Yatsu, FM (Eds), Churchill Livingstone, New York 1998. p.1209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/134\">",
"      Hosoda K, Kawaguchi T, Ishii K, et al. Prediction of hyperperfusion after carotid endarterectomy by brain SPECT analysis with semiquantitative statistical mapping method. Stroke 2003; 34:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/135\">",
"      Powers AD, Smith RR. Hyperperfusion syndrome after carotid endarterectomy: a transcranial Doppler evaluation. Neurosurgery 1990; 26:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/136\">",
"      Dalman JE, Beenakkers IC, Moll FL, et al. Transcranial Doppler monitoring during carotid endarterectomy helps to identify patients at risk of postoperative hyperperfusion. Eur J Vasc Endovasc Surg 1999; 18:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/137\">",
"      Fujimoto S, Toyoda K, Inoue T, et al. Diagnostic impact of transcranial color-coded real-time sonography with echo contrast agents for hyperperfusion syndrome after carotid endarterectomy. Stroke 2004; 35:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/138\">",
"      Kieburtz K, Ricotta JJ, Moxley RT 3rd. Seizures following carotid endarterectomy. Arch Neurol 1990; 47:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/139\">",
"      Cunningham EJ, Bond R, Mayberg MR, et al. Risk of persistent cranial nerve injury after carotid endarterectomy. J Neurosurg 2004; 101:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/140\">",
"      Zierler RE, Bandyk DF, Thiele BL, Strandness DE Jr. Carotid artery stenosis following endarterectomy. Arch Surg 1982; 117:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/141\">",
"      LaMuraglia GM, Stoner MC, Brewster DC, et al. Determinants of carotid endarterectomy anatomic durability: effects of serum lipids and lipid-lowering drugs. J Vasc Surg 2005; 41:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/142\">",
"      Goodney PP, Nolan BW, Eldrup-Jorgensen J, et al. Restenosis after carotid endarterectomy in a multicenter regional registry. J Vasc Surg 2010; 52:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/143\">",
"      Sadideen H, Taylor PR, Padayachee TS. Restenosis after carotid endarterectomy. Int J Clin Pract 2006; 60:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/144\">",
"      Ladowski JS, Shinabery LM, Peterson D, et al. Factors contributing to recurrent carotid disease following carotid endarterectomy. Am J Surg 1997; 174:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/145\">",
"      Hellings WE, Moll FL, De Vries JP, et al. Atherosclerotic plaque composition and occurrence of restenosis after carotid endarterectomy. JAMA 2008; 299:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/146\">",
"      Pauletto P, Puato M, Faggin E, et al. Specific cellular features of atheroma associated with development of neointima after carotid endarterectomy: the carotid atherosclerosis and restenosis study. Circulation 2000; 102:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/147\">",
"      Bond R, Rerkasem K, Naylor AR, et al. Systematic review of randomized controlled trials of patch angioplasty versus primary closure and different types of patch materials during carotid endarterectomy. J Vasc Surg 2004; 40:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/148\">",
"      Mansour MA, Kang SS, Baker WH, et al. Carotid endarterectomy for recurrent stenosis. J Vasc Surg 1997; 25:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/149\">",
"      Kresowik TF, Bratzler DW, Kresowik RA, et al. Multistate improvement in process and outcomes of carotid endarterectomy. J Vasc Surg 2004; 39:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/150\">",
"      Stoner MC, Cambria RP, Brewster DC, et al. Safety and efficacy of reoperative carotid endarterectomy: a 14-year experience. J Vasc Surg 2005; 41:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/151\">",
"      Rosenthal D, Archie JP Jr, Avila MH, et al. Secondary recurrent carotid stenosis. J Vasc Surg 1996; 24:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/27/40378/abstract/152\">",
"      DeBakey ME, Glaeser DH. Patterns of atherosclerosis: effect of risk factors on recurrence and survival-analysis of 11,890 cases with more than 25-year follow-up. Am J Cardiol 2000; 85:1045.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8193 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40378=[""].join("\n");
var outline_f39_27_40378=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H83591810\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838457\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838464\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592415\">",
"      Special considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83591930\">",
"      - Bilateral carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83593145\">",
"      - Prophylactic carotid endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93838471\">",
"      Coronary artery bypass surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H93838478\">",
"      General surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H83593195\">",
"      Vascular procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592089\">",
"      - Endarterectomy in patients with intracranial aneurysm",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592452\">",
"      Relative contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838506\">",
"      Perioperative risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592219\">",
"      Preoperative imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592226\">",
"      - Duplex ultrasound",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592233\">",
"      - Other imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H101623404\">",
"      Laryngoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83592460\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medication management",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93838520\">",
"      - Aspirin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93838527\">",
"      - Statins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592851\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83592468\">",
"      SURGICAL ANATOMY AND PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592483\">",
"      Carotid artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441529762\">",
"      - External carotid artery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H441529769\">",
"      - Internal carotid artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H441529887\">",
"      Carotid baroreceptor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83592649\">",
"      CHOICE OF ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838534\">",
"      SURGICAL TECHNIQUE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592614\">",
"      Endarterectomy procedure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83596031\">",
"      - High access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592621\">",
"      - Conventional versus eversion endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93838549\">",
"      - Patch angioplasty versus primary closure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838556\">",
"      Assessing brain perfusion",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592875\">",
"      - Awake endarterectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592882\">",
"      - EEG monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H83592896\">",
"      - Stump pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838563\">",
"      Carotid shunting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83592498\">",
"      POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592525\">",
"      Labile blood pressure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H83592832\">",
"      Bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838577\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H709631791\">",
"      Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838584\">",
"      Postoperative stroke",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93838591\">",
"      - Evaluation and treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838598\">",
"      Hyperperfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H93838605\">",
"      - Treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838612\">",
"      Nerve injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H93838633\">",
"      Parotitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20417841\">",
"      FOLLOW-UP CARE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20417848\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20417855\">",
"      Duplex surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H93838640\">",
"      CAROTID RESTENOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Reoperation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      PREDICTORS OF LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H83591810\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8193\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8193|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/4/2122\" title=\"figure 1\">",
"      Cerebral arterial circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/61/32728\" title=\"figure 2\">",
"      External carotid artery anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/48/4874\" title=\"figure 3\">",
"      Lateral view of the internal carotid artery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8193|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/1/34844\" title=\"table 1\">",
"      Antimicrobial prophylaxis for vascular surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/31/22014\" title=\"table 2\">",
"      Processed EEG brain monitors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/35/2618?source=related_link\">",
"      Antiplatelet therapy for secondary prevention of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/44/34504?source=related_link\">",
"      Awareness with recall following general anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/12/37066?source=related_link\">",
"      Benefits and risks of aspirin in secondary and primary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/66?source=related_link\">",
"      Carotid artery stenting and its complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/29/6617?source=related_link\">",
"      Coronary artery bypass grafting in patients with cerebrovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/26/18853?source=related_link\">",
"      Drug treatment of hypertensive emergencies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/60/36810?source=related_link\">",
"      Estimation of cardiac risk prior to noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/19/31033?source=related_link\">",
"      Evaluation of carotid artery stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/40/16009?source=related_link\">",
"      Hoarseness in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/61/2010?source=related_link\">",
"      Intracranial large artery atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/33/16922?source=related_link\">",
"      Management of asymptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/16/10506?source=related_link\">",
"      Noninvasive diagnosis of arterial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/24/9608?source=related_link\">",
"      Pathophysiology of symptoms from carotid atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?12/14/12512?source=related_link\">",
"      Patient information: Carotid artery disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/17/29975?source=related_link\">",
"      Perioperative myocardial infarction after noncardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/39/18042?source=related_link\">",
"      Peripheral nerve block: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/8/41098?source=related_link\">",
"      Reperfusion therapy for acute ischemic stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/58/24488?source=related_link\">",
"      Screening for abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/31/13818?source=related_link\">",
"      Triple antithrombotic therapy in patients with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/40/25225?source=related_link\">",
"      Unruptured intracranial aneurysms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_27_40379="Diagnosis autoimmune hepatitis";
var content_f39_27_40379=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63858&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of autoimmune hepatitis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other autoimmune liver diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary biliary cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary sclerosing cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hepatitis/primary biliary cirrhosis overlap syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Autoimmune cholangiopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chronic viral hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis B",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis C",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis delta",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic hepatitis due to other viruses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic drug-induced hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha-1-antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wilson disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cholangiopathy related to AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Steatohepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Nonalcoholic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Alcoholic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Granulomatous hepatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Systemic lupus erythematosus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Graft-versus-host disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cryptogenic chronic hepatitis or cirrhosis",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40379=[""].join("\n");
var outline_f39_27_40379=null;
var title_f39_27_40380="Psoralen drugs for PUVA";
var content_f39_27_40380=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83021&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Psoralens used with ultraviolet A light therapy (PUVA) for psoriasis and vitiligo",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Trade name(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        US generic available",
"       </td>",
"       <td class=\"subtitle1\">",
"        Manufacturer",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preparation",
"       </td>",
"       <td class=\"subtitle1\">",
"        Suggested initial dose* (adult)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"3\">",
"        <p>",
"         Methoxsalen (8-methoxypsoralen, 8-MOP)",
"        </p>",
"       </td>",
"       <td>",
"        Oxsoralen-Ultra",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Valeant",
"       </td>",
"       <td>",
"        10 mg soft-gelatin capsule",
"       </td>",
"       <td>",
"        0.4 mg/kg orally 1 hour prior to UVA",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8-MOP",
"        <sup>",
"         &reg;",
"        </sup>",
"       </td>",
"       <td>",
"        No",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Valeant",
"       </td>",
"       <td>",
"        10 mg hard-gelatin capsule",
"       </td>",
"       <td>",
"        0.6 mg/kg orally 2 hours prior to UVA",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oxsoralen",
"        <sup>",
"         &reg;",
"        </sup>",
"        (lotion)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        Valeant",
"       </td>",
"       <td>",
"        10 mg/mL lotion (in 71 percent ethanol)",
"       </td>",
"       <td>",
"        Diluted 1:10 with ethanol to deliver 0.1 percent strength; applied to affected area according to PUVA protocol (see topic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Trioxsalen",
"        <sup>",
"         &loz;",
"        </sup>",
"        (4,5',8-trimethylpsoralen, trioxysalen, TMP)",
"       </td>",
"       <td>",
"        Trisoralen",
"        <sup>",
"         &reg;",
"        </sup>",
"        , (inactive trade name)",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        ICN pharmaceuticals; Valeant (former US manufacturer)",
"       </td>",
"       <td>",
"        5 mg",
"       </td>",
"       <td>",
"        0.6 mg/kg orally 2 hours prior to UVA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bergapten",
"        <sup>",
"         &loz;",
"        </sup>",
"        (5-methoxypsoralen, 5-MOP)",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        Pentaderm, Psoraderm 5",
"        <sup>",
"         &reg;",
"        </sup>",
"        , Geralen",
"       </td>",
"       <td>",
"        No",
"       </td>",
"       <td>",
"        May be available in some countries as an unlicensed product",
"       </td>",
"       <td>",
"        20 mg tablet",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        1.2 mg/kg orally 2 hours prior to UVA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosages must be given at least 48 hours apart.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Weight based doses are rounded to nearest 10 mg increment. For patients weighing &gt;115 kg, dose is 70 mg.",
"     <br/>",
"     &Delta; Older formulation having lower oral bioavailability and longer time to onset than newer Oxsoralen-Ultra",
"     <sup>",
"      &reg;",
"     </sup>",
"     .",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Not available in US.",
"     <br/>",
"     &sect; Micronized preparations appear to provide greater cutaneous absorption than unmicronized.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       McNeely W. 5-Methoxypsoralen: A review of its effects in psoriasis and vitiligo. Drugs 1998; 56:4.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40380=[""].join("\n");
var outline_f39_27_40380=null;
var title_f39_27_40381="Severity of obstructive sleep apnea";
var content_f39_27_40381=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F55763%7EPULM%2F70982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F55763%7EPULM%2F70982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Severity of obstructive sleep apnea",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Apnea hypopnea index (AHI)",
"       </td>",
"       <td class=\"subtitle1\">",
"        OSA severity",
"       </td>",
"       <td class=\"subtitle1\">",
"        OSA score",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-20",
"       </td>",
"       <td>",
"        Mild",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        21-40",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;41",
"       </td>",
"       <td>",
"        Severe",
"       </td>",
"       <td>",
"        3",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The apnea-hypopnea index (AHI) is the number of apneas and hypopneas per hour of sleep as measured in the sleep laboratory.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Gross JB, Bachenberg KL, Benumof JL, et al. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of patients with obstructive sleep apnea. Anesthesiology 2006; 104:1081.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Obstructive sleep apnea (OSA) severity scoring system: American Society of Anesthesiologists example",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        A. Severity of sleep apnea based on sleep study (or clinical indicators if sleep study not available).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Severity of OSA",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        None (apnea hypopnea index [AHI]) 0 to 5 adults; 0 children)",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Mild (AHI 6 to 20 adults; 1 to 5 children)",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Moderate (AHI 21 to 40 adults; 6 to 10 children)",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Severe (AHI greater than 40 adults; greater than 10 children)",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"        *",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        B. Invasiveness of surgery and anesthesia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Type of surgery and anesthesia",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Superficial surgery under local or peripheral nerve block anesthesia without sedation",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Superficial surgery with moderate sedation or general anesthesia",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Peripheral surgery with spinal or epidural anesthesia (with no more than moderate sedation)",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Peripheral surgery with general anesthesia",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Airway surgery with moderate sedation",
"       </td>",
"       <td>",
"        2 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Major surgery, general anesthesia",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Airway surgery, general anesthesia",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        C. Requirement for postoperative opioids.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"2\">",
"        <strong>",
"         Opioid requirement",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        None",
"       </td>",
"       <td>",
"        0 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Low-dose oral opioids",
"       </td>",
"       <td>",
"        1 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        High-dose oral opioids, parenteral or neuraxial opioids",
"       </td>",
"       <td>",
"        3 points",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Point score ____ (0 to 3)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        D. Estimation of perioperative risk. Overall score = the score for A plus the greater of the score for either B or C.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <strong>",
"         Total point score ____ (0 to 6)",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * One point may be subtracted if a patient has been on continuous positive airway pressure or noninvasive positive pressure ventilation before surgery and will be using his or her appliance consistently during the postoperative period.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      One point should be added if a patient with mild or moderate obstructive sleep apnea (OSA) also has a resting arterial carbon dioxide tension (PaCO",
"      <sub>",
"       2",
"      </sub>",
"      greater than 50 mmHg).",
"      <br>",
"       &Delta; Patients with a score of 4 may be at increased perioperative risk from OSA; patients with a score of 5 or 6 may be at significantly increased perioperative risk from OSA.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Practice guidelines for the perioperative management of patients with obstructive sleep apnea: a report by the American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea. Anesthesiology 2006; 104:1081. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40381=[""].join("\n");
var outline_f39_27_40381=null;
var title_f39_27_40382="Heart rate and VO2";
var content_f39_27_40382=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F63482%7ECARD%2F65079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F63482%7ECARD%2F65079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relation between heart rate and VO2 during exercise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between attained heart rate and oxygen uptake during exercise. One metabolic equivalent (MET) is defined as 3.5 mL O2 uptake/kg per min. Mean values of approximately 10 METs (VO2 35 mL/kg per min) can be achieved by nonathletic, healthy, middle-aged men; this should occur at a heart rate of approximately 175 beats/min.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Impaired hemodynamic response to exercise in HF",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 227px; background-image: url(data:image/gif;base64,R0lGODlh7wHjAOYAAP///wAAAH9/f+7u7qqqqjMzM3d3d7+/vxEREYiIiMzMzFVVVTNmmd3d3URERCIiIpmZmbu7u2ZmZswAZubs883Z5oCAgGaMs/P2+fzw9k15pkBwn4Cgv+JwqdIgeZmzzPLA2bPG2eV/sj8/P5myzPzv9c8QcOyfxfXP4lmDrNnj7LLF2aa808DQ39Ywg3OWub/P342pxvK/2PL1+Png7O+vz/bQ499goO+w0OmPvObs8vjf7Nni7KW80uygxumQvMzZ5szY5aa80uaAs+Xs8tg/jNxQltlAjIypxQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADvAeMAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09bEEBvkGDfb9/v+KCAQYOJAAwIMI+xkIkICAwwEJI0p0ByEAxIkYM6JTgGCBPn4aQ4rcJpBgAIOHEiAIgADCyJcwjQ1wSPNiIYEOABQIoCCmz5+6CCRooC8fyEILEwBIwBCouABOuRkoUJIgykJMFyxtOsiCya8WokaDKjZbgwgzaRKwWcjBwAcB/1wiIltWGt26Gx8UUHQXr7O+fqcNmFqgcAREKwNIYGsIcGBljh8/Y2ryKqXIko1hzryMaYMBoDFt5jwK38dMo0kfG1Cg4cNLqVV7qloQtWxoHCvDvo0qaU3bvJstlHDaUuzgmSoyxkpQKwAIcAM4ODroOHJfAqnvvj6Ko0ejhgwYTNogwIPnAZwTss59VwQEhQ1vbw+K9slEEgIYAACXeNzG9CFjn2WTsBcgJGn9ltJAPVEmXU8AePXVQGEdGAxoGIpmISdCEVWUdgAM4FZTCki31XmFGLjhWCtqMtWAhqzUkiARBLBXiSiu1yIwECjViYoHHSDAkAIc8MpZCb5WSP9iAyGwVGLTAbjjIUISaSQsCyEgAYTA/SSASQKwOKUhXxIU5j0LDNTacpIACVCZA535ymDxFXCYhmMWAmcAcsbSQAI7dXTnZU7t2WcrDtaGZ56DGHpLBAvAZ1yhYMbiWYZdMgqAo7eARmAkbv5T5ZBXekIBgq0pOJ+moxZ5i0CfgqqpICFooAEkuVmV6ay7wLrqlBVowAADGpzqyHDF/corLRh6et+kY1ZwwbAbfBBJdj8u2+mEz1YSqmQUTMtAtRhI8l6dg0KrLbPcxgrJt35RwMGwDHBgrCQwLrruLM1iqm48aXLZCgYf0PvCvZT0qwm8+/bCsC0l6geAQOptErD/KwRvMOwFFeDysD8X0/MxLRHzRLEnIa9S67ApdHxJj6CMjNtA+53cScryyCwLjjaerMBO0n3GklsDDG1eAnBpVXJTAYtIkI+jtCAssSG4yNKW2apTsgI2c4JzPDrHUuIC+bml1QMIDFBjAUUTVLSTTEnAXwBHlehkwMOZIi21LHRCQJo2JsBmgevwTFV6APw80HRvE230A0gjvrRSTY/I1TQLCK4sMmMPEN0CJe7V9tuCkM7Ufjsp0ADgAw0QsALRISBwJyqISy4ofwa6QLqEap1e2YijrbaNbbfO0lZyw1X38Xgrho1bCOx301fSHxI2LGNPPNDZaa9NeojHn64T/09pKrWS6zwNkrep8w7LQbmkQCrp5uR0/nno4Ft0PPhwS5z66iZBnwJg16TZdQJhr1BAAipmCLi4CwDXSyDiAJAmpQGNcfsznf94kpsCnC9grIsSJzAQA3rZyxGtcpUkPKWvc2SvJNwbHtsyGL4NKqB8APhg+gSxPk/U6lataIBcGpEVvkykSqWKRMY25jJH7IlP+OrWv1w4wQom7oJCcxL/toI6Dq7EgxYBIUFEyIlgDatYrRBIR4aiiAGsZHYS4laF/lGmIhFJhYsIgcYYwDFJPPFQjfBVC3m1t3FZyxV0IgjvCNHDuUykjpxKxMqoRok/NqJfgqTfmMJFrQ/AD/8WEViIFAlht8FV55FxiqQhKpACalWtEpZcRPF0M8hNtq9eCGxFBODyAAkM0RBuqV4iIggOSFZqlbbz5CVi2cZ27WpKBDNhLl0hkAcsAAKmfAQxv2FMMxVCXvSKwScB0KokLiKF5kREv0LzzBUtkY9NpMWfHLCSRcpKIkgs5yAwcMsT6umYr3CQcwRqvTzpkWXxrAU+gPZAR2wzHe+8wDQ3BVBXiAcAScHoeC53yh1NUgOvxEVJOvLL3sGEBXvsYyJUCYv8CNOlUtpQITcQ0lxEQAL2NKlIPtoCRrDUFZThUlAFEUew4POO6bzETJXpC66BiHAiMSMlG/FTUWRuOU7/40pWoaYjjVSVEuAcljiBkZ+BcFWnE1nqOM+JVFRAT5g5ZMkQZVTSjmbkq0rs50RzkRUDuMWA9+yHPgVBgRfQi6lNXeCSTOIkJu2vq3etKCVgkFIVDGMqpRtlm+hYqbDi8hfZhGpkvQkJdJIAnsVQSUMWAth3cdZMlB3WwX5hABnBdYoSwSsi/riCnsoEaM7TJDwMdVqV+qKsBJFbOxMy2EcwczUJMEBdRWsPQ60gobwo0ZYGoID8tDawmZnBc4dhmqLsQ7jvaC4wBGKTojVUm5wpLAnGKwxRfuW9jHgoNSqABBKQoAczKIZABlUj/DZCv/IIKwnQeYwGqEVVaIUH/ycNuVZhoM0jkcoRemMSTdnqABQMNoVQQsQJBDvDs+9LRq5Y8l3wRiWi2OUEfUPxIotswsTMgIE0mTGA6GpuYXWZZMtIMWNQMGUn6NrwN0yLWmYsICeCcAADvSWWj9ZUFEX+RFZpSWV1/BEGMT5GiaDGlBbDFygz7dspsgyKCLDNX11OB5uNkclM4lYktetkhUcxZ17geBji/QoglSGQ6i3EwPmNCYr3TIoQF+PPwKjdfAUdjaQZIE1arOVESLhjgEC6Fwp2tDNWPKPlJiSilvVGkghg5kSPg58m/DA2emwANgJZIyhlYjjsE9wIcwPVIL4jHsU0ESuPgwAPyEek/v8aZ2/kusmg6DMyPm0NVp7xyuAAVGYrguiCesPYfKb0NKg9DbUqQr3SYMpq46LZM2/D2lMlsrhpEYEInOXWB+GBf0kgBEYTQrc8ZpKddjiIWbZbEOQuhXrNbQppn4I1NqrIUzcrKmEn9RAA57GPIYLV1rn6GZzyLGJNIWpYMMUBM+y2EfuBAR44POPMqPe9DzHL20LWGYYigl4Nge5qvKgA5VH5MO2RsUlLdqVHhwbECyDxRezkl0U16jKIu7GJwrwZKplKfibuYnhM0uikZUTPoXHylC8io46EBnGNi/GkUwO4yjWE5zL9JEXdXBxjl9q1Kep2cfw86If4myBSN3T/aJQzwIu4ejNoPV2MNkl9HE2ROVi61EGUvBxZL8DWD9GA6Dyg8QifxgpW4Ny+R4MouXsgAjK9ergUwIAJz0UkJ3y7esBd08vYK5Xamg2VRIzuS9Ii/ioC5agTZI7ecNSi/cF4UzcMKUxnyMFXL4jynOd7dw+HdTtdj/J+SMnPR1qaAH8I6g8+ABGoyJRjj4tyFjfM8bAvl339fEM0YCUOqIgB5a+UBoxoAcvBfr0QBEBwEA72YGsBfs+HDwMAM86nDQx2eWUhgHjRIebFda41DpbkcDBBgXVRY/PXbMUwdoxQATCwgfPmFx5YFkjyYKHlUMmgeIQ1L2AXJ3wXdv0g/3M5lYH1pwgNwHQYBWW4BwyK51krgIKm5w5L13R3xgwSOA5IIwglInRpRwxCIiRJKAgRdSoRaHH+UHbupYBWOAJZ6A2YBT5U6G3E8CVDkoUfkFLwhxF/d3DupgyjciWjMgKDNg4VIR6bN4S8wIbNpU8UMDUa4Fs+kXl/KILIACd2ZCVDsg6394C78CV6OGyCUCVkeCa2gm0xMYlNWAyOaCiRqAgZQAPfEF2gR3FreEzoxIaEVRfNB4jCMIpgcgAXJwgg4AEekAHc4GY7SH++wCl/BIt4gXqAkoaSxwy2iIOGkAEdMAET4AGouA1TmDVWyHsHQIZmYox14XuPJ4a9cP+H2+iMhLCL0tgBvsgNP/gd50WL44hUpAhFeDEVFcEUymhXdohUd3gI0CiNHgAC35Av4ogL82gmV+gX4kc3dAiDzJiE6DgB6ggOq/aCBxaDt8iPmBgV9ycd+leQqECC/2SOg/CP0yiQ46CD+GYMkaSJ9FiBBtCAZ0VdtgBzXxWREykOS0g3lNgLnFICMsgdK9h2JEkmR2eSAYl50mF28MgL5VQCNyACQTkRFvh9oRgLNilZOLmO5DCH+Zh9yLADRTABUlmGIQGCunKVsMBSg9VcSImS5qCIPNmUv4ADJjABJoACIgkTZwE7DQEXFrly7cd7jWJ6W6kOoAiSuRCNE+D/AlyZGVGYOA15ka1YlG/JDrPYk74wBOl4G2cYhnJnOTMJlsOYdIe5Dp9RcBhYh8FQTiJgAj7AG31IAItISg4AETuxg0MZCSx1me1AAK+XOA/wlfoYDIZSAzaAHImJCB5kSjqDP463H441mrtnJYWgXqfZDp3XEQjwAE81d4OgOBO0jKAAnQshnSZBndVpR2YZGKq4CIATd0TFLRSCCeYpMefDm5I1WL4JD55jHmwiSpkmPOJDnp9wn+gZmP/Wje1ZF8D4CGkCes9pIzyEnzYGCSzlKNn5DuiTNINjfvgDnaSpCQgaVwpamKlUKU9YFteoCAmgXG4hoZ2wNDQTVwTR/2qCwJZDsoknAJBwGQ8CoRQq4S7m5zMUGiH0iXyZQKMWeqOlFyf6BCd6mIti0Y7JQkrREXkGuqRHep4mqp/e9Ip8IgIS+ZiRsJfQUG8ylwA5BaIUKqLFOaNdaqEnmqMEMaUjySdoGhMEKYyUUKL5WVptVYx8cgI/OglTiQw7OXHmxx9pU6AjyqV7EZ1fCqbO2Iw26BcVqZiJAKgXagmEuoeW+pLXAIaaxX9XtD1qeKBzmqCNQI5euKApWpRRoZKcygp/lJCYkKjH4JWa2QpSSqXkBIkNGhKLequrwIFUVazJIJer6ZCyIKa0SpSZihemSpy76VMpiAl7+gzLyYiuQP+o02qU4xoTvqqWtrCi9JCZdFkK4lqtr0qY3xg9mjeX4NoK6NZz6tqBtJCrGkkqFvKtrIiVAAUCJ/BTypoRQ+mvpFKO8Noe7HqvuFop/1iW5uiSpBoVCytomJqx15GapfOsi7CxZoICHiCNBwtQ5VRH8gCyExOMrPkK6HSHAnCJG4kcwNkTsIOt/QomZJqUkXSQopoOwMkPh/armjB2KJCJg/qIANse25lhIiuYseCaOdlchoJELbt6O+GdSJsJWRurNwhFuMirZfGfD1CnqxoLJZADIiACJ1ACy1quqLkTi7GS7gomzBS0zCqLaeKhyNoJG6oIZjuQRdER7xi4o9r/hgDFt3QrGUH6JDx7Co7Wn/FqnfMgf2mpuBiqt/PmuA8bHGpqb2zKuShUs6Q1uCNxgC74tdwqj/M2iPKKHMeKrq9LrHFSAoyZlGcLZ7brCSjwtjKwrztyraaLdAwaJzLwtjkgt2KxZZMJradQA3eZlz2oPlQBdNE7svKWvHo6u4loHnqBADArvZsws6RCpkewjt26Is56vLs1EFNKs32LEFNhFAT3u6PKJ3UkAh0gq6E7KwLbdZ5QR1HqimK7njf7Dvb4edv7cTLGsbmbpx47KxHrp5rQTTY4WGxWuOBQEe/BElPLvQUswR7rwdcbeqOARGGLuWNbwSgawP6ZOAaA/6OU2QniCkgonMI6k6/cyL+Nu60UPLTuYKvt+gjou5Htm8JUC7YZibtAHHYdXL86iWRMCL+EUANvewJM7IM2QQDlS8KbcJBQCsUvqa5LfA7Ge8SOkAE3II1GYKZdTAhF63iTWwkra7NY6IxpPBHnyghuMakxtQk24ALS+ANz7INcax4jXIWVpLePuMfw2scT8b6MUFtHOsiZYJd4+aOUzCg/qBjZVCNTtqV+dIt7zLjwusP/MMCFAAEtkcmmbAmM6ZhD3MXeh7gTBzSlHKlzq7wyoMGkysrM956MUCMQAKfGV5+UkAGGLJHUCsP7orl2ZwjZ08SnbCZva8DySsz14P86BRCTjsA6arK2lIAC1YsD8fu4msK6amFK10wIy8zMgmolKACU8rvA3kwPltPLnSrLvowIrtmYyWl5ZkzEDdMsihDPjjwJbbvFBu3CtxwVRSMBtPmpjQCnAR3NAiACN2CmjvjJYwK9D8TQ5gwJqstWEv0T7jUTFqG2De1EYOK8eToCwtqDTPEA45tTwJW/s9wIlhsgBlfNEku4brfPG3K/++DTA/sINHCyZdoiQ/3AYty5RYnUFtLA3AaSGcCLh7oh6wTTJy124Mu0K53IICwjjTzWjLADNJ3IEAzXqAARClDDbKyvCczDq6CkpsDXpODXf+0LRlzU6xy64wXYooD/2M2g2K1AbY6tCo+9C7VL2BxNrs74adTG2J+QrRC0CpGNCp/NV0sJmpRt2Se8rZjt2ZB9C6F9Cqm92rvwxxhc2RScsa+dCrdNC/S527zd277928Ad3MI93MRd3MDNC5Zc2hMNwA+b264N27XQ2qbg3NPdC66sTcPttOyJkBb3RMb93eAd3uJt3Kyt2tD93OedCxdMk6VA3e2d3rIg3e+N2+at3gsQzmKtyfMN2vWN3tHd3/4d4AJuC/2Mt/s94Ade3bag2Z/A4J7g4JwA4RGuCxV90fm90diI4KTg3nKdDS3NXheuwqgg4ZpA4iWuCibe4YvnTJaQ4ir+4uwyIcQJ/+M0XgxhXeM4bg+wbFZG1hyCsONcIZ7+fMzjOQDIRde8LIVJLgmsw1WBrOSqmqrjyQhb5iNNDuUTJOSoAOTqaQnow+PPkRg+wuVejjaEAAFAsx9ZFSVr3sgENQg1ch9tHiIjQkaOgFwAmDhQwg9zPucqRqFpMuOGoH4AkB8JgD+B7qg9JjGSsOQ6ITuEQKASI+k2B5/8kJs89EWCQOmKDqmLoAC3OT6HsQCXjn6dPumPyuikgOhU/QiGPjcDBOgnwerKKKCD0DUUNOuyzmoAfXYb5SPbeR+BTusaDcg98eoJoBQ4keu8vhfD3uvEID6eTqIscWkI8CcSczohCu0ZPf9BNRIdt7ntr/em3N4IO2EQsFwRN0Lu477ugvwIzUkI5y7u4m4K0q7qm3BkSLMX915r2Y7vktCobgEXM5Kf52PwGH3njF4AC5DoCO9GNhaokZAflqHuX3rwEZ/wxJBR064JrAOAHK8fRvruuDJB4mPoIz/ylDDwAIDM+JPyklPuhxCfhMDyMK80Ms8JIV/pl5ClSrHzO28JjXo+95c2+3M+R6/xizBUKMfs34P0WiTxjkAZ704AKyE4Sf/0Si8M/e4J6gYAbiEB/V7vk3DNFSE3FEPv7C4JBATp5Gwjau/uTP4fba+z7E72pND1N4N+odwj/+7v+9HxkNCoyjM+uQH/ERiP+FtPcyOiFExq9RkP8YoP03EjCGXlHA//8H++F24h6MwhN3GDP51/6jz/6RPkRmn76pzO6SUP94UAnauf6qVPCC8aZXERMcG56bJP+qYg+q3uCDGa68lMoZ3v+1/ZqOTRncy+Nsuf84tVaoSQ6IHO/NPv/LbJD5UPONVT/c5+EsyvDGT+CcilXOGv5ZPQ0z2BbGBu/ubf+j4uhUfK/o7OCATE4zRqQVHe/qUQ/p0ACA0OAQEICQAAEAiEh4mLAY2IkpOUlAaEjIgLhA4KAAODAQ4Nn6GjlaiSj4QIk5sEpZykoLKpqbSECwMAm5gBCrinwaS2xcbHyMnKy8zN/87P0NHS09TV1tfY2drb3N3e3+Dh4uPk5ebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/AAMKHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPqdHcp0kgEBnYKJanAV6dkPcMV+LVsEAREgw4RWBqgAKxpryolYFpsQKGhYCUWLQAgQlWkkOhBEPUJAYIBZgsMGLA0AtYAVycVIBu2L8exn75CeJALQFFMh3oSqLoL0YBeDwg0IBxh6wIAWzNdWgD0MSYCm4CFSps57SS3AywDkBDgaaIAEpBdcrBIwv8mBJ6yTirqenbt257cAvAd4LLf4wIBr10AmLVrw18vGUAg1xXeBgEeAGjglu3WoIQbXCJkYFOk0JdiI/oOIPwk1gnqAljqCTrfubaSLmqwNrZuSdMBmNZ+/QEgnH5cIacgP4flkpovARjQQC+EDDAebJSsUuFwhNhFISEEJGVgAI3x8osChBWiwId4TWIWYdqt1hoiBbKGISoIDrDYZf8h8oB6HB6yiI7FGdhKUvQtqKQ+gEnSpCYDktjTUs+ZWKUCCBBG1lZABgnleQmmx6UtKTYS11zyJdDAVgSYFZSAQpK4o4l5vWYXIjnOeWBaSS7pZz1P0pgiJFhWNWRP3CGRQMwnFCr6gKJbOYCZLwqI6BmIoVF4SmkJrkfIolMRYtUkWylQ6iR5FvnhZQ7whWeURF625yF9/mnrralgGZsDxj2DnU+4BissNAQgIMEuCNTZTAJvDevss8p4hcmb0FZr7TZz4Xftttx26+234IYr7rjklmvuueimq+667Lbr7rvwxivvvPTWa++9+OarbzuBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peak VO2 achieved with exercise in normal subjects and those with chronic heart failure (HF) in relation to peak leg blood flow and cardiac output (CO). These parameters were linearly related in both groups, an expected finding since peak VO2 is determined in part by tissue perfusion. However, when compared to normals, patients with HF had lower levels of oxygen consumption, leg blood flow, and cardiac output.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Sullivan MJ, Knight JD, Higginbotham MB, Cobb FR. Circulation 1989; 80:769.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40382=[""].join("\n");
var outline_f39_27_40382=null;
var title_f39_27_40383="Mesothelioma MRI II";
var content_f39_27_40383=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78690&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mesothelioma with thickened fissures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 354px; height: 317px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sagittal T2-weighted image shows high signal caused by tumor extending from the diaphragmatic pleura into the thickened major and minor fissures.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_27_40383=[""].join("\n");
var outline_f39_27_40383=null;
